Patent Publication Number: US-2003228617-A1

Title: Method for predicting autoimmune diseases

Description:
CROSS REFERENCE TO RELATED APPLICATIONS  
     [0001] This application is based on and claims priority to U.S. Provisional Application Serial No. 60/381,055, filed May 16, 2002, herein incorporated by reference in its entirety. 
    
    
     GRANT STATEMENT  
     [0002] This work was supported by grants A144924, AR02027, AR41943, and DK58765 from the U.S. National Institutes of Health. Thus, the U.S. government has certain rights in the presently claimed subject matter. 
    
    
     
       TECHNICAL FIELD  
       [0003] The presently claimed subject matter generally relates to the diagnosis of autoimmune disease. More specifically, this presently claimed subject matter relates to identifying a reduced probability of having an autoimmune disease, such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or Type 1 diabetes.  
                               Table of Abbreviations                                            6-JOE   -   6-carboxy-4′,5′-dichloro-2′,7′-               dimethoxyfluorescein, succinimidyl ester       aaRNA   -   amplified antisense RNA       Ags   -   antigens       AP3S2   -   adaptor-related protein complex 3, sigma 2               subunit       ASL   -   argininosuccinate lyase       BMP8   -   bone morphogenetic protein 8 (osteogenic               protein 2)       BPHL   -   biphenyl hydrolase-like (serine hydrolase; breast               epithelial mucin-associated antigen)       BRCA1   -   breast cancer 1, early onset, transcript variant               BRCA1a       CASP6   -   caspase 6       CDH1   -   cadherin 1, type 1, E-cadherin (epithelial)       CDKN1B   -   cyclin-dependent kinase inhibitor 1B       cDNA   -   complementary DNA       CYB5-M   -   cytochrome b5 outer mitochondrial membrane               precursor       DEPC   -   diethylpyrocarbonate       DIPA   -   hepatitis delta antigen-interacting protein A       DMARDs   -   disease-modifying anti-rheumatic drugs       DNAJA1   -   DnaJ homolog, subfamily A, member 1       EPB72   -   erythrocyte membrane protein band 7.2               (stomatin)       EST   -   expressed sequence tag       FITC   -   fluorescein isothiocyanate       GMBS   -   gamma-maleimidobutyryloxy-succimide       GNB5   -   human guanine nucleotide binding protein, beta 5       GUCY1B3   -   guanylate cyclase 1, soluble, beta 3       HSJ2   -   heat shock protein, DNAJ-like 2       IDDM   -   insulin-dependent (type 1) diabetes mellitus       IFN   -   interferon       LabMAP   -   Laboratory Multiple Analyte Profiling       LIF   -   leukemia inhibitory factor       LLGL2   -   lethal giant larvae homolog 2       MAN1A1   -   mannosidase, alpha, class 1A, member 1       MMP17   -   matrix metalloproteinase 17       MS   -   multiple sclerosis       MYO1C   -   myosin I C       NSAIDs   -   nonsteroidal anti-inflammatory drugs       ORC1L   -   origin recognition complex, subunit 1-like       PCR   -   polymerase chain reaction       PMBC   -   peripheral blood mononuclear cell(s)       RA   -   rheumatoid arthritis       RAPD   -   rapid amplification of polymorphic DNA       ROCK   -   Random Oligonucleotide Construction Kit       RTN4   -   reticulon 4       RT-PCR   -   reverse transcription PCR       SC65   -   synaptonemal complex protein 65       SD   -   standard deviation(s)       SIP1   -   survival of motor neuron protein interacting               protein 1       SISPA   -   Sequence-Independent, Single-Primer               Amplification       SLC16A4   -   solute carrier family 16, member 4       SLE   -   systemic lupus erythematosus       SSP29   -   silver-stainable protein 29, also called acidic               (leucine-rich) nuclear phosphoprotein 32               family, member B       STOM   -   alternate abbreviation for stomatin       SUDD   -   human sudD suppressor of bimD6 homolog               (SUDD) from  Aspergillus nidulans , transcript               variant 1       TAF11   -   TATA box binding protein- associated factor 11       TAF2I   -   TAF11 RNA polymerase II, TATA box binding               protein-associated factor, 28 kilodalton       TBP   -   TATA box binding protein       TGM2   -   transglutaminase 2       TNF-α   -   tumor necrosis factor alpha       TNFAIP2   -   tumor necrosis factor, alpha-induced protein 2       TP53   -   human tumor protein p53 (Li-Fraumeni               syndrome)       TXK   -   TXK tyrosine kinase       UBE2G2   -   ubiquitin-conjugating enzyme E2G 2 (UBC7               homolog, yeast)                  
 
       [0004]                              Amino Acid Abbreviations and Corresponding mRNA Codons                             Amino Acid   3-Letter   1-Letter   mRNA Codons               Alanine   Ala   A   GCA GCC GCG GCU       Arginine   Arg   R   AGA AGG CGA CGC CGG CGU       Asparagine   Asn   N   AAC AAU       Aspartic Acid   Asp   D   GAC GAU       Cysteine   Cys   C   UGC UGU       Glutamic Acid   Glu   E   GAA GAG       Glutamine   Gln   Q   CAA CAG       Glycine   Gly   G   GGA GGC GGG GGU       Histidine   His   H   CAC CAU       Isoleucine   Ile   I   AUA AUC AUU       Leucine   Leu   L   UUA UUG CUA CUC CUG CUU       Lysine   Lys   K   AAA AAG       Methionine   Met   M   AUG       Proline   Pro   P   CCA CCC CCG CCU       Phenylalanine   Phe   F   UUC UUU       Serine   Ser   S   ACG AGU UCA UCC UCG UCU       Threonine   Thr   T   ACA ACC ACG ACU       Tryptophan   Trp   W   UGG       Tyrosine   Tyr   Y   UAC UAU       Valine   Val   V   GUA GUC GUG GUU                    
       BACKGROUND ART  
       [0005] Autoimmune diseases affect millions of people in the United States, with approximately 3-5% of the population being affected. See Jacobson et al., 1997; Marrack et al., 2001. The pathogenesis of autoimmune disease generally involves an attack by the patient&#39;s immune system on an organ or tissue, such as seen in cases of type 1 (insulin-dependent) diabetes (pancreatic β cells; see Kukreja &amp; Maclaren 2000), multiple sclerosis (myelin basic protein; see Ufret-Vincenty et al., 1998), and thyroiditis (thyroglobulin or thyroid peroxidase; see Martin et al., 1999). Certain autoimmune diseases are also characterized by systemic attacks, including immunological responses against the synovial lining, lung, and heart in rheumatoid arthritis (see Quayle et al., 1992) and the skin, kidney, and heart in systemic lupus erythematosus (see Kotzin 1996).  
       [0006] Classification of disease syndromes, prediction of disease course, and understanding disease pathogenesis are three fundamental goals of research in autoimmunity. Diagnosis of autoimmune diseases often requires several patient visits to the doctor and repeated clinical testing. This is largely due to the fact that no single test or combination of clinical tests presently available is an absolute predictor of autoimmune disease. For example, reliably establishing a diagnosis of rheumatoid arthritis (RA) using existing criteria requires a history of at least 3 months of symptoms.  
       [0007] The importance of the need for a rapid and accurate diagnostic test for autoimmune diseases is underscored by changes in the approaches to treatment of these diseases. Until recently, rheumatologists initiated therapy for a newly diagnosed patient with nonsteroidal anti-inflammatory drugs (NSAIDs) and low dose corticosteroids. As the disease progressed, additional disease modifying anti-rheumatic drugs (DMARDs) were added. Rheumatologists now recognize that early and aggressive therapy with newer agents such as methotrexate, leflunomide, or the new tumor necrosis factor-α (TNF-α) inhibitors (for example, etanercept and infliximab) can provide improved outcomes and actually preserve function and improve quality of life. See Jacobson et al., 1997. However, these newer drugs are expensive and can result in significant side effects, and thus are better used in patients that clearly have RA.  
       [0008] Therefore, improved diagnostic tests that can readily exclude an individual from the classification of having an autoimmune disease are needed. This and other needs in the art are addressed by the present disclosure.  
       SUMMARY  
       [0009] The presently claimed subject matter provides method and compositions for detecting an autoimmune disorder in a subject. In one embodiment, the method comprises (a) obtaining a biological sample from the subject; (b) determining expression levels of at least two genes in the biological sample; and (c) comparing the expression level of each gene determined in step (b) with a standard, wherein the comparing detects the presence of an autoimmune disorder in the subject. In one embodiment, the autoimmune disorder is selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 (i.e. insulin-dependent) diabetes (IDDM), and combinations thereof. In one embodiment, the biological sample is a cell. In one embodiment, the cell is a peripheral blood mononuclear cell. In one embodiment, the subject is an animal. In one embodiment, the animal is a mammal. In one embodiment, the mammal is a human. In one embodiment of the present method, the determining in step (b) comprises a technique selected from the group consisting of a Northern blot, hybridization to a nucleic acid microarray, and a reverse transcription-polymerase chain reaction (RT-PCR). In one embodiment, the RT-PCR is quantitative RT-PCR.  
       [0010] In alternative embodiments of the present method, the determining in step (b) is of the expression levels of at least two genes, of at least five genes, of at least ten genes, of at least twenty genes, of at least twenty-five genes, or of all of the genes identified in SEQ ID NOs: 1-70.  
       [0011] In accordance with the methods of the presently claimed subject matter, in one embodiment the comparing comprises: (a) establishing an average expression level for each gene in a population, wherein the population comprises statistically significant numbers of normal subjects and subjects that have one or more different autoimmune disorders; (b) assigning a first value to each gene for which the expression level in the subject is higher than the average expression level in the population and a second value to each gene for which the expression level in the subject is lower than the average expression level in the population; and (c) adding the values assigned in step (b) to arrive at a sum, wherein the sum is indicative of the presence or absence of an autoimmune disorder in the subject.  
       [0012] The presently claimed subject matter also provides a method of diagnosing an autoimmune disorder in a subject comprising: (a) providing an array comprising a plurality of nucleic acid sequences, wherein each nucleic acid sequence corresponds to a known gene; (b) providing a biological sample derived from the subject, wherein the biological sample comprises a nucleic acid; (c) hybridizing the biological sample to the array; (d) detecting all nucleic acids on the array to which the biological sample hybridizes; (e) determining a relative expression level for each nucleic acid detected; (f) creating a profile of the relative expression levels for the detected nucleic acids; and (g) comparing the profile created with a standard profile, wherein the comparing diagnoses an autoimmune disease in a subject. In one embodiment, the autoimmune disorder is selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 (insulin-dependent) diabetes (IDDM), and combinations thereof. In one embodiment, the array is selected from the group consisting of a microarray chip and a membrane-based filter array. In alternative embodiments, the array comprises at least two genes, at least five genes, at least ten genes, at least twenty genes, at least twenty-five genes, or all of the genes identified in SEQ ID NOs: 1-70. In another embodiment, the array further comprises at least one internal control gene. In one embodiment, the biological sample is a cell. In one embodiment, the cell is a peripheral blood mononuclear cell. In one embodiment, the subject is an animal. In one embodiment, the animal is a mammal. In one embodiment, the mammal is a human.  
       [0013] In one embodiment of the present method, the determining comprises a technique selected from the group consisting of a Northern blot, hybridization to a nucleic acid microarray, and a reverse transcription-polymerase chain reaction (RT-PCR). In one embodiment, the RT-PCR is quantitative RT-PCR. In alternative embodiments, the determining is of the expression levels of at least two genes, of at least five genes, at least ten genes, at least twenty genes, at least twenty-five genes, or of all of the genes identified in SEQ ID NOs: 1-70.  
       [0014] In one embodiment of the present method, the comparing comprises: (a) establishing an average expression level for each gene in a population, wherein the population comprises statistically significant numbers of normal subjects and subjects that have one or more different autoimmune disorders; (b) assigning a first value to each gene for which the expression level in the subject is higher than the average expression level in the population and a second value to each gene for which the expression level in the subject is lower than the average expression level in the population; and (c) adding the values assigned in step (b) to arrive at a sum, wherein the sum is indicative of the presence or absence of an autoimmune disorder in the subject.  
       [0015] The presently claimed subject matter also provides a kit comprising a plurality of oligonucleotide primers and instructions for employing the plurality of oligonucleotide primers to determine the expression level of, in alternative embodiments, at least one, at least five, at least ten, at least twenty, at least thirty, or all of the genes represented by SEQ ID NOs: 1-70. In one embodiment, the kit further comprises oligonucleotide primers to determine the expression level of a control gene. 
     
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS  
     [0016]FIGS. 1A and 1B depict Cluster Analysis of Pre- and Post-Immune Data.  
     [0017]FIG. 1A depicts an unsupervised self-organizing map that compares individuals before immunization (CONTROL) or after immunization (IMM, days 6-9 postimmunization) with influenza antigen. In the upper panel of FIG. 1A, profiles from the analysis of all genes are depicted. In the lower panel of FIG. 1A, profiles after removal of invariant genes are depicted. Individuals (designated 11 through 18) are connected by brackets.  
     [0018]FIG. 1B depicts K-means analysis of the data set. In FIG. 1B, data are presented as the natural logarithm of the ratio of the experimental group indicated on the X-axis to the control group. Individual lines in the plot represent expression ratios of the individual genes over the time course.  
     [0019]FIGS. 2A and 2B depict a comparison of the immune and autoimmune classes by cluster analysis.  
     [0020] In FIG. 2A, the immune (6-8 days post-immunization), RA and SLE groups were analyzed using a hierarchical clustering algorithm (upper panel). The immune, MS, and type 1 diabetes groups were subjected to similar cluster analysis (lower panel).  
     [0021] In FIG. 2B, K-means analysis was used to identify two distinct clusters of genes that were uniformly over-expressed (left panel) or under-expressed (right panel) in all four autoimmune groups. Data are presented as the natural logarithm of the ratio of the immune group or each autoimmune group (type 1 diabetes, MS, RA, or SLE) to the control group.  
     [0022]FIGS. 3A and 3B depict the analysis of the most under- and over-expressed genes in the autoimmune population on an individual basis. Expression levels of the individual genes were compared among 10 control individuals (black solid bars) and 25 individuals with autoimmune disease (gray stippled bars).  
     [0023]FIG. 3A depicts the expression levels of the ten most over-expressed genes.  
     [0024]FIG. 3B depicts the expression levels of the ten most under-expressed genes.  
     [0025]FIG. 4 depicts the classification and predication of autoimmune disease. The score (Y-axis) is shown for each individual sample analyzed from the different populations (X-axis). P-values are depicted in the legend, which is repeated here as follows immune=0.9; SLE=1E-08; RA=4E-07; IDDM=1E-06; MS=1E-06; SLE(2)=8E-07; RA(2)=5E-07; and family=1E-06. The 35 genes employed to derive this score were as follows: TGM2, SSP29, TAF21, LLGL2, TNFAIP2, SIP1, BPHL, TP53, DIPA, ASL, GNB5, MAN1A1, R09503, LOC51643, BMP8, ORC1L, W04674, R94175, CDH1, SUDD, EPB72, CDKN1B, CASP6, TXK, MYO1C, LIF, HSJ2, BRCA1, GUCY1B3, AP3S2, N68565, SC65, UB32G2, SLC16A4, and MMP17. 
    
    
     BRIEF DESCRIPTION OF THE SEQUENCE LISTING  
     [0026] SEQ ID NOs: 1 and 2 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human transglutaminase 2 (TGM2) gene (GenBank Accession Nos. AA156324 and NM — 004613).  
     [0027] SEQ ID NOs: 3 and 4 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human acidic (leucine-rich) nuclear phosphoprotein 32 family, member B (ANP32B, also called silver-stainable protein 29; SSP29) gene (GenBank Accession Nos. AA489201 and NM — 006401).  
     [0028] SEQ ID NOs: 5 and 6 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human TATA box binding protein (TBP)-associated factor 11 (TAF11) RNA polymerase II, 28 kilodalton (kDa) gene (TAF2I) (GenBank Accession Nos. N92711 and NM — 005643).  
     [0029] SEQ ID NOs: 7 and 8 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human lethal giant larvae homolog 2 (LLGL2) gene (GenBank Accession Nos. T40541 and NM — 004524).  
     [0030] SEQ ID NOs: 9 and 10 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human tumor necrosis factor, alpha-induced protein 2 (TNFAIP2) gene (GenBank Accession Nos. AA457114 and NM — 006291).  
     [0031] SEQ ID NOs: 11 and 12 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human survival of motor neuron protein interacting protein 1 (SIP1) gene (GenBank Accession Nos. N26026 and NM — 003616).  
     [0032] SEQ ID NOs: 13 and 14 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human biphenyl hydrolase-like (BPHL; serine hydrolase; breast epithelial mucin-associated antigen) gene (GenBank Accession Nos. AA171449 and NM — 004332).  
     [0033] SEQ ID NOs: 15 and 16 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human tumor protein p53 (TP53; Li-Fraumeni syndrome) gene (GenBank Accession Nos. R39356 and NM — 000546).  
     [0034] SEQ ID NOs: 17 and 18 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human hepatitis delta antigen-interacting protein A (DIPA) gene (GenBank Accession Nos. N94820 and NM — 006848).  
     [0035] SEQ ID NOs: 19 and 20 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human argininosuccinate lyase (ASL) gene (GenBank Accession Nos. AA486741 and NM — 000048).  
     [0036] SEQ ID NO: 21 and 22 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human gene identified as DKFZp586O1922 (GenBank Accession Nos. H08753 and AL117471).  
     [0037] SEQ ID NOs: 23 and 24 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human mannosidase, alpha, class 1A, member 1 (MAN1A1) gene (GenBank Accession Nos. T91261 and NM — 005907).  
     [0038] SEQ ID NO: 25 is a nucleic acid sequence of an expressed sequence tag (EST) designated R09503 in the GenBank database. This gene shows substantial homology to bases 106283 to 106592 of the BAC sequence from the SPG4 candidate region at 2p21-2p22 BAC 41M14 of library CITB — 978_SKB from human chromosome 2 (SEQ ID NO: 26; GenBank Accession Number AL121657.4).  
     [0039] SEQ ID NO: 27 is a nucleic acid sequence of a partial cDNA with GenBank Accession number AA130874. This gene shows substantial homology to the human CGI-119 gene (SEQ ID NO: 28; GenBank Accession Number NM — 016056).  
     [0040] SEQ ID NOs: 29 and 30 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human bone morphogenetic protein 8 (osteogenic protein 2; BMP8) gene (GenBank Accession Nos. AA779480 and NM — 001720).  
     [0041] SEQ ID NOs: 31 and 32 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human cytochrome b5 outer mitochondrial membrane precursor (CYB5-M) gene (GenBank Accession Nos. W04674 and NM — 030579.).  
     [0042] SEQ ID NOs: 33 and 34 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human origin recognition complex, subunit 1-like (ORC1L) gene (GenBank Accession Nos. R83277 and NM — 004153.).  
     [0043] SEQ ID NO: 35 is a nucleic acid sequence of an EST designated R94175 in the GenBank database. This EST shows substantial homology to bases 68656 to 68886 of BAC clone R-431H16 of library RPCI-11 from human chromosome 14 (SEQ ID NO: 36; GenBank Accession Number AL161665.5).  
     [0044] SEQ ID NOs: 37 and 38 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human cadherin 1, type 1, E-cadherin (epithelial; CDH1) gene (GenBank Accession Nos. H97778 and NM — 004360).  
     [0045] SEQ ID NOs: 39 and 40 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human sudD suppressor of bimD6 homolog (SUDD) from  Aspergillus nidulans,  transcript variant 1 gene (GenBank Accession Nos. T54144 and NM — 003831).  
     [0046] SEQ ID NOs: 41 and 42 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human stomatin (STOM; also called EPB72) gene (GenBank Accession Nos. R62817 and NM — 004099).  
     [0047] SEQ ID NOs: 43 and 44 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human cyclin-dependent kinase inhibitor 1B (CDKN1B) gene (GenBank Accession Nos. AA630082 and NM — 004064).  
     [0048] SEQ ID NOs: 45 and 46 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human caspase 6 (CASP6) gene (GenBank Accession Nos. W45688 and NM — 001226).  
     [0049] SEQ ID NOs: 47 and 48 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human TXK tyrosine kinase (TXK) gene (GenBank Accession Nos. H12312 and NM — 003328).  
     [0050] SEQ ID NOs: 49 and 50 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human myosin IC (MYO1C) gene (GenBank Accession Nos. M485871 and NM — 033375).  
     [0051] SEQ ID NOs: 51 and 52 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human leukemia inhibitory factor (LIF) gene (GenBank Accession Nos. AA026609 and NM — 002309).  
     [0052] SEQ ID NOs: 53 and 54 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human DnaJ homolog, subfamily A, member 1 (DNAJA1) gene (GenBank Accession Nos. R45428 and NM — 001539).  
     [0053] SEQ ID NOs: 55 and 56 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human breast cancer 1, early onset (BRCA1), transcript variant BRCA1 a gene (GenBank Accession Nos. H90415 and NM — 007294).  
     [0054] SEQ ID NOs: 57 and 58 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human guanylate cyclase 1, soluble, beta 3 (GUCY1B3) gene (GenBank Accession Nos. AA458785 and NM — 000857).  
     [0055] SEQ ID NOs: 59 and 60 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human adaptor-related protein complex 3, sigma 2 subunit (AP3S2) gene (GenBank Accession Nos. R33031 and NM — 005829).  
     [0056] SEQ ID NOs: 61 and 62 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human reticulon 4 (RTN4) gene, listed in the GenBank database at accession number N68565 (GenBank Accession Nos. N68565 and NM — 007008).  
     [0057] SEQ ID NOs: 63 and 64 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human 55 kDa nucleolar autoantigen similar to rat synaptonemal complex protein (SC65) gene (GenBank Accession Nos. W81191 and NM — 006455).  
     [0058] SEQ ID NOs: 65 and 66 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast; UBE2G2) gene (GenBank Accession Nos. AA443634 and NM — 003343).  
     [0059] SEQ ID NOs: 67 and 68 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human solute carrier family 16, member 4 (SLC16A4) gene (GenBank Accession Nos. R73608 and NM — 004696).  
     [0060] SEQ ID NO: 69 and 70 are the nucleic acid sequences of a partial cDNA and a full-length cDNA, respectively, corresponding to the human matrix metalloproteinase 17 (MMP17) gene (GenBank Accession Nos. R42600 and NM — 016155).  
     DETAILED DESCRIPTION  
     [0061] The presently claimed subject matter relates to methods for detecting an autoimmune disorder in a subject by analyzing gene expression profiles for selected genes in biological samples isolated from the subject and comparing the gene expression profiles to standards. In one embodiment, the methods involve determining the expression levels of a set of genes expressed in peripheral blood mononuclear cells isolated from a subject suspected of having an autoimmune disease and comparing the expression levels of these genes with the levels of expression of these genes in normal subjects and subjects with confirmed autoimmune diseases. Using the methods of the presently claimed subject matter, it is possible to determine whether or not a subject has an autoimmune disease (for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and/or type 1 (insulin-dependent) diabetes) or whether the subject does not have autoimmune disease.  
     [0062] In determining whether or not a subject has an autoimmune disease, the expression levels of many genes can be analyzed simultaneously using microarrays or membrane-based filter arrays. A representative filter array is the GF211 Human “Named Genes” GENEFILTERS® Microarrays Release 1 (available from RESGEN™, a division of Invitrogen Corporation, Carlsbad, Calif., United States of America), although other arrays can also be used. Using the GF211 array, it is possible to determine the expression levels of over 4000 genes simultaneously in a biological sample. Additionally, the presence on the GF211 filter of certain “housekeeping” genes allows for the comparison of data from experiment to experiment. This facilitates the comparison of newly obtained data to a standard (e.g. a previously generated standard).  
     [0063] I. Definitions  
     [0064] While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently claimed subject matter.  
     [0065] Following long-standing patent law convention, the terms “a” and “an” mean “one or more” when used in this application, including the claims.  
     [0066] As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of ±20% or ±10%, in another example ±5%, in another example ±1%, and in still another example ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.  
     [0067] As used herein, “significance” or “significant” relates to a statistical analysis of the probability that there is a non-random association between two or more entities. To determine whether or not a relationship is “significant” or has “significance”, statistical manipulations of the data can be performed to calculate a probability, expressed as a “p-value”. Those p-values that fall below a user-defined cutoff point are regarded as significant.  
     [0068] In one example, a p-value less than or equal to 0.05, in another example less than 0.01, in another example less than 0.005, and in yet another example less than 0.001, are regarded as significant.  
     [0069] I.A. Nucleic acids  
     [0070] The nucleic acid molecules employed in accordance with the presently claimed subject matter include any nucleic acid molecule for which expression is desired to be assessed in evaluating the presence or absence of an autoimmune disease. Representative nucleic acid molecules include, but are not limited to, the isolated nucleic acid molecules of any one of SEQ ID NOs: 1-70, complementary DNA molecules, sequences having 80% identity as disclosed herein to any one of SEQ ID NOs: 1-70, sequences capable of hybridizing to any one of SEQ ID NOs: 1-70 under conditions disclosed herein, and corresponding RNA molecules.  
     [0071] As used herein, “nucleic acid” and “nucleic acid molecule” refer to any of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acids can comprise monomers that are naturally occurring nucleotides (such as deoxyribonucleotides and ribonucleotides), or analogs of naturally occurring nucleotides (e.g., α-enantiomeric forms of naturally occurring nucleotides), or a combination of both. Modified nucleotides can have modifications in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups. Sugars can also be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of phosphodiester bonds. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like.  
     [0072] Unless otherwise indicated, a particular nucleotide sequence also implicitly encompasses complementary sequences, subsequences, elongated sequences, as well as the sequence explicitly indicated. The terms “nucleic acid molecule” or “nucleotide sequence” can also be used in place of “gene”, “cDNA”, or “mRNA”. Nucleic acids can be derived from any source, including any organism. In one embodiment, a nucleic acid is derived from a biological sample isolated from a subject.  
     [0073] The term “subsequence” refers to a sequence of nucleic acids that comprises a part of a longer nucleic acid sequence. An exemplary subsequence is a probe, or a primer. The term “primer” as used herein refers to a contiguous sequence comprising in one example about 8 or more deoxyribonucleotides or ribonucleotides, in another example 10-20 nucleotides, and in yet another example 20-30 nucleotides of a selected nucleic acid molecule. The primers disclosed herein encompass oligonucleotides of sufficient length and appropriate sequence so as to provide initiation of polymerization on a target nucleic acid molecule.  
     [0074] The term “elongated sequence” refers to an addition of nucleotides (or other analogous molecules) incorporated into the nucleic acid. For example, a polymerase (e.g., a DNA polymerase) can add sequences at the 3′ terminus of the nucleic acid molecule. In addition, the nucleotide sequence can be combined with other DNA sequences, such as promoters, promoter regions, enhancers, polyadenylation signals, intronic sequences, additional restriction enzyme sites, multiple cloning sites, and other coding segments.  
     [0075] As used herein, the phrases “open reading frame” and “ORF” are given their common meaning and refer to a contiguous series of deoxyribonucleotides or ribonucleotides that encode a polypeptide or a fragment of a polypeptide. In an organism that splices precursor RNAs to form mRNAs, the ORF will be discontinuous in the genome. Splicing produces a continuous ORF that can be translated to produce a polypeptide. In a full-length cDNA, the complete ORF includes those nucleic acid sequences beginning with the start codon and ending with the stop codon. In a cDNA molecule that is not full-length, the ORF includes those nucleic acid sequences present in the non-full-length cDNA that are included within the complete ORF of the corresponding full-length cDNA.  
     [0076] As used herein, the phrase “coding sequence” is used interchangeably with “open reading frame” and “ORF” and refers to a nucleic acid sequence that is transcribed into RNA including, but not limited to mRNA, rRNA, tRNA, snRNA, sense RNA, or antisense RNA. The RNA can then be translated in vitro or in vivo to produce a protein.  
     [0077] The terms “complementary” and “complementary sequences”, as used herein, refer to two nucleotide sequences that comprise antiparallel nucleotide sequences capable of pairing with one another upon formation of hydrogen bonds between base pairs. As used herein, the term “complementary sequences” means nucleotide sequences which are substantially complementary, as can be assessed by the same nucleotide comparison set forth herein, or is defined as being capable of hybridizing to the nucleic acid segment in question under relatively stringent conditions such as those described herein. In one embodiment, a complementary sequence is at least 80% complementary to the nucleotide sequence with which is it capable of pairing. In another embodiment, a complementary sequence is at least 85% complementary to the nucleotide sequence with which is it capable of pairing. In another embodiment, a complementary sequence is at least 90% complementary to the nucleotide sequence with which is it capable of pairing. In another embodiment, a complementary sequence is at least 95% complementary to the nucleotide sequence with which is it capable of pairing. In another embodiment, a complementary sequence is at least 98% complementary to the nucleotide sequence with which is it capable of pairing. In another embodiment, a complementary sequence is at least 99% complementary to the nucleotide sequence with which is it capable of pairing. In still another embodiment, a complementary sequence is at 100% complementary to the nucleotide sequence with which is it capable of pairing. A particular example of a complementary nucleic acid segment is an antisense oligonucleotide.  
     [0078] The term “gene” refers broadly to any segment of DNA associated with a biological function. A gene encompasses sequences including, but not limited to a coding sequence, a promoter region, a transcriptional regulatory sequence, a non-expressed DNA segment that is a specific recognition sequence for regulatory proteins, a non-expressed DNA segment that contributes to gene expression, a DNA segment designed to have desired parameters, or combinations thereof. A gene can be obtained by a variety of methods, including isolation or cloning from a biological sample, synthesis based on known or predicted sequence information, and recombinant derivation of an existing sequence.  
     [0079] As used herein, the terms “known gene” and “reference gene” are used interchangeably and refer to nucleic acid sequences that can be identified as corresponding to a particular expressed sequence tag (EST), partial cDNA, full-length cDNA, or gene. In one embodiment, a reference gene is a gene, a cDNA, or an EST for which the nucleic acid sequence has been determined (i.e. is known). In another embodiment, a reference gene is represented by one of the nucleic acid sequences disclosed in SEQ ID NOs: 1-70. In another embodiment, a reference gene is represented by a nucleic acid sequence complementary to one of the nucleic acid sequences disclosed in SEQ ID NOs: 1-70. In another embodiment, a reference gene is represented by a nucleic acid sequence having 80% identity to any one of SEQ ID NOs: 1-70. In another embodiment, a reference gene is represented by a nucleic acid sequence capable of hybridizing to any one of SEQ ID NOs: 1-70 under conditions disclosed herein. In another embodiment, a reference gene is represented by an RNA molecule corresponding to any one of SEQ ID NOs: 1-70. In another embodiment, a reference gene is represented by a nucleic acid sequence present on an array.  
     [0080] As used herein, the terms “corresponding to” and “representing”, “represented by” and grammatical derivatives thereof, when used in the context of a nucleic acid sequence corresponding to or representing a gene, refers to a nucleic acid sequence that results from transcription, reverse transcription, or replication from a particular genetic locus, gene, or gene product (for example, an mRNA). In other words, an EST, partial cDNA, or full-length cDNA corresponding to a particular reference gene is a nucleic acid sequence that one of ordinary skill in the art would recognize as being a product of either transcription or replication of that reference gene (for example, a product produced by transcription of the reference gene). One of ordinary skill in the art would understand that the EST, partial cDNA, or full- length cDNA itself is produced by in vitro manipulation to convert the mRNA into an EST or cDNA, for example by reverse transcription of an isolated RNA molecule that was transcribed from the reference gene. One of ordinary skill in the art will also understand that the product of a reverse transcription is a double-stranded DNA molecule, and that a given strand of that double-stranded molecule can embody either the coding strand or the non-coding strand of the gene. The sequences presented in the Sequence Listing are single-stranded, however, and it is to be understood that the presently claimed subject matter is intended to encompass the genes represented by the sequences presented in SEQ ID NOs: 1-70, including the specific sequences set forth as well as the reverse/complement of each of these sequences.  
     [0081] A known gene and/or reference gene also includes, but is not limited to those genes that have been identified as being differentially expressed in autoimmune patients versus normal patients, such as but not limited to those set forth in Table 1. A reference gene is also intended to include nucleic acid sequences that substantially hybridize to one of such genes, including but not limited to one of the nucleic acid sequences disclosed in SEQ ID NOs: 1-70. As such, a reference gene includes a nucleic acid sequence that has one or more polymorphisms such that while the particular nucleic acid sequence might diverge somewhat from one of such genes, including but not limited to one of those disclosed in SEQ ID NOs: 1-70, one of ordinary skill in the art would nonetheless recognize the particular nucleic acid sequence as corresponding to a gene represented by one of such genes, including but not limited to one of the sequences disclosed in SEQ ID NOs: 1-70. For example, the GenBank database has at least three accession numbers that are identified as corresponding to the human breast cancer 1, early onset (BRCA1) mRNA. These three represent transcript variants a, a′, and b, and have accession numbers NM — 007294, NM — 007296, and NM — 007295, respectively. It is understood that the presently claimed subject matter, which identifies NM — 007294 as SEQ ID NO: 56, also encompasses the other transcript variants.  
     [0082] In the context of the presently claimed subject matter, a reference gene is also intended to include nucleic acid sequences that substantially hybridize to a nucleic acid corresponding to a gene represented by one of the nucleic acid sequences disclosed in SEQ ID NOs: 1-70. As such, a reference gene includes a nucleic acid sequence that has one or more polymorphisms such that while the particular nucleic acid sequence might diverge somewhat from those disclosed in SEQ ID NOs: 1-70, one of ordinary skill in the art would nonetheless recognize the particular nucleic acid sequence as corresponding to a gene represented by one of the sequences disclosed in SEQ ID NOs: 1-70.  
     [0083] The term “gene expression” generally refers to the cellular processes by which a biologically active polypeptide is produced from a DNA sequence. Generally, gene expression comprises the processes of transcription and translation, along with those modifications that normally occur in the cell to modify the newly translated protein to an active form and to direct it to its proper subcellular or extracellular location.  
     [0084] The terms “gene expression level” and “expression level” as used herein refer to an amount of gene-specific RNA or polypeptide that is present in a biological sample. When used in relation to an RNA molecule, the term “abundance” can be used interchangeably with the terms “gene expression level” and “expression level”. While an expression level can be expressed in standard units such as “transcripts per cell” for RNA or “nanograms per microgram tissue” for RNA or a polypeptide, it is not necessary that expression level be defined as such. Alternatively, relative units can be employed to describe an expression level. For example, when the assay has an internal control (referred to herein as a “control gene”), which can be, for example, a known quantity of a nucleic acid derived from a gene for which the expression level is either known or can be accurately determined, unknown expression levels of other genes can be compared to the known internal control. More specifically, when the assay involves hybridizing labeled total RNA to a solid support comprising a known amount of nucleic acid derived from known genes, an appropriate internal control could be a housekeeping gene (e.g. glucose-6-phosphate dehydrogenase or elongation factor-1), a ideal housekeeping gene being defined as a gene for which the expression level in all cell types and under all conditions is the same. Use of such an internal control allows relative expression levels to be determined (e.g. relative to the expression of the housekeeping gene) both for the nucleic acids present on the solid support and also between different experiments using the same solid support. This discrete expression level can then be normalized to a value relative to the expression level of the control gene (for example, a housekeeping gene).  
     [0085] As used herein, the term “normalized”, and grammatical derivatives thereof, refers to a manipulation of discrete expression level data wherein the expression level of a reference gene is expressed relative to the expression level of a control gene. For example, the expression level of the control gene can be set at 1, and the expression levels of all reference genes can be expressed in units relative to the expression of the control gene.  
     [0086] The term “average expression level” as used herein refers to the mean expression level, in whatever units are chosen, of a gene in a particular biological sample of a population. To determine an average expression level, a population is defined, and the expression level of the gene in that population is determined for each member of the population by analyzing the same biological sample from each member of the population. The determined expression levels are then added together, and the sum is divided by the number of members in the population.  
     [0087] The term “average expression level” is also used to refer to a calculated value that can be used to compare two populations. For example, the average expression level in a population consisting of all patients regardless of autoimmune disease status can be calculated using the method above for a population that consists of statistically significant numbers of patients with and without autoimmune disease (the latter can also be referred to as the “unaffected subpopulation”). However, when the population is made up of unequal numbers of patients with and without autoimmune disease, the calculated value for all genes differentially expressed in these two subpopulations will likely be skewed towards the expression level determined for the subpopulation having the greater number of members. In order to remove this skewing effect, the average expression level in the described population can also be calculated by: (a) determining the average expression level of a gene in the autoimmune patient subpopulation; (b) determining the average expression level of the same gene in the unaffected subpopulation; (c) adding the two determined values together; and (d) dividing the sum of the two determined values by 2 to achieve a value: this value also being defined herein as an “average expression level”.  
     [0088] Once an expression level is determined for a gene, a profile can be created. As used herein, the term “profile” refers to a repository of the expression level data that can be used to compare the expression levels of different genes among various subjects. For example, for a given subject, the term “profile” can encompass the expression levels of all genes detected in whatever units (as described herein above) are chosen.  
     [0089] The term “profile” is also intended to encompass manipulations of the expression level data derived from a subject. For example, once relative expression levels are determined for a given set of genes in a subject, the relative expression levels for that subject can be compared to a standard to determine if the expression levels in that subject are higher or lower than for the same genes in the standard. Standards can include any data deemed to be relevant for comparison. In one embodiment, a standard is prepared by determining the average expression level of a gene in a normal population, a normal population being defined as subjects that do not have autoimmune disease. In another embodiment, a standard is prepared by determining the average expression level of a gene in a population of subjects that have an autoimmune disease (for example, RA, MS, IDDM, and/or SLE). In a third embodiment, a standard is prepared by determining the average expression level of a gene in the population as a whole (i.e. subjects are grouped together irrespective of autoimmune disease status). In yet another embodiment, a standard is prepared by determining the average expression level of a gene in a normal population, the average expression level of a gene in an autoimmune population, adding those two values, and dividing the sum by two to determine the midpoint of the average expression in these populations. In this latter embodiment, a profile for a “new” subject can be compared to the standard, and the profile can further comprise data indicating whether for each gene, the expression level in the new subject is higher or lower than the expression level of that gene in the standard. For example, a new subject&#39;s profile can comprise a score of “1” for each gene for which the expression in the subject is higher than in the standard, and a score of “0” for each gene for which the expression in the subject is lower than in the standard. In this way, a profile can comprise an overall “score”, the score being defined as the sum total of all the ones and zeroes present in the profile. These scores can then be used to predict the presence or absence of autoimmune disease in the new subject. It is understood that the use of 1s and 0s is exemplary only, and any convenient value can be assigned in the practice of the methods of the presently claimed subject matter.  
     [0090] The term “isolated”, as used in the context of a nucleic acid molecule, indicates that the nucleic acid molecule exists apart from its native environment and is not a product of nature. An isolated DNA molecule can exist in a purified form or can exist in a non-native environment such as, for example, in a host cell transformed with a vector comprising the DNA molecule.  
     [0091] The phrases “percent identity” and “percent identical,” in the context of two nucleic acid or protein sequences, refer to two or more sequences or subsequences that have in one embodiment at least 60%, in another embodiment at least 70%, in another embodiment at least 80%, in another embodiment at least 85%, in another embodiment at least 90%, in another embodiment at least 95%, in another embodiment at least 98%, and in yet another embodiment at least 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. The percent identity exists in one embodiment over a region of the sequences that is at least about 50 residues in length, in another embodiment over a region of at least about 100 residues, and in still another embodiment the percent identity exists over at least about 150 residues. In yet another embodiment, the percent identity exists over the entire length of a given region, such as a coding region. In one embodiment, a nucleic acid is at least 80% identical to one of SEQ ID NOs: 1-70.  
     [0092] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.  
     [0093] Optimal alignment of sequences for comparison can be conducted, for example, by the local homology algorithm described in Smith &amp; Waterman 1981, by the homology alignment algorithm described in Needleman &amp; Wunsch 1970, by the search for similarity method described in Pearson &amp; Lipman 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin Package, available from Accelrys, Inc., San Diego, Calif., United States of America), or by visual inspection. See generally, Ausubel et al., 1994.  
     [0094] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., 1990. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., 1990). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always&gt;0) and N (penalty score for mismatching residues; always&lt;0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=−4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix. See Henikoff &amp; Henikoff 1989.  
     [0095] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences. See e.g., Karlin &amp; Altschul 1993. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is in one embodiment less than about 0.1, in another embodiment less than about 0.01, and in still another embodiment less than about 0.001.  
     [0096] The term “substantially identical”, in the context of two nucleotide sequences, refers to two or more sequences or subsequences that have in one embodiment at least about 80% nucleotide identity, in another embodiment at least about 85% nucleotide identity, in another embodiment at least about 90% nucleotide identity, in another embodiment at least about 95% nucleotide identity, in another embodiment at least about 98% nucleotide identity, and in yet another embodiment at least about 99% nucleotide identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. In one example, the substantial identity exists in nucleotide sequences of at least 50 residues, in another example in nucleotide sequence of at least about 100 residues, in another example in nucleotide sequences of at least about 150 residues, and in yet another example in nucleotide sequences comprising complete coding sequences. In one aspect, polymorphic sequences can be substantially identical sequences. The term “polymorphic” refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. An allelic difference can be as small as one base pair. Nonetheless, one of ordinary skill in the art would recognize that the polymorphic sequences correspond to the same gene. For example, SEQ ID NO: 1-70 is an EST derived from the human TP53 gene. The human TP53 complete cDNA sequence (SEQ ID NO: 16) is present in the GenBank database under Accession Number NM — 000546, and according to the description presented therein, the TP53 gene is characterized by polymorphisms at nucleotide positions 390, 466, 1470, 1927, 1950, 1976, 1977, 2075, 2076, 2497, and 2498. Nucleic acid sequences comprising any or all of these polymorphisms are substantially identical to SEQ ID NO: 1-70, and thus are intended to be encompassed within the claimed subject matter.  
     [0097] Another indication that two nucleotide sequences are substantially identical is that the two molecules specifically or substantially hybridize to each other under stringent conditions. In the context of nucleic acid hybridization, two nucleic acid sequences being compared can be designated a “probe sequence” and a “target sequence”. A “probe sequence” is a reference nucleic acid molecule, and a “target sequence” is a test nucleic acid molecule, often found within a heterogeneous population of nucleic acid molecules. A “target sequence” is synonymous with a “test sequence”.  
     [0098] An exemplary nucleotide sequence employed for hybridization studies or assays includes probe sequences that are complementary to or mimic in one embodiment at least an about 14 to 40 nucleotide sequence of a nucleic acid molecule of the presently claimed subject matter. In one example, probes comprise 14 to 20 nucleotides, or even longer where desired, such as 30, 40, 50, 60, 100, 200, 300, or 500 nucleotides or up to the full length of any of the genes represented by SEQ ID NOs: 1-70. Such fragments can be readily prepared by, for example, directly synthesizing the fragment by chemical synthesis, by application of nucleic acid amplification technology, or by introducing selected sequences into recombinant vectors for recombinant production. The phrase “hybridizing specifically to” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex nucleic acid mixture (e.g., total cellular DNA or RNA).  
     [0099] The phrase “hybridizing substantially to” refers to complementary hybridization between a probe nucleic acid molecule and a target nucleic acid molecule and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired hybridization.  
     [0100] “Stringent hybridization conditions” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and Northern blot analysis are both sequence- and environment-dependent. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, 1993. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. Typically, under “stringent conditions” a probe will hybridize specifically to its target subsequence, but to no other sequences.  
     [0101] The T m  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the T m  for a particular probe. An example of stringent hybridization conditions for Southern or Northern Blot analysis of complementary nucleic acids having more than about 100 complementary residues is overnight hybridization in 50% formamide with 1 mg of heparin at 42° C. An example of highly stringent wash conditions is 15 minutes in 0.1×SSC, SM NaCl at 65° C. An example of stringent wash conditions is 15 minutes in 0.2×SSC buffer at 65° C. (see Sambrook and Russell, 2001, for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example of medium stringency wash conditions for a duplex of more than about 100 nucleotides is 15 minutes in 1×SSC at 45° C. An example of low stringency wash for a duplex of more than about 100 nucleotides is 15 minutes in 4-6×SSC at 40° C. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1M Na +  ion, typically about 0.01 to 1M Na +  ion concentration (or other salts) at pH 7.0-8.3, and the temperature is typically at least about 30° C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2-fold (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.  
     [0102] The following are examples of hybridization and wash conditions that can be used to clone homologous nucleotide sequences that are substantially identical to reference nucleotide sequences of the presently claimed subject matter: a probe nucleotide sequence hybridizes in one example to a target nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5M NaPO 4 , 1 mm EDTA at 50° C. followed by washing in 2×SSC, 0.1% SDS at 50° C.; in another example, a probe and target sequence hybridize in 7% SDS, 0.5M NaPO 4 , 1 mm EDTA at 50° C. followed by washing in 1×SSC, 0.1% SDS at 50° C.; in another example, a probe and target sequence hybridize in 7% SDS, 0.5M NaPO 4 , 1 mm EDTA at 50° C. followed by washing in 0.5×SSC, 0.1% SDS at 50° C.; in another example, a probe and target sequence hybridize in 7% SDS, 0.5M NaPO 4 , 1 mm EDTA at 50° C. followed by washing in 0.1×SSC, 0.1% SDS at 50° C.; in yet another example, a probe and target sequence hybridize in 7% SDS, 0.5M NaPO 4 , 1 mm EDTA at 50° C. followed by washing in 0.1×SSC, 0.1% SDS at 65° C. In one embodiment, hybridization conditions comprise hybridization in a roller tube for at least 12 hours at 42° C.  
     [0103] Pre-made hybridization solutions are also commercially available from various suppliers. In one embodiment, a hybridization solution comprises MICROHYB™ (RESGEN™), and in another embodiment a hybridization solution comprises MICROHYB™ further comprising 5.0 μg COT-1® DNA (Invitrogen Corporation, Carlsbad, Calif., United States of America) and 5.0 μg poly-dA. In one embodiment, post-hybridization wash conditions comprise two washes in 2×SSC/1% SDS at 50° C. for 20 minutes each followed by a third wash in 0.5×SSC/1% SDS at 55° C. for 15 minutes.  
     [0104] As used herein, the term “purified”, when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It can be in a homogeneous state although it also can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. The term “purified” denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is in one embodiment at least about 50% pure, in another embodiment at least about 85% pure, and in still another embodiment at least about 99% pure.  
     [0105] I.B. Biological Samples  
     [0106] The presently claimed subject matter provides methods that can be used to detect the expression level of a gene in a biological sample. The term “biological sample” as used herein refers to a sample that comprises a biomolecule that permits the expression level of a gene to be determined. Representative biomolecules include, but are not limited to total RNA, mRNA, and polypeptides. As such, a biological sample can comprise a cell or a group of cells. Any cell or group of cells can be used with the methods of the presently claimed subject matter, although cell-types and organs that would be predicted to show differential gene expression in subjects with autoimmune disease versus normal subjects are best suited. In one embodiment, gene expression levels are determined where the biological sample comprises PBMCs. In one embodiment, the biological sample comprises one or more of the constituent cell types that make up a PBMC preparation, including but not limited to T cells, B cells, monocytes, and NK/NKT cells. A representative PMBC preparation can comprise about 75% T cells, about 5% to about 10% B cells, about 5% to about 10% monocytes, and a small percentage of NK/NKT cells. In another embodiment, the biological sample comprises epithelial cells, such as cheek epithelial cells. Also encompassed within the phrase “biological sample” are biomolecules that are derived from a cell or group of cells that permit gene expression levels to be determined, e.g. nucleic acids and polypeptides.  
     [0107] The expression level of the gene can be determined using molecular biology techniques that are well known in the art. For example, if the expression level is to be determined by analyzing RNA isolated from the biological sample, techniques for determining the expression level include, but are not limited to Northern blotting, quantitative PCR, and the use of nucleic acid arrays and microarrays.  
     [0108] In one embodiment, the expression level of a gene is determined by hybridizing  33 P-labeled cDNA generated from total RNA isolated from a biological sample to one or more DNA sequences representing one or more genes that has been affixed to a solid support, e.g. a membrane. When a membrane comprises nucleic acids representing many genes (including internal controls), the relative expression level of many genes can be determined. The presence of internal control sequences on the membrane also allows experiment-to-experiment variations to be detected, yielding a strategy whereby the raw expression data derived from each experiment can be compared from experiment-to-experiment.  
     [0109] Alternatively, gene expression can be determined by analyzing protein levels in a biological sample using antibodies. Representative antibody-based techniques include, but are not limited to immunoprecipitation, Western blotting, and the use of immunoaffinity columns.  
     [0110] The term “subject” as used herein refers to any vertebrate species. The methods of the presently claimed subject matter are particularly useful in the diagnosis of warm-blooded vertebrates. Thus, the presently claimed subject matter concerns mammals. More particularly contemplated is the diagnosis of mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also contemplated is the diagnosis of autoimmune disease in livestock, including, but not limited to domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.  
     [0111] II. Isolation and Analysis of Nucleic Acids  
     [0112] II.A. Enrichment of Nucleic Acids  
     [0113] The presently claimed subject matter encompasses use of a sufficiently large biological sample to enable a comprehensive survey of low abundance nucleic acids in the sample. Thus, the sample can optionally be concentrated prior to isolation of nucleic acids. Several protocols for concentration have been developed that alternatively use slide supports (Kohsaka &amp; Carson 1994; Millar et al., 1995), filtration columns (Bej et a/., 1991), or immunomagnetic beads (Albert et al., 1992; Chiodi et al., 1992). Such approaches can significantly increase the sensitivity of subsequent detection methods.  
     [0114] As one example, SEPHADEX® matrix (Sigma, St. Louis, Mo., United States of America) is a matrix of diatomaceous earth and glass suspended in a solution of chaotropic agents and has been used to bind nucleic acid material (Boom et al., 1990; Buffone et al., 1991). After the nucleic acid is bound to the solid support material, impurities and inhibitors are removed by washing and centrifugation, and the nucleic acid is then eluted into a standard buffer. Target capture also allows the target sample to be concentrated into a minimal volume, facilitating the automation and reproducibility of subsequent analyses (Lanciotti et al., 1992).  
     [0115] II.B. Nucleic Acid Isolation  
     [0116] Methods for nucleic acid isolation can comprise simultaneous isolation of total nucleic acid, or separate and/or sequential isolation of individual nucleic acid types (e.g., genomic DNA, cDNA, organelle DNA, genomic RNA, mRNA, polyA +  RNA, rRNA, tRNA) followed by optional combination of multiple nucleic acid types into a single sample.  
     [0117] When total RNA or purified mRNA is selected as a biological sample, the disclosed method enables an assessment of a level of gene expression. For example, detecting a level of gene expression in a biological sample can comprise determination of the abundance of a given mRNA species in the biological sample.  
     [0118] RNA isolation methods are known to one of skill in the art. See Albert et al., 1992; Busch et al., 1992; Hamel et al., 1995; Herrewegh et al., 1995; Izraeli et al., 1991; McCaustland et al., 1991; Natarajan et al., 1994; Rupp et al., 1988; Tanaka et al., 1994; Vankerckhoven et al., 1994. A representative procedure for RNA isolation from a biological sample is set forth in Example 2.  
     [0119] Simple and semi-automated extraction methods can also be used for nucleic acid isolation, including for example, the SPLIT SECOND™ system (Boehringer Mannheim, Indianapolis, Ind., United States of America), the TRIZOL™ Reagent system (Life Technologies, Gaithersburg, Md., United States of America), and the FASTPREP™ system (Bio 101, La Jolla, Calif., United States of America). See also Paladichuk 1999.  
     [0120] Nucleic acids that are used for subsequent amplification and labeling can be analytically pure as determined by spectrophotometric measurements or by visual inspection following electrophoretic resolution. The nucleic acid sample can be free of contaminants such as polysaccharides, proteins, and inhibitors of enzyme reactions. When an RNA sample is intended for use as probe, it can be free of nuclease contamination. Contaminants and inhibitors can be removed or substantially reduced using resins for DNA extraction (e.g., CHELEX™ 100 from BioRad Laboratories, Hercules, Calif., United States of America) or by standard phenol extraction and ethanol precipitation. Isolated nucleic acids can optionally be fragmented by restriction enzyme digestion or shearing prior to amplification.  
     [0121] II.C. (PCR Amplification of Nucleic Acids  
     [0122] The terms “template nucleic acid” and “target nucleic acid” as used herein each refers to nucleic acids isolated from a biological sample as described herein above. The terms “template nucleic acid pool”, “template pool”, “target nucleic acid pool”, and “target pool” each refers to an amplified sample of “template nucleic acid”. Thus, a target pool comprises amplicons generated by performing an amplification reaction using the template nucleic acid. In one embodiment, a target pool is amplified using a random amplification procedure as described herein.  
     [0123] The term “target-specific primer” refers to a primer that hybridizes selectively and predictably to a target sequence, for example a sequence that shows differential expression in a patient with an autoimmune disease relative to a normal patient, in a target nucleic acid sample. A target-specific primer can be selected or synthesized to be complementary to known nucleotide sequences of target nucleic acids.  
     [0124] The term “random primer” refers to a primer having an arbitrary sequence. The nucleotide sequence of a random primer can be known, although such sequence is considered arbitrary in that it is not designed for complementarity to a nucleotide sequence of the target-specific probe. The term “random primer” encompasses selection of an arbitrary sequence having increased probability to be efficiently utilized in an amplification reaction. For example, the Random Oligonucleotide Construction Kit (ROCK; available from http://www.sru.edu/depts/artsci/bio/ROCK.htm) is a macro-based program that facilitates the generation and analysis of random oligonucleotide primers (Strain &amp; Chmielewski 2001). Representative primers include, but are not limited to random hexamers and rapid amplification of polymorphic DNA (RAPD)-type primers as described in Williams et al., 1990.  
     [0125] A random primer can also be degenerate or partially degenerate as described in Telenius et al., 1992. Briefly, degeneracy can be introduced by selection of alternate oligonucleotide sequences that can encode a same amino acid sequence.  
     [0126] In one embodiment, random primers can be prepared by shearing or digesting a portion of the template nucleic acid sample. Random primers so-constructed comprise a sample-specific set of random primers.  
     [0127] The term “heterologous primer” refers to a primer complementary to a sequence that has been introduced into the template nucleic acid pool. For example, a primer that is complementary to a linker or adaptor is a heterologous primer. Representative heterologous primers can optionally include a poly(dT) primer, a poly(T) primer, or as appropriate, a poly(dA) primer or a poly(A) primer.  
     [0128] The term “primer” as used herein refers to a contiguous sequence comprising in one embodiment about 6 or more nucleotides, in another embodiment about 10-20 nucleotides (e.g. 15-mer), and in still another embodiment about 20-30 nucleotides (e.g. a 22-mer). Primers used to perform the method of the presently claimed subject matter encompass oligonucleotides of sufficient length and appropriate sequence so as to provide initiation of polymerization on a nucleic acid molecule.  
     [0129] II.C.1. Quantitative RT-PCR  
     [0130] In one embodiment of the presently claimed subject matter, the abundance of specific mRNA species present in a biological sample (for example, mRNA extracted from peripheral blood mononuclear cells) is assessed by quantitative RT-PCR. In this embodiment, standard molecular biological techniques are used in conjunction with specific PCR primers to quantitatively amplify those mRNA molecules corresponding to the genes of interest. Methods for designing specific PCR primers and for performing quantitative amplification of nucleic acids including mRNA are well known in the art. See e.g. Sambrook &amp; Russell, 2001; Vandesompele et al., 2002; Joyce 2002.  
     [0131] II.C.2. Amplified Antisense RNA (aaRNA)  
     [0132] Several procedures have been developed specifically for random amplification of RNA, including but not limited to Amplified Antisense RNA (aaRNA) and Global RNA Amplification, also described further herein below. A population of RNA can be amplified using a technique referred to as Amplified Antisense RNA (aaRNA). See Van Gelder et al., 1990; Wang et al., 2000. Briefly, an oligo(dT) primer is synthesized such that the 5′ end of the primer includes a T7 RNA polymerase promoter. This oligonucleotide can be used to prime the poly(A) +  mRNA population to generate cDNA. Following first strand cDNA synthesis, second strand cDNA is generated using RNA nicking and priming (Sambrook &amp; Russell 2001). The resulting cDNA is treated briefly with S1 nuclease and blunt-ended with T4 DNA polymerase. The cDNA is then used as a template for transcription-based amplification using the T7 RNA polymerase promoter to direct RNA synthesis.  
     [0133] Eberwine et al. adapted the aaRNA procedure for in situ random amplification of RNA followed by target-specific amplification. The successful amplification of under represented transcripts suggests that the pool of transcripts amplified by aaRNA is representative of the initial mRNA population (Eberwine et al., 1992).  
     [0134] II.C.3. Global RNA Amplification  
     [0135] U.S. Pat. No. 6,066,457 to Hampson et al. describes a method for substantially uniform amplification of a collection of single stranded nucleic acid molecules such as RNA. Briefly, the nucleic acid starting material is anchored and processed to produce a mixture of directional shorter random size DNA molecules suitable for amplification of the sample.  
     [0136] In accordance with the methods of the presently claimed subject matter, any one of the above-mentioned PCR techniques or related techniques can be employed to perform the step of amplifying the nucleic acid sample. In addition, such methods can be optimized for amplification of a particular subset of nucleic acid (e.g., specific mRNA molecules versus total mRNA), and representative optimization criteria and related guidance can be found in the art. See Cha &amp; Thilly 1993; Linz et al., 1990; Robertson &amp; Walsh-Weller 1998; Roux 1995; Williams 1989; McPherson et al., 1995.  
     [0137] II.C.4. Kits for Gene Expression Analysis  
     [0138] The presently claimed subject matter also provides for kits comprising a plurality of oligonucleotide primers that can be used in the methods of the presently claimed subject matter to assess gene expression levels of genes of interest. In non-limiting embodiments, the kit can comprise oligonucleotide primers designed to be used to determine the expression level of one or more (e.g. 1, 5, 10, 20, 30, or all) of the genes set forth in SEQ ID NOs: 1-70. Additionally, the kit can comprise instructions for using the primers, including but not limited to information regarding proper reaction conditions and the sizes of the expected amplified fragments.  
     [0139] III. Nucleic Acid Labeling  
     [0140] In one embodiment, the expression level of a gene in a biological sample is determined by hybridizing total RNA isolated from the biological sample to an array containing known quantities of nucleic acid sequences corresponding to known genes. For example, the array can comprise single-stranded nucleic acids (also referred to herein as “probes” and/or “probe sets”) in known amounts for specific genes, which can then be hybridized to nucleic acids isolated from the biological sample. The array can be set up such that the nucleic acids are present on a solid support in such a manner as to allow the identification of those genes on the array to which the total RNA hybridizes. In this embodiment, the total RNA is hybridized to the array, and the genes to which the total RNA hybridizes are detected using standard techniques. In one embodiment of the presently claimed subject matter, the amplified nucleic acids are labeled with a radioactive nucleotide prior to hybridization to the array, and the genes on the array to which the RNA hybridizes are detected by autoradiography or phosphorimage analysis.  
     [0141] Alternatively, nucleic acids isolated from a biological sample are hybridized with a set of probes without prior labeling of the nucleic acids. For example, unlabeled total RNA isolated from the biological sample can be detected by hybridization to one or more labeled probes, the labeled probes being specific for those genes found to be useful in the methods of the presently claimed subject matter (e.g. those genes represented by SEQ ID NOs: 1-70). In another embodiment, both the nucleic acids and the one or more probes include a label, wherein the proximity of the labels following hybridization enables detection. An exemplary procedure using nucleic acids labeled with chromophores and fluorophores to generate detectable photonic structures is described in U.S. Pat. No. 6,162,603.  
     [0142] The nucleic acids or probes/probe sets can be labeled using any detectable label. It will be understood to one of skill in the art that any suitable method for labeling can be used, and no particular detectable label or technique for labeling should be construed as a limitation of the disclosed methods.  
     [0143] Direct labeling techniques include incorporation of radioisotopic (e.g.  32 P,  33 P, or  35 S) or fluorescent nucleotide analogues into nucleic acids by enzymatic synthesis in the presence of labeled nucleotides or labeled PCR primers. A radio-isotopic label can be detected using autoradiography or phosphorimaging. A fluorescent label can be detected directly using emission and absorbance spectra that are appropriate for the particular label used. Any detectable fluorescent dye can be used, including but not limited to fluorescein isothiocyanate (FITC), FLUOR X™, ALEXA FLUOR® 488, OREGON GREEN® 488, 6-JOE (6-carboxy-4′,5′-dichloro-2′, 7′-dimethoxyfluorescein, succinimidyl ester), ALEXA FLUOR® 532, Cy3, ALEXA FLUOR® 546, TMR (tetramethylrhodamine), ALEXA FLUOR® 568, ROX (X-rhodamine), ALEXA FLUOR® 594, TEXAS RED®, BODIPY® 630/650, and Cy5 (available from Amersham Pharmacia Biotech, Piscataway, N.J., United States of America, or from Molecular Probes Inc., Eugene, Oreg., United States of America). Fluorescent tags also include sulfonated cyanine dyes (available from Li-Cor, Inc., Lincoln, Nebr., United States of America) that can be detected using infrared imaging. Methods for direct labeling of a heterogeneous nucleic acid sample are known in the art and representative protocols can be found in, for example, DeRisi et al., 1996; Sapolsky &amp; Lipshutz 1996; Schena et al., 1995; Schena et al., 1996; Shalon et al., 1996; Shoemaker et al., 1996; Wang et al., 1998. A representative procedure is set forth herein as Example 6.  
     [0144] Indirect labeling techniques can also be used in accordance with the methods of the presently claimed subject matter, and in some cases, can facilitate detection of rare target sequences by amplifying the label during the detection step. Indirect labeling involves incorporation of epitopes, including recognition sites for restriction endonucleases, into amplified nucleic acids prior to hybridization with a set of probes. Following hybridization, a protein that binds the epitope is used to detect the epitope tag.  
     [0145] In one embodiment, a biotinylated nucleotide can be included in the amplification reactions to produce a biotin-labeled nucleic acid sample. Following hybridization of the biotin-labeled sample with probes as described herein, the label can be detected by binding of an avidin-conjugated fluorophore, for example streptavidin-phycoerythrin, to the biotin label. Alternatively, the label can be detected by binding of an avidin-horseradish peroxidase (HRP) streptavidin conjugate, followed by colorimetric detection of an HRP enzymatic product.  
     [0146] The quality of probe or nucleic acid sample labeling can be approximated by determining the specific activity of label incorporation. For example, in the case of a fluorescent label, the specific activity of incorporation can be determined by the absorbance at 260 nm and 550 nm (for Cy3) or 650 nm (for Cy5) using published extinction coefficients (Randolph &amp; Waggoner 1995). Very high label incorporation (specific activities of &gt;1 fluorescent molecule/20 nucleotides) can result in a decreased hybridization signal compared with probe with lower label incorporation. Very low specific activity (&lt;1 fluorescent molecule/100 nucleotides) can give unacceptably low hybridization signals. See Worley et al., 2000. Thus, it will be understood to one of skill in the art that labeling methods can be optimized for performance in various hybridization assays, and that optimal labeling can be unique to each label type.  
     [0147] IV. Microarrays  
     [0148] In one embodiment of the presently claimed subject matter, nucleic acids isolated from a biological sample are hybridized to a microarray, wherein the microarray comprises nucleic acids corresponding to those genes to be tested as well as internal control genes. The genes are immobilized on a solid support, such that each position on the support identifies a particular gene. Solid supports include, but are not limited to nitrocellulose and nylon membranes. Solid supports can also be glass or silicon-based (i.e. gene “chips”). Any solid support can be used in the methods of the presently claimed subject matter, so long as the support provides a substrate for the localization of a known amount of a nucleic acid in a specific position that can be identified subsequent to the hybridization and detection steps. In one embodiment, a microarray comprises a nylon membrane (for example, the GF211 Human “Named Genes” GENEFILTERS® Microarrays Release 1 available from RESGEN™).  
     [0149] A microarray can be assembled using any suitable method known to one of skill in the art, and any one microarray configuration or method of construction is not considered to be a limitation of the presently claimed subject matter. Representative microarray formats that can be used in accordance with the methods of the presently claimed subject matter are described herein below.  
     [0150] IV.A. Array Substrate and Configuration  
     [0151] The substrate for printing the array should be substantially rigid and amenable to DNA immobilization and detection methods (e.g., in the case of fluorescent detection, the substrate must have low background fluorescence in the region of the fluorescent dye excitation wavelengths). The substrate can be nonporous or porous as determined most suitable for a particular application. Representative substrates include, but are not limited to a glass microscope slide, a glass coverslip, silicon, plastic, a polymer matrix, an agar gel, a polyacrylamide gel, and a membrane, such as a nylon, nitrocellulose or ANAPORE™ (Whatman, Maidstone, United Kingdom) membrane.  
     [0152] Porous substrates (membranes and polymer matrices) are preferred in that they permit immobilization of relatively large amount of probe molecules and provide a three-dimensional hydrophilic environment for biomolecular interactions to occur (Dubiley et al., 1997; Yershov et al., 1996). A BIOCHIP ARRAYER™ dispenser (Packard Instrument Company, Meriden, Conn., United States of America) can effectively dispense probes onto membranes such that the spot size is consistent among spots whether one, two, or four droplets were dispensed per spot (Englert 2000). The array can also comprise a dot blot or a slot blot.  
     [0153] A microarray substrate for use in accordance with the methods of the presently claimed subject matter can have either a two-dimensional (planar) or a three-dimensional (non-planar) configuration. An exemplary three-dimensional microarray is the FLOW-THRU™ chip (Gene Logic, Inc., Gaithersburg, Md., United States of America), which has implemented a gel pad to create a third dimension. Such a three-dimensional microarray can be constructed of any suitable substrate, including glass capillary, silicon, metal oxide filters, or porous polymers. See Yang et al., 1998; Steel et al., 2000.  
     [0154] Briefly, a FLOW-THRU™ chip (Gene Logic, Inc.) comprises a uniformly porous substrate having pores or microchannels connecting upper and lower faces of the chip. Probes are immobilized on the walls of the microchannels and a hybridization solution comprising sample nucleic acids can flow through the microchannels. This configuration increases the capacity for probe and target binding by providing additional surface relative to two-dimensional arrays. See U.S. Pat. No. 5,843,767.  
     [0155] IV.B. Surface Chemistry  
     [0156] The particular surface chemistry employed is inherent in the microarray substrate and substrate preparation. Immobilization of nucleic acids probes post-synthesis can be accomplished by various approaches, including adsorption, entrapment, and covalent attachment. Preferably, the binding technique does not disrupt the activity of the probe.  
     [0157] For substantially permanent immobilization, covalent attachment is preferred. Since few organic functional groups react with an activated silica surface, an intermediate layer is advisable for substantially permanent probe immobilization. Functionalized organosilanes can be used as such an intermediate layer on glass and silicon substrates (Liu &amp; Hlady 1996; Shriver-Lake 1998). A hetero-bifunctional cross-linker requires that the probe have a different chemistry than the surface, and is preferred to avoid linking reactive groups of the same type. A representative hetero-bifunctional cross-linker comprises gamma-maleimidobutyryloxy-succimide (GMBS) that can bind maleimide to a primary amine of a probe. Procedures for using such linkers are known to one of skill in the art and are summarized in Hermanson 1990. A representative protocol for covalent attachment of DNA to silicon wafers is described in O&#39;Donnell et al., 1997.  
     [0158] When using a glass substrate, the glass should be substantially free of debris and other deposits and have a substantially uniform coating. Pretreatment of slides to remove organic compounds that can be deposited during their manufacture can be accomplished, for example, by washing in hot nitric acid. Cleaned slides can then be coated with 3-aminopropyltrimethoxysilane using vapor-phase techniques. After silane deposition, slides are washed with deionized water to remove any silane that is not attached to the glass and to catalyze unreacted methoxy groups to cross-link to neighboring silane moieties on the slide. The uniformity of the coating can be assessed by known methods, for example electron spectroscopy for chemical analysis (ESCA) or ellipsometry (Ratner &amp; Castner 1997; Schena et al., 1995). See also Worley et al., 2000.  
     [0159] For attachment of probes greater than about 300 base pairs, noncovalent binding is suitable. A representative technique for noncovalent linkage involves use of sodium isothiocyanate (NaSCN) in the spotting solution, as described in Example 7. When using this method, amino-silanized slides can be used since this coating improves nucleic acid binding when compared to bare glass. This method works well for spotting applications that use about 100 ng/μl (Worley et al., 2000).  
     [0160] In the case of nitrocellulose or nylon membranes, the chemistry of nucleic acid binding to these membranes has been well characterized (Southern 1975; Sambrook &amp; Russell 2001). One-such nylon filter array is the GF211 Human “Named Genes” GENEFILTERS® Microarrays Release 1 (available from RESGEN™, a division of Invitrogen Corporation, Calsbad, Calif., United States of America), although other arrays can also be used.  
     [0161] IV.C. Arraying Techniques  
     [0162] A microarray for the detection of gene expression levels in a biological sample can be constructed using any one of several methods available in the art including, but not limited to photolithographic and microfluidic methods, further described herein below. In one embodiment, the method of construction is flexible, such that a microarray can be tailored for a particular purpose.  
     [0163] As is standard in the art, a technique for making a microarray should create consistent and reproducible spots. Each spot can be uniform, and appropriately spaced away from other spots within the configuration. A solid support for use in the presently claimed subject matter comprises in one embodiment about 10 or more spots, in another embodiment about 100 or more spots, in another embodiment about 1,000 or more spots, and in still another embodiment about 10,000 or more spots. In one embodiment, the volume deposited per spot is about 10 picoliters to about 10 nanoliters, and in another embodiment about 50 picoliters to about 500 picoliters. The diameter of a spot is in one embodiment about 50 μm to about 1000 μm, and in another embodiment about 100 μm to about 250 μm.  
     [0164] Light-directed synthesis. This technique was developed by Fodor et al. (Fodor et al., 1991; Fodor et al., 1993; U.S. Pat. No. 5,445,934), and commercialized by Affymetrix, Inc. of Santa Clara, Calif., United States of America. Briefly, the technique uses precision photolithographic masks to define the positions at which single, specific nucleotides are added to growing single-stranded nucleic acid chains. Through a stepwise series of defined nucleotide additions and light-directed chemical linking steps, high-density arrays of defined oligonucleotides are synthesized on a solid substrate. A variation of the method, called Digital Optical Chemistry, employs mirrors to direct light synthesis in place of photolithographic masks (International Publication No. WO 99/63385). This approach is generally limited to probes of about 25 nucleotides in length or less. See also Warrington et al., 2000.  
     [0165] Contact Printing. Several procedures and tools have been developed for printing microarrays using rigid pin tools. In surface contact printing, the pin tools are dipped into a sample solution, resulting in the transfer of a small volume of fluid onto the tip of the pins. Touching the pins or pin samples onto a microarray surface leaves a spot, the diameter of which is determined by the surface energies of the pin, fluid, and microarray surface. Typically, the transferred fluid comprises a volume in the nanoliter or picoliter range.  
     [0166] One common contact printing technique uses a solid pin replicator. A replicator pin is a tool for picking up a sample from one stationary location and transporting it to a defined location on a solid support. A typical configuration for a replicating head is an array of solid pins, generally in an 8 ×12 format, spaced at 9-mm centers that are compatible with 96- and 384-well plates. The pins are dipped into the wells, lifted, moved to a position over the microarray substrate, lowered to touch the solid support, whereby the sample is transferred. The process is repeated to complete transfer of all the samples. See Maier et al., 1994. A recent modification of solid pins involves the use of solid pin tips having concave bottoms, which print more efficiently than flat pins in some circumstances. See Rose 2000.  
     [0167] Solid pins for microarray printing can be purchased, for example, from TeleChem International, Inc. of Sunnyvale, Calif. in a wide range of tip dimensions. The CHIPMAKER™ and STEALTH™ pins from TeleChem contain a stainless steel shaft with a fine point. A narrow gap is machined into the point to serve as a reservoir for sample loading and spotting. The pins have a loading volume of 0.2 μl to 0.6 μl to create spot sizes ranging from 75 μm to 360 μm in diameter.  
     [0168] To permit the printing of multiple arrays with a single sample loading, quill-based et al. tools, including printing capillaries, tweezers, and split pins have been developed. These printing tools hold larger sample volumes than solid pins and therefore allow the printing of multiple arrays following a single sample loading. Quill-based arrayers withdraw a small volume of fluid into a depositing device from a microwell plate by capillary action. See Schena et al., 1995. The diameter of the capillary typically ranges from about 10 μm to about 100 μm. A robot then moves the head with quills to the desired location for dispensing. The quill carries the sample to all spotting locations, where a fraction of the sample is deposited. The forces acting on the fluid held in the quill must be overcome for the fluid to be released. Accelerating and then decelerating by impacting the quill on a microarray substrate accomplishes fluid release. When the tip of the quill hits the solid support, the meniscus is extended beyond the tip and transferred onto the substrate. Carrying a large volume of sample fluid minimizes spotting variability between arrays. Because tapping on the surface is required for fluid transfer, a relatively rigid support, for example a glass slide, is appropriate for this method of sample delivery.  
     [0169] A variation of the pin printing process is the PIN-AND-RING™ technique developed by Genetic MicroSystems Inc. of Woburn, Mass., United States of America. This technique involves dipping a small ring into the sample well and removing it to capture liquid in the ring. A solid pin is then pushed through the sample in the ring, and the sample trapped on the flat end of the pin is deposited onto the surface. See Mace et al., 2000. The PIN-AND-RING™ technique is suitable for spotting onto rigid supports or soft substrates such as agar, gels, nitrocellulose, and nylon. A representative instrument that employs the PIN-AND-RING™ technique is the 417™ Arrayer available from Affymetrix, Inc. of Santa Clara, Calif., United States of America.  
     [0170] Additional procedural considerations relevant to contact printing methods, including array layout options, print area, print head configurations, sample loading, preprinting, microarray surface properties, sample solution properties, pin velocity, pin washing, printing time, reproducibility, and printing throughput are known in the art, and are summarized in Rose 2000.  
     [0171] Noncontact Ink-Jet Printing. A representative method for noncontact ink-jet printing uses a piezoelectric crystal closely apposed to the fluid reservoir. One configuration places the piezoelectric crystal in contact with a glass capillary that holds the sample fluid. The sample is drawn up into the reservoir and the crystal is biased with a voltage, which causes the crystal to deform, squeeze the capillary, and eject a small amount of fluid from the tip. Piezoelectric pumps offer the capability of controllable, fast jetting rates and consistent volume deposition. Most piezoelectric pumps are unidirectional pumps that need to be directly connected, for example by flexible capillary tubing, to a source of sample supply or wash solution. The capillary and jet orifices should be of sufficient inner diameter so that molecules are not sheared. The void volume of fluid contained in the capillary typically ranges from about 100 μl to about 500 μl and generally is not recoverable. See U.S. Pat. No. 5,965,352.  
     [0172] Devices that provide thermal pressure, sonic pressure, or oscillatory pressure on a liquid stream or surface can also be used for ink-jet printing. See Theriault et al., 1999.  
     [0173] Syringe-Solenoid Printing. Syringe-solenoid technology combines a syringe pump with a microsolenoid valve to provide quantitative dispensing of nanoliter sample volumes. A high-resolution syringe pump is connected to both a high-speed microsolenoid valve and a reservoir through a switching valve. For printing microarrays, the system is filled with a system fluid, typically water, and the syringe is connected to the microsolenoid valve. Withdrawing the syringe causes the sample to move upward into the tip. The syringe then pressurizes the system such that opening the microsolenoid valve causes droplets to be ejected onto the surface. With this configuration, a minimum dispense volume is on the order of 4 nl to 8 nl. The positive displacement nature of the dispensing mechanism creates a substantially reliable system. See U.S. Pat. Nos. 5,743,960 and 5,916,524.  
     [0174] Electronic Addressing. This method involves placing charged molecules at specific positions on a blank microarray substrate, for example a NANOCHIP™ substrate (Nanogen Inc., San Diego, Calif., United States of America). A nucleic acid probe is introduced to the microchip, and the negatively-charged probe moves to the selected charged position, where it is concentrated and bound. Serial application of different probes can be performed to assemble an array of probes at distinct positions. See U.S. Pat. No. 6,225,059 and International Publication No. WO 01/23082.  
     [0175] Nanoelectrode Synthesis. An alternative array that can also be used in accordance with the methods of the presently claimed subject matter provides ultra small structures (nanostructures) of a single or a few atomic layers synthesized on a semiconductor surface such as silicon. The nanostructures can be designed to correspond precisely to the three-dimensional shape and electrochemical properties of molecules, and thus can be used to recognize nucleic acids of a particular nucleotide sequence. See U.S. Pat. No. 6,123,819.  
     [0176] V. Hybridization  
     [0177] V.A. General Considerations  
     [0178] The terms “specifically hybridizes” and “selectively hybridizes” each refer to binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex nucleic acid mixture (e.g., total cellular DNA or RNA).  
     [0179] The phrase “substantially hybridizes” refers to complementary hybridization between a probe nucleic acid molecule and a substantially identical target nucleic acid molecule as defined herein. Substantial hybridization is generally permitted by reducing the stringency of the hybridization conditions using art-recognized techniques.  
     [0180] “Stringent hybridization conditions” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments are both sequence- and environment-dependent. Longer sequences hybridize specifically at higher temperatures. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. The T m  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the T m  for a particular probe. Typically, under “stringent conditions” a probe hybridizes specifically to its target sequence, but to no other sequences.  
     [0181] An extensive guide to the hybridization of nucleic acids is found in Tijssen 1993. In general, a signal to noise ratio of 2-fold (or higher) than that observed for a negative control probe in a same hybridization assay indicates detection of specific or substantial hybridization.  
     [0182] It is understood that in order to determine a gene expression level by hybridization, a full-length cDNA need not be employed. To determine the expression level of a gene represented by one of SEQ ID NOs: 1-70, any representative fragment or subsequence of the sequences set forth in SEQ ID NOs: 1-70 can be employed in conjunction with the hybridization conditions disclosed herein. As a result, a nucleic acid sequence used to assay a gene expression level can comprise sequences corresponding to the open reading frame (or a portion thereof), the 5′ untranslated region, and/or the 3′ untranslated region. It is understood that any nucleic acid sequence that allows the expression level of a reference gene to be specifically determined can be employed with the methods and compositions of the presently claimed subject matter.  
     [0183] V.B. Hybridization on a Solid Support  
     [0184] In another embodiment of the presently claimed subject matter, an amplified and labeled nucleic acid sample is hybridized to probes or probe sets that are immobilized on a continuous solid support comprising a plurality of identifying positions.  
     [0185] Representative hybridization conditions are set forth herein. For some high-density glass-based microarray experiments, hybridization at 65° C. is too stringent for typical use, at least in part because the presence of fluorescent labels destabilizes the nucleic acid duplexes (Randolph &amp; Waggoner 1997). Alternatively, hybridization can be performed in a formamide-based hybridization buffer as described in Piétu et al., 1996.  
     [0186] A microarray format can be selected for use based on its suitability for electrochemical-enhanced hybridization. Provision of an electric current to the microarray, or to one or more discrete positions on the microarray facilitates localization of a target nucleic acid sample near probes immobilized on the microarray surface. Concentration of target nucleic acid near arrayed probe accelerates hybridization of a nucleic acid of the sample to a probe. Further, electronic stringency control allows the removal of unbound and nonspecifically bound DNA after hybridization. See U.S. Pat. Nos. 6,017,696 and 6,245,508.  
     [0187] V.C. Hybridization in Solution  
     [0188] In another embodiment of the presently claimed subject matter, an amplified and labeled nucleic acid sample is hybridized to one or more probes in solution. Representative stringent hybridization conditions for complementary nucleic acids having more than about 100 complementary residues are overnight hybridization in 50% formamide with 1 mg of heparin at 42° C. An example of highly stringent wash conditions is 15 minutes in 0.1×SSC, 5M NaCl at 65° C. An example of stringent wash conditions is 15 minutes in 0.2×SSC buffer at 65° C. (See Sambrook &amp; Russell 2001 for a description of SSC buffer). A high stringency wash can be preceded by a low stringency wash to remove background probe signal. An example of medium stringency wash conditions for a duplex of more than about 100 nucleotides, is 15 minutes in 1×SSC at 45° C. An example of low stringency wash for a duplex of more than about 100 nucleotides, is 15 minutes in 4-6×SSC at 40° C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide.  
     [0189] For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1 M Na+ion, typically about 0.01M to 1M Na +  ion concentration (or other salts) at pH 7.0-8.3, and the temperature is typically at least about 30° C.  
     [0190] Optionally, nucleic acid duplexes or hybrids can be captured from the solution for subsequent analysis, including detection assays. For example, in a simple assay, a single probe set is hybridized to an amplified and labeled RNA sample derived from a target nucleic acid sample. Following hybridization, an antibody that recognizes DNA:RNA hybrids is used to precipitate the hybrids for subsequent analysis. The expression level of the gene is determined by detection of the label in the precipitate.  
     [0191] Alternate capture techniques can be used as will be understood to one of skill in the art, for example, purification by a metal affinity column when using probes comprising a histidine tag. As another example, the hybridized sample can be hydrolyzed by alkaline treatment wherein the double-stranded hybrids are protected while non-hybridizing single-stranded template and excess probe are hydrolyzed. The hybrids are then collected using any nucleic acid purification technique for further analysis.  
     [0192] To determine the expression levels of multiple genes simultaneously, probes or probe sets can be distinguished by differential labeling of probes or probe sets. Alternatively, probes or probe sets can be spatially separated in different hybridization vessels. Representative embodiments of each approach are described herein below.  
     [0193] In one embodiment, a probe or probe set having a unique label is prepared for each gene to be analyzed. For example, a first probe or probe set can be labeled with a first fluorescent label, and a second probe or probe set can be labeled with a second fluorescent label. Multi-labeling experiments should consider label characteristics and detection techniques to optimize detection of each label. Representative first and second fluorescent labels are Cy3 and Cy5 (Amersham Pharmacia Biotech, Piscataway, N.J., United States of America), which can be analyzed with good contrast and minimal signal leakage.  
     [0194] A unique label for each probe or probe set can further comprise a labeled microsphere to which a probe or probe set is attached. A representative system is LabMAP (Luminex Corporation, Austin, Tex., United States of America). Briefly, LabMAP (Laboratory Multiple Analyte Profiling) technology involves performing molecular reactions, including hybridization reactions, on the surface of color-coded microscopic beads called microspheres. When used in accordance with the methods of the presently claimed subject matter, an individual probe or probe set is attached to beads having a single color-code such that they can be identified throughout the assay. Successful hybridization is measured using a detectable label of the amplified nucleic acid sample, wherein the detectable label can be distinguished from each color-code used to identify individual microspheres. Following hybridization of the amplified, labeled nucleic acid sample with a set of microspheres comprising probe sets, the hybridization mixture is analyzed to detect the signal of the color-code as well as the label of a sample nucleic acid bound to the microsphere. See Vignali 2000; Smith et al., 1998; International Publication Nos. WO 01/13120, WO 01/14589, WO 99/19515, and WO 97/14028.  
     [0195] VI. Detection  
     [0196] Methods for detecting a hybridization duplex or triplex are selected according to the label employed.  
     [0197] In the case of a radioactive label (e.g.,  32 P-,  33 P-, or  35 S-dNTP) detection can be accomplished by autoradiography or by using a phosphorimager as is known to one of skill in the art. In one embodiment, a detection method can be automated and is adapted for simultaneous detection of numerous samples.  
     [0198] Common research equipment has been developed to perform high-throughput fluorescence detecting, including instruments from GSI Lumonics (Watertown, Mass., United States of America), Amersham Pharmacia Biotech/Molecular Dynamics (Sunnyvale, Calif., United States of America), Applied Precision Inc. (Issauah, Wash., United States of America), Genomic Solutions Inc. (Ann Arbor, Mich., United States of America), Genetic MicroSystems Inc. (Woburn, Mass., United States of America), Axon (Foster City, Calif., United States of America), Hewlett Packard (Palo Alto, Calif., United States of America), and Virtek (Woburn, Mass., United States of America). Most of the commercial systems use some form of scanning technology with photomultiplier tube detection. Criteria for consideration when analyzing fluorescent samples are summarized by Alexay et al, 1996.  
     [0199] In another embodiment, a nucleic acid sample or probes are labeled with far infrared, near infrared, or infrared fluorescent dyes. Following hybridization, the mixture of amplified nucleic acids and probes is scanned photoelectrically with a laser diode and a sensor, wherein the laser scans with scanning light at a wavelength within the absorbance spectrum of the fluorescent label, and light is sensed at the emission wavelength of the label. See U.S. Pat. Nos. 6,086,737; 5,571,388; 5,346,603; 5,534,125; 5,360,523; 5,230,781; 5,207,880; and 4,729,947. An ODYSSEY™ infrared imaging system (Li-Cor, Inc., Lincoln, Nebr., United States of America) can be used for data collection and analysis.  
     [0200] If an epitope label has been used, a protein or compound that binds the epitope can be used to detect the epitope. For example, an enzyme-linked protein can be subsequently detected by development of a calorimetric or luminescent reaction product that is measurable using a spectrophotometer or luminometer, respectively.  
     [0201] In one embodiment, INVADER® technology (Third Wave Technologies, Madison, Wis., United States of America) is used to detect target nucleic acid/probe complexes. Briefly, a nucleic acid cleavage site (such as that recognized by a variety of enzymes having 5′ nuclease activity) is created on a target sequence, and the target sequence is cleaved in a site-specific manner, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. See U.S. Pat. Nos. 5,846,717; 5,985,557; 5,994,069; 6,001,567; and 6,090,543.  
     [0202] In another embodiment, target nucleic acid/probe complexes are detected using an amplifying molecule, for example a poly-dA oligonucleotide as described in Lisle et al., 2001. Briefly, a tethered probe is employed against a target nucleic acid having a complementary nucleotide sequence. A target nucleic acid having a poly-dt sequence, which can be added to any nucleic acid sequence using methods known to one of skill in the art, hybridizes with an amplifying molecule comprising a poly-dA oligonucleotide. Short oligo-dT 40  signaling moieties are labeled with any suitable label (e.g., fluorescent, chemiluminescent, radioisotopic labels). The short oligo-dT 40  signaling moieties are subsequently hybridized along the molecule, and the label is detected.  
     [0203] Surface plasmon resonance spectroscopy can also be used to detect hybridization duplexes formed between a randomly amplified nucleic acid and a probe as disclosed herein. See e.g., Heaton et al., 2001; Nelson et al., 2001; Guedon et al., 2000.  
     [0204] VII. Autoimmune Disease Gene Expression Equation  
     [0205] VII.A. General Description of the Equation  
     [0206] Genes that were the most underexpressed in patients with SLE compared to control population with greatest statistical significance were chosen to determine if they could be used to classify individuals with autoimmune disease and predict whether new samples were derived from autoimmune or control individuals.  
               TABLE 1                          Genes Used in the Equation                         Gene       SEQ ID       Symbol   Gene Name   NOs:               TGM2   transglutaminase 2    1, 2       SSP29   silver-stainable protein 29    3, 4       TAF2I   TAF11 RNA polymerase II, TATA box    5, 6           binding protein-associated factor, 28           kilodalton       LLGL2   lethal giant larvae homolog 2    7, 8       TNFAIP2   tumor necrosis factor, alpha-induced protein    9, 10           2       SIP1   survival of motor neuron protein interacting   11, 12           protein 1       BPHL   biphenyl hydrolase-like   13, 14       TP53   human tumor protein p53   15, 16       DIPA   hepatitis delta antigen-interacting protein A   17, 18       ASL   argininosuccinate lyase   19, 20       GNB5   human guanine nucleotide binding protein,   21, 22           beta 5       MAN1A1   mannosidase, alpha, class 1A, member 1   23, 24       —   EST   25, 26       LOC51643   CGI-119 protein   27, 28       BMP8   bone morphogenetic protein 8   29, 30       —   human mRNA for cytochrome b5, partial   31, 32           coding sequence       ORC1L   origin recognition complex, subunit 1-like   33, 34       —   EST   35, 36       CDH1   cadherin 1, type 1, E-cadherin   37, 38       SUDD   human sudD suppressor of bimD6 homolog   39, 40           (SUDD)       EPB72   erythrocyte membrane protein band 7.2   41, 42       CDKN1B   cyclin-dependent kinase inhibitor 1B   43, 44       CASP6   caspase 6   45, 46       TXK   TXK tyrosine kinase   47, 48       MYO1C   myosin IC   49, 50       —   EST   51, 52       HSJ2   heat shock protein, DNAJ-like 2   53, 54       BRCA1   breast cancer 1, early onset, transcript   55, 56           variant BRCA1a       GUCY1B3   guanylate cyclase 1, soluble, beta 3   57, 58       AP3S2   adaptor-related protein complex 3, sigma 2   59, 60           subunit       —   EST   61, 62       SC65   synaptonemal complex protein 65   63, 64       UBE2G2   ubiquitin-conjugating enzyme E2G 2   65, 66       SLC16A4   solute carrier family 16, member 4   67, 68       MMP17   matrix metalloproteinase 17   69, 70                  
 
     [0207] VII.B. Use of the Equations to Predict the Presence of Autoimmune Disease  
     [0208] The expression level of each of the genes listed in Table 1 was determined as described hereinabove. For each gene, the average expression level in the control population and the SLE population was summed and divided by 2 (i.e. (control ave +SLE ave )/2). After determining this value, the expression levels of each of the 35 genes were examined for each subject. For each gene, a value of 0 was assigned for that gene in that subject if the expression level for that gene was less than the average expression level as determined above. If the individual subject&#39;s expression level was higher than the average expression level, that gene was assigned a value of 1. The assigned values were then added to arrive at a score (minimum=0; maximum=35).  
     [0209] The range of scores for control individuals was 18-35, and 8 out of 11 control individuals achieved a score of 35. When this analysis was applied to the normal immune subjects, the scores ranged from 26-35. In contrast, however, the range of scores for subjects with autoimmune disease was as follows: 0-5 for SLE; 0-6 for RA; 0-1 for type 1 diabetes; and 0 for MS (p&lt;0.000001).  
     [0210] A group of SLE and RA patients not included in the initial analysis were then tested to examine the predictive value of the above disclosed strategy. The range of scores obtained in these patients was 0-5 for SLE and 0-6 for RA. Thus, the methods disclosed herein can be used to detect the presence or absence of autoimmune disease in a subject whose disease status is unknown by subjecting total RNA isolated from the subject to the aforementioned analysis and generating a score as previously described. In this embodiment, scores of 8 or less suggest the presence of autoimmune disease, while scores of 15 or above suggest the absence of autoimmune disease.  
     EXAMPLES  
     [0211] The following Examples have been included to illustrate modes of the presently claimed subject matter. Certain aspects of the following Examples are described in terms of techniques and procedures found or contemplated by the present inventors to work well in the practice of the presently claimed subject matter. These Examples illustrate standard laboratory practices of the inventors. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently claimed subject matter.  
     Example 1  
     Patient Population  
     [0212] Nine control subjects (27-58 years of age) were studied before and after influenza vaccination. Patients with RA (n=20; 46-68 years of age), SLE (n=24; 22-73 years), type 1 diabetes (n=5; 20-46 years), and MS (n =4; 37-54 years) were also enrolled in the study. A clinical diagnosis of each autoimmune disorder was the sole criterion for inclusion. Unaffected family members were also included in the study (n=4, 33-54 years); three were parents of individuals with SLE and one was the child of an individual with RA. The ratio of females to males in the test groups was approximately 3:1.  
     Example 2  
     Sample Preparation  
     [0213] Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood drawn from the population of Example 1 by centrifugation on a Ficoll-Hypaque (Sigma-Aldrich, St. Louis, Mo., United States of America) gradient. Leukocyte distribution in PBMC was determined by flow cytometry. Total RNA was isolated with TRI REAGENT® according to the manufacturer&#39;s protocol (Molecular Research Center, Cincinnati, Ohio, United States of America).  
     [0214] RNA Labeling. RNA labeling required three steps: priming, elongation, and probe purification. For priming, 1-10 μg of total RNA (in a volume of less than 8.0 μl diethylpyrocarbonate (DEPC)-treated water) and 2.0 μg oligo-dt (10-20 mer mixture; 1 μg/μl) were mixed in a total volume of 10 μl (balance DEPC-treated water) in a 1.5 ml microcentrifuge tube. The tube was placed at 70° C. for 10 minutes and then briefly chilled on ice. For elongation, 6.0 μl 5× First Strand Buffer (Invitrogen catalogue number Y00146), 1.0 μl 0.1 M DTT, 1.5 μl dNTP mixture (each dNTP at 20 mM), and 1.5 μl SUPERSCRIPT™ II reverse transcriptase (Invitrogen) was added to the microcentrifuge tube. 10 μl  33 P-dCTP (10 mCi/ml; specific activity 3000 Ci/mmol; ICN Biomedicals Inc., Irvine, Calif., United States of America) was added to the microcentrifuge tube, the contents mixed thoroughly, and the tube was incubated at 37° C. for 90 minutes. Probe purification was accomplished by passing the elongation reaction mixture through a Bio-Spin 6 chromatography column (Bio-Rad Laboratories, Hercules, Calif., United States of America).  
     [0215] Hybridization of the Labeled RNA to the Membrane. 5 μg of 33P-labeled total RNA isolated from PBMCs were hybridized to GF211 GENEFILTERS® membranes (RESGEN™, a division of Invitrogen Corporation, Carlsbad, Calif., United States of America; the genes present on the GF211 membrane can be found at RESGEN™&#39;s ftp site: ftp://ftp.resgen.com/pub/GENEFILTERS). Prior to hybridization, the filter was pre-treated with 0.5% SDS. The SDS solution was heated to boiling and poured over the membrane, which was then incubated in the SDS solution with gentle agitation for 5 minutes.  
     [0216] After pre-treatment, the filter was prehybridized by placing the filter in a hybridization roller tube (35×150 mm; DNA side facing the interior of the tube) and 5 ml MICROHYB™ solution (RESGEN™) is added to the tube. Additional blocking agents (5 μg COT-1® DNA, Invitrogen Corporation, Carlsbad, Calif., United States of America; 5 μg poly-dA) were added and the tube was vortexed to mix thoroughly. Bubbles between the membrane and the tube were removed and the membranes were incubated in the prehybridization solution at 42° C. for at least 2 hours. For hybridization, the probe was denatured by boiling, cooled, and pipetted into the roller tube containing the GENEFILTERS® membrane and prehybridization solution. The now denatured probe-containing solution was mixed by vortexing. Hybridization occurred overnight, or alternatively for at least 12-18 hours, at 42° C.  
     [0217] Post-Hybridization Washes and Imaging. After hybridization, the filters were washed in the roller tube. The following wash conditions were used: first and second washes were in 2×SSC/1% SDS/50° C. for 20 minutes; third wash was in 0.5×SSC/1% SDS/55° C. for 15 minutes. After washing, the membrane was wrapped in plastic wrap and placed in a phosphorimaging cassette. Filters were exposed to imaging screens for 2-4 hours (short exposure) and then an additional 24 hours (long exposure) and screens were scanned using a PHOSPHORIMAGER™ apparatus (Molecular Dynamics, Piscataway, N.J., United States of America). Data were normalized to yield an average intensity of 1.0 for each clone (4329 clones total) represented on the microarray. Reproducibility of the method was established by performing replicate hybridizations to separate microarrays. Linear regression analysis demonstrated that separate hybridizations yielded R 2  values ranging from 0.87 to 0.96. Different exposure lengths of identical filters also produced high R 2  values (0.99).  
     Example 3  
     Data Analysis  
     [0218] Following phosphorimaging, data were collected in digital format and normalized against a common control filter using the Pathways 3.0 software program (available from Invitrogen). Eisen&#39;s Cluster and Treeview software (Stanford University, Palo Alto, Calif., United States of America; (Eisen et al., 1998) were used to compare similarities among individual samples. Data sets were analyzed using hierarchical, K-means, and self-organizing map algorithms (Sherlock 2000). The PATHWAYS™ 3.0 program (RESGEN™) was used to identify differentially expressed genes in the immune and autoimmune disease classes. Expression levels of genes that did not change significantly (99% confidence, Chen test) over any of the conditions were removed from the database (Kim et al., 2000). The remaining genes in the data set were clustered using an unsupervised K-means clustering algorithm with ten centroids (Eisen et al., 1998; Sherlock 2000).  
     Example 4  
     Gene Expression Profiles During a Normal Immune Response  
     [0219] To test the hypothesis that the mononuclear cell population represented a suitable source to measure alterations in gene expression, changes in gene expression in PBMC from healthy control subjects (n=9) were measured before and after immunization with influenza vaccine. It was most likely that a gene expression profile derived from these subjects would involve a secondary immune response because all subjects had prior exposure to many influenza antigens (Ags). Samples were collected from subjects at three time points: 3, 6-9, and 19-21 days after immunization. A self-organizing map algorithm was used to compare the preimmune to the immune group. This method segregated individuals based upon identity rather than immune status, as demonstrated by the relative proximity of individual samples (See FIG. 1A, upper panel). Thus, total gene expression patterns remained relatively unchanged after immunization. To focus on distinctions that arose from the most differentially expressed genes, genes for which expression levels did not vary by more than 3 standard deviations (SD) from their respective means were filtered out. After filtering, expression profiles were segregated primarily by pre- and postimmune status (See FIG. 1A, lower panel), suggesting that uniform changes in expression levels of a smaller subset of genes distinguished pre- and postimmunization groups. To identify these genes, K-means clustering was used to group genes on the basis of similarity in expression patterns.  
     [0220] Three distinct clusters associated with the normal immune response were found (See FIG. 1B). The first cluster consisted of 304 genes that were overexpressed 3 days after immunization. This cluster mainly contained genes that encode proteins involved in key signal transduction pathways (e.g., protein kinase C, phospholipase C, 1,2-diacylglycerol kinase, mitogen-activated protein kinase, STATs and STAT inhibitors, AP-1 transcription factors, interferon regulatory factors, and proteins required for proliferation). Genes in this cluster exhibited an increase in expression from 3- to 21-fold compared with the control group.  
     [0221] The second cluster of 88 late (19-21 days) response genes represented a shift away from signaling and proliferation pathways toward increased functional activity. Among the late immune response gene cluster, chemokines (SCYA3, SCYA13, SCYA14), complement components (CIS), interferon (IFN) -inducible proteins (IFI35), and leukocyte homing/adhesion (ICAM2) genes were overexpressed. Receptors for serotonin, glutamate, estrogen, and retinoic acid were also overexpressed. Increases in expression levels of this group of genes varied from 2- to 11 -fold.  
     [0222] The final immune response cluster contained 78 genes that exhibited reduced expression levels over the entire time course. Over 15% of these genes encode ribosomal proteins. This represents a decrease in the expression of one-third of all ribosomal protein encoding genes present on the microarrays. Coordinate changes in ribosomal protein gene expression have been linked to differentiation in eukaryotic cells (Krichevsky et al., 1999) and the observed changes could reflect differentiation of lymphocytes to an effector state in response to immunization. While applicants do not wish to be bound by any particular theory of operation, taken together, these data illustrate dynamic, coordinate changes in mRNA expression that accompany the immune response in vivo. First, genes appeared to be induced that are required for signal transduction and cell proliferation, two key elements of the early immune response. Later, a shift away from these genes to other classes that are necessary to undertake the immune functions of lymphocytes occurred.  
     Example 5  
     Expression Profiles of Immunized Subiects Versus Autoimmune Patients  
     [0223] In order to determine if the observations described above are differ between subjects undergoing a normal immune response (i.e. subjects immunized with influenza vaccine) and subjects undergoing an autoimmune response, samples were obtained from patients diagnosed with one of four common autoimmune disorders: RA, MS, type 1 diabetes, and SLE. The relatedness of global gene expression profiles associated with autoimmune disease was examined relative to the normal immune response using a hierarchical clustering algorithm (See FIG. 2A). Other clustering algorithms yielded similar results. Comparison between the RA/SLE class and the normal immune response class yielded four major branches from the clustering analysis. One major branch contained all normal immune samples and none of the autoimmune samples. The autoimmune samples segregated into the other three major branches. This analysis revealed that some of the RA samples (e.g., RA2 and RA5, or RA1, RA6, and RA4) and some of the SLE samples (e.g., SLE2, SLE3, and SLE4, or SLE6, SLE8, and SLE9) were highly related. However, unlike distinctions between the RA/SLE and the normal immune response samples, it was not possible to segregate the majority of RA samples from the majority of SLE samples, suggesting that RA and SLE might represent a common autoimmune class that is distinct from the immune class. Similar results were obtained from clustering of normal immune response samples with MS/type 1 diabetes samples. Again, there was good segregation of the normal immune response group from the MS/type 1 diabetes group, but MS and type 1 diabetes profiles did not segregate from each other. This inability to segregate within autoimmune class was retained even when invariant genes were removed from the data set.  
     [0224] The data set was further analyzed to identify genes that were most differentially expressed in autoimmune diseases relative to the normal immune response. Non-autoimmune groups were segregated into control (no treatment) and immune (6-9 days after immunization). Individual samples from the autoimmune groups were segregated based upon disease type and compared with the immune response gene profiles. Gene expression differences among different groups were plotted as the natural logarithm of the ratio between experimental condition and control group.  
     [0225] Two clusters of differentially expressed genes distinguished between (1) patients with autoimmune disease, and (2) control and immune individuals (See FIG. 2B). The first major cluster comprised 95 genes that were overexpressed in all four autoimmune diseases (type 1 diabetes, MS, RA, and SLE). The genes in this overexpressed autoimmune cluster were relatively heterogeneous, representing several distinct functional categories: receptors (CSF3R, HLA-DMB, HLALS, TGFBR2, and BMPR2), inflammatory mediators (MSTP9, BDNF, CES1, ELA3, and CYR61), signaling/second messenger molecules (FASTK, DGKA, and DGKD), and autoantigens (GARS and GAD2). The second major cluster contained 117 genes that were strongly underexpressed in all autoimmune groups. Levels of expression of these genes did not change in the immune response group. Many of the down-regulated genes play key roles in apoptosis (TRADD, TRAP1, TRIP, TRAF2, CASP6, CASP8, TP53, and SIVA) and ubiquitin/proteasome function (UBE2M, UBE2G2, and POH1). Inhibitors of various cellular functions were also widely represented in this cluster. These include direct inhibitors of cell cycle progression (CDKN1B, CDKN2A, and BRCA1), as well as inducers of cell differentiation (LIF and CD24). Certain enzyme inhibitors (APOC3 and KALL) were also found in this class.  
     [0226] K-means clustering indicated that it was not possible to identify clusters of genes that overlapped between the immune and autoimmune classes, suggesting that the gene expression patterns that characterize the normal immune response are considerably different from those found in autoimmune disease. In addition, clusters of genes that distinguished among the distinct autoimmune diseases were not found, suggesting that the autoimmune diseases studied are more similar to each other than they are to a normal immune response.  
     [0227] The expression levels of single genes between preimmune controls and individuals with each of four autoimmune diseases were investigated further. Ten genes were chosen that exhibited the greatest level of over- and underexpression (see FIGS. 3A and 3B) at the population level and were highly consistent in each individual with autoimmune disease. Overexpressed genes in the autoimmune population showed greater individual variation (see FIG. 3A). Among the overexpressed genes, no individual gene was overexpressed in all autoimmune individuals compared with all control individuals. However, each of these overexpressed genes was significantly overexpressed in the autoimmune population considered together when compared to the control population taken as a whole (p&lt;0.05). In contrast, the expression levels of the underexpressed genes (FIG. 3B) were lower in each autoimmune individual than in any control individual.  
     [0228] Differences in gene expression between the control and the autoimmune populations might be attributed to alterations in distribution or activation status of cells that make up the PBMC. Two analyses were performed to test this possibility. First, PBMC preparations were analyzed for frequency of CD3 (T cells), CD14 (monocytes), CD19 (B cells), and leukocyte alkaline phosphatase (neutrophils) by flow cytometry. All PBMC preparations from both subject groups contained 75-80% T cells, about 10% monocytes, about 5% B cells, and less than 1% neutrophils. Second, it was determined whether expression levels of genes that are either restricted to a given subpopulation or reflect activation status were differentially expressed in the control compared with the autoimmune population (Table 2). Expression levels of these genes varied by less than 2-fold between the control and autoimmune groups and this difference did not achieve statistical significance. Taken together, these data suggest that alterations in the composition or activation status of PBMC did not account for the observed differences in gene expression between the control and autoimmune populations.  
               TABLE 2                          Expression Levels of Genes Encoding Proteins that Distinguish       Among Lymphocyte Subsets or Activation State                                         Control   SLE   RA   IDDM   MS                                                 T cell Ags                           CD3δ    0.7 ± 0.2 a     0.6 ± 0.4   0.5 ± 0.2   0.5 ± 0.2   0.4 ± 0.2       CD3γ   0.5 ± 0.1   0.6 ± 0.9   0.4 ± 0.1   0.3 ± 0.1   0.4 ± 0.1       CD8β (Tc)   0.8 ± 0.3   0.8 ± 0.2   0.6 ± 0.2   0.5 ± 0.2   0.5 ± 0.2       CD44   0.5 ± 0.1   0.8 ± 0.5   0.7 ± 0.4   0.8 ± 0.5   0.7 ± 0.4       (memory)       CD69   0.5 ± 0.2   0.7 ± 0.3   0.6 ± 0.2   0.8 ± 0.3   0.7 ± 0.4       (activation)       CD62   1.3 ± 0.6   1.4 ± 0.9   1.8 ± 0.1   1.7 ± 1.1   1.9 ± 1.1       (L-selectin)       CD122   0.4 ± 0.1   0.4 ± 0.2   0.5 ± 0.2   0.3 ± 0.1   0.3 ± 0.1       (IL-2R β)       B Cell Ags       CD79a   0.6 ± 0.3   0.4 ± 0.2   0.4 ± 0.2   0.4 ± 0.2   0.4 ± 0.2       CD79b   0.5 ± 0.2   0.6 ± 0.3   0.8 ± 0.7   0.8 ± 0.4   0.7 ± 0.3       CD72   0.4 ± 0.1   0.4 ± 0.3   0.4 ± 0.2   0.3 ± 0.1   0.3 ± 0.1       CD22   0.3 ± 0.1   0.4 ± 0.3   0.4 ± 0.4   0.3 ± 0.1   0.3 ± 0.1                 Monocyte Ags                                     CD14   0.5 ± 0.2   0.4 ± 0.2   0.3 ± 0.1   0.3 ± 0.2   0.3 ± 0.2       CD163   0.3 ± 0.1   0.4 ± 0.2   0.4 ± 0.2   0.3 ± 0.1   0.3 ± 0.2       CD32   0.3 ± 0.1   0.5 ± 0.4   0.5 ± 0.3   0.3 ± 0.1   0.4 ± 0.2       (B/mθ)                 Activation-induced Ags                                     CD54   4.4 ± 1.8   3.1 ± 2.1   4.3 ± 0.7   4.3 ± 2.2   3.9 ± 1.0       (ICAM-1)       CD38   0.4 ± 0.3   0.3 ± 0.2   0.3 ± 0.1   0.3 ± 0.1   0.3 ± 0.1       CD71   0.2 ± 0.1   0.2 ± 0.2   0.2 ± 0.1   0.2 ± 0.1   0.2 ± 0.1                          
 
     Example 6  
     Fluorescent Labeling of Nucleic Acids  
     [0229] A nucleic acid sample can be used as a template for direct incorporation of fluorescent nucleotide analogs (e.g., Cy3-dUTP and Cy5- dUTP, available from Amersham Pharmacia Biotech of Piscataway, N.J., United States of America) by a polymerization reaction. In brief, a 50 μl labeling reaction can contain 2 μg of template DNA, 5 μl of 10×buffer, 1.5 μl of fluorescent dUTP, 0.5 μl each of dATP, dCTP, and dGTP, 1 μl of hexamers and decamers (i.e. primers, whether random or derived from a gene of interest), and 2 μl of Klenow ( E. coli  DNA polymerase 3′ to 5′ exo- from New England Biolabs of Beverly, Mass., United States of America).  
     Example 7  
     Noncovalent Binding of Nucleic Acid Probes onto Glass  
     [0230] PCR fragments are suspended in a solution of 3 to 5M NaSCN and spotted onto amino-silanized slides using a GMS 417™ arrayer from Affymetrix of Santa Clara, Calif., United States of America. After spotting, the slides are heated at 80° C. for 2 hours to dehydrate the spots. Prior to hybridization, the slides are washed in isopropanol for 10 minutes, followed by washing in boiling water for 5 minutes. The washing steps remove any nucleic acid that is not bound tightly to the glass and help to reduce background created by redistribution of loosely attached DNA during hybridization. Contaminants such as detergents and carbohydrates should be minimized in the spotting solution. See also Maitra &amp; Thakur 1992; Maitra &amp; Thakur 1994.  
     Example 8  
     Hybridization to a Microarray Comprising Gene-specific Probes  
     [0231] Labeled nucleic acids from the sample are prepared in a solution of 4×SSC buffer, 0.7 μg/μl tRNA, and 0.3% SDS to a total volume of 14.75 μl. The hybridization mixture is denatured at 98° C. for 2 minutes, cooled to 65° C., applied to the microarray, and covered with a 22-mm 2  cover slip. The slide is placed in a waterproof hybridization chamber for hybridization in a 65° C. water bath for 3 hours. Following hybridization, slides are washed in 1×SSC buffer with 0.06% SDS followed by 2 minutes in 0.06×SSC buffer.  
     REFERENCES  
     [0232] The references listed below as well as all references cited in the specification are incorporated herein by reference to the extent that they supplement, explain, provide a background for, or teach methodology, techniques, and/or compositions employed herein.  
     [0233] Albert J, Wahlberg J, Lundeberg J, Cox S, Sandstrom E, Wahren B &amp; Uhlen M (1992) Persistence of Azidothymidine-Resistant Human Immunodeficiency Virus Type 1 RNA Genotypes in Posttreatment Sera.  J Virol  66:5627-5630.  
     [0234] Alexay C, Kain R C, Hanzel D K &amp; Johnston R F (1996) Fluorescence scanner employing a macro scanning objective, in Menzel E R, ed, Fluorescence Detection IV.  Proc SPIE  2705:63-72.  
     [0235] Altschul S F, Gish W, Miller W, Myers E W &amp; Lipman D J (1990) Basic Local Alignment Search Tool.  J Mol Biol  215:403-410.  
     [0236] Ausubel F M, Brent R, Kingston R E, Moore D D, Seidman J G, Smith J A &amp; Struhl K, eds (1994)  Current Protocols in Molecular Biology.  Wiley, New York.  
     [0237] Bej A K, Mahbubani M H, Dicesare J L &amp; Atlas R M (1991) Polymerase Chain Reaction-Gene Probe Detection of Microorganisms by Using Filter-Concentrated Samples.  Appl Environ Microbiol  57:3529-3534.  
     [0238] Boom R, Sol C J, Salimans M M, Jansen C L, Wertheim-van Dillen P M &amp; van der Noordaa J (1990) Rapid and Simple Method for Purification of Nucleic Acids.  J Clin Microbiol  28:495-503.  
     [0239] Buffone G J, Demmler G J, Schimbor C M &amp; Greer J (1991) Improved Amplification of Cytomegalovirus DNA from Urine after Purification of DNA with Glass Beads.  Clin Chem  37:1945-1949.  
     [0240] Busch M P, Wilber J C, Johnson P, Tobler L &amp; Evans C S (1992) Impact of Specimen Handling and Storage on Detection of Hepatitis C Virus RNA.  Transfusion  32:420-425.  
     [0241] Cha R S &amp; Thilly W G (1993) Specificity, Efficiency, and Fidelity of Pcr.  PCR Methods Appl  3:S18-29.  
     [0242] Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlen M, Fenyo E M &amp; Norkrans G (1992) Human Immunodeficiency Virus Type 1 Is Present in the Cerebrospinal Fluid of a Majority of Infected Individuals.  J Clin Microbiol  30:1768-1771.  
     [0243] DeRisi J, Penland L, Brown P O, Bittner M L, Meltzer P S, Ray M, Chen Y, Su Y A &amp; Trent J M (1996) Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer.  Nat Genet  14:457-460.  
     [0244] Dubiley S, Kirillov E, Lysov Y &amp; Mirzabekov A (1997) Fractionation, Phosphorylation and Ligation on Oligonucleotide Microchips to Enhance Sequencing by Hybridization.  Nucleic Acids Res  25:2259-2265.  
     [0245] Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M &amp; Coleman P (1992) Analysis of Gene Expression in Single Live Neurons.  Proc Natl Acad Sci U S A  89:3010-3014.  
     [0246] Eisen M B, Spellman P T, Brown P O &amp; Botstein D (1998) Cluster Analysis and Display of Genome-Wide Expression Patterns.  Proc Natl Acad Sci U S A  95:14863-14868.  
     [0247] Englert D (2000) in Schena M, ed,  Microarray Biochip Technology,  pp. 231-246, Eaton Publishing, Natick, Mass., United States of America.  
     [0248] Fodor S P, Read J L, Pirrung M C, Stryer L, Lu A T &amp; Solas D (1991) Light-Directed, Spatially Addressable Parallel Chemical Synthesis.  Science  251:767-773.  
     [0249] Fodor S P, Rava R P, Huang X C, Pease A C, Holmes C P &amp; Adams C L (1993) Multiplexed Biochemical Assays with Biological Chips.  Nature  364:555-556.  
     [0250] Guedon P, Livache T, Martin F, Lesbre F, Roget A, Bidan G &amp; Levy Y (2000) Characterization and Optimization of a Real-Time, Parallel, Label-Free, Polypyrrole-Based DNA Sensor by Surface Plasmon Resonance Imaging.  Anal Chem  72:6003-6009.  
     [0251] Hamel A L, Wasylyshen M D &amp; Nayar G P (1995) Rapid Detection of Bovine Viral Diarrhea Virus by Using RNA Extracted Directly from Assorted Specimens and a One-Tube Reverse Transcription Pcr Assay.  J Clin Microbiol  33:287-291.  
     [0252] Heaton R J, Peterson A W &amp; Georgiadis R M (2001) Electrostatic Surface Plasmon Resonance: Direct Electric Field-Induced Hybridization and Denaturation in Monolayer Nucleic Acid Films and Label-Free Discrimination of Base Mismatches.  Proc Natl Acad Sci U S A  98:3701-3704.  
     [0253] Henikoff S &amp; Henikoff J G (1992) Amino Acid Substitution Matrices from Protein Blocks.  Proc Nat Acad Sci U S A  89:10915-10919.  
     [0254] Hermanson G T (1990)  Bioconjugate Techniques,  Academic Press, San Diego, Calif., United States of America.  
     [0255] Herrewegh A A, de Groot R J, Cepica A, Egberink H F, Horzinek M C &amp; Rottier P J (1995) Detection of Feline Coronavirus RNA in Feces, Tissues, and Body Fluids of Naturally Infected Cats by Reverse Transcriptase Pcr.  J Clin Microbiol  33:684-689.  
     [0256] Izraeli S, Pfleiderer C &amp; Lion T (1991) Detection of Gene Expression by Pcr Amplification of RNA Derived from Frozen Heparinized Whole Blood.  Nucleic Acids Res  19:6051.  
     [0257] Jacobson D L, Gange S J, Rose N R &amp; Graham N M (1997) Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States.  Clin Immunol Immunopathol  84:223-243.  
     [0258] Joyce C (2002) Quantitative RT-PCR. A Review of Current Methodologies.  Methods Mol Biol  193:83-92.  
     [0259] Karlin S &amp; Altschul S F (1993) Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences.  Proc Natl Acad Sci U S A  90:5873-5877.  
     [0260] Kim S, Dougherty E R, Chen Y, Sivakumar K, Meltzer P, Trent J M &amp; Bittner M (2000) Multivariate Measurement of Gene Expression Relationships.  Genomics  67:201-209.  
     [0261] Kohsaka H &amp; Carson D A (1994) Solid-Phase Polymerase Chain Reaction.  J Clin Lab Anal  8:452-455.  
     [0262] Kotzin B L (1996) Systemic Lupus Erythematosus.  Cell  85:303-306.  
     [0263] Krichevsky A M, Metzer E &amp; Rosen H (1999) Translational Control of Specific Genes During Differentiation of HI-60 Cells.  J Biol Chem  274:14295-14305.  
     [0264] Kukreja A &amp; Maclaren N K (2000) Current Cases in Which Epitope Mimicry Is Considered as a Component Cause of Autoimmune Disease: Immune-Mediated (Type 1) Diabetes.  Cell Mol Life Sci  57:534-541.  
     [0265] Lanciotti R S, Calisher C H, Gubler D J, Chang G J &amp; Vorndam A V (1992) Rapid Detection and Typing of Dengue Viruses from Clinical Samples by Using Reverse Transcriptase-Polymerase Chain Reaction.  J Clin Microbiol  30:545-551.  
     [0266] Linz U, Delling U &amp; Rubsamen-Waigmann H (1990) Systematic Studies on Parameters Influencing the Performance of the Polymerase Chain Reaction.  J Clin Chem Clin Biochem  28:5-13.  
     [0267] Lisle C M, Bortolin S, Benight A S, Janeczko R A &amp; Zastawny R L (2001) Novel Signal Amplification Technology with Applications in DNA and Protein Detection Systems.  Biotechniques  30:1268-1272.  
     [0268] Liu J &amp; Hlady V (1996) Chemical pattern on silica surface prepared by UV irradiation of 3-mercapto - propyltriethoxy silane layer: Surface characterization and fibrinogen adsorption.  Colloids and Surfaces B. Biointerfaces  8:25-37.  
     [0269] Mace M L, Jr., Montagu J, Rose S D &amp; McGuinness G (2000) in Schena M ed,  Microarray Biochip Technology, pp.  39-64, Eaton Publishing, Natick, Mass., United States of America  
     [0270] Maier E, Meier-Ewert S, Ahmadi A R, Curtis J &amp; Lehrach H (1994) Application of Robotic Technology to Automated Sequence Fingerprint Analysis by Oligonucleotide Hybridisation.  J Biotechnol  35:191-203.  
     [0271] Maitra R &amp; Thakur A R (1992)  Curr Sci  62:586-588.  
     [0272] Maitra R &amp; Thakur A R (1994) Multiple Fragment Ligation on Glass Surface: A Novel Approach.  Indian J Biochem Biophys  31:97-99.  
     [0273] Marrack P, Kappler J &amp; Kotzin B L (2001) Autoimmune Disease: Why and Where It Occurs.  Nat Med  7:899-905.  
     [0274] Martin A, Barbesino G &amp; Davies T F (1999) T-Cell Receptors and Autoimmune Thyroid Disease—Signposts for T-Cell-Antigen Driven Diseases.  Int Rev Immunol  18:111-140.  
     [0275] McCaustland K A, Bi S, Purdy M A &amp; Bradley D W (1991) Application of Two RNA Extraction Methods Prior to Amplification of Hepatitis E Virus Nucleic Acid by the Polymerase Chain Reaction. J Virol Methods 35:331-342.  
     [0276] McPherson M J, Hames B D &amp; Taylor G, eds, (1995)  PCR  2: A Practical Approach, IRL Press, New York, N.Y., United States of America.  
     [0277] Millar D S, Withey S J, Tizard M L, Ford J G &amp; Hermon-Taylor J (1995) Solid-Phase Hybridization Capture of Low-Abundance Target DNA Sequences: Application to the Polymerase Chain Reaction Detection of Mycobacterium Paratuberculosis and Mycobacterium Avium Subsp. Silvaticum.  Anal Biochem  226:325-330.  
     [0278] Natarajan V, Plishka R J, Scott E W, Lane H C &amp; Salzman N P (1994) An Internally Controlled Virion Pcr for the Measurement of Hiv-1 RNA in Plasma.  PCR Methods Appl  3:346-350.  
     [0279] Needleman S B &amp; Wunsch C D (1970) A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins.  J Mol Biol  48:443-453.  
     [0280] Nelson B P, Grimsrud T E, Liles M R, Goodman R M &amp; Corn R M (2001) Surface Plasmon Resonance Imaging Measurements of DNA and RNA Hybridization Adsorption onto DNA Microarrays.  Anal Chem  73:1-7.  
     [0281] O&#39;Donnell M J, Tang K, Koster H, Smith C L &amp; Cantor C R (1997) High-Density, Covalent Attachment of DNA to Silicon Wafers for Analysis by MALDI-TOF Mass Spectrometry.  Anal Chem  69:2438-2443.  
     [0282] Paladichuk A (1999) Isolating RNA: Pure and Simple. The Scientist 13(16):20-23.  
     [0283] PCT International Publication No. WO 97/14028.  
     [0284] PCT International Publication No. WO 99/19515  
     [0285] PCT International Publication No. WO 99/63385  
     [0286] PCT International Publication No. WO 01/13120  
     [0287] PCT International Publication No. WO 01/14589  
     [0288] PCT International Publication No. WO 01/23082  
     [0289] Pearson W R &amp; Lipman D J (1988) Improved Tools for Biological Sequence Comparison.  Proc Natl Acad Sci U S A  85:2444-2448.  
     [0290] Pietu G, Alibert O, Guichard V, Lamy B, Bois F, Leroy E, Mariage-Sampson R, Houlgatte R, Soularue P &amp; Auffray C (1996) Novel Gene Transcripts Preferentially Expressed in Human Muscles Revealed by Quantitative Hybridization of a High Density Cdna Array.  Genome Res  6:492-503.  
     [0291] Quayle A J, Wilson K B, Li S G, Kjeldsen-Kragh J, Oftung F, Shinnick T, Sioud M, Forre O, Capra J D &amp; Natvig J B (1992) Peptide Recognition,  T Cell Receptor Usage and HIa Restriction Elements of Human Heat-Shock Protein (Hsp)  60 and Mycobacterial 65-Kda Hsp-Reactive T Cell Clones from Rheumatoid Synovial Fluid.  Eur J Immunol  22:1315-1322.  
     [0292] Randolph J B &amp; Waggoner A S (1997) Stability, Specificity and Fluorescence Brightness of Multiply-Labeled Fluorescent DNA Probes.  Nucleic Acids Res  25:2923-2929.  
     [0293] Ratner B D &amp; Castner D G (1997) in Vickerman J C, ed, Surface Analysis: The Principal Techniques, John Wiley &amp; Sons, New York, N.Y., United States of America.  
     [0294] Robertson J M &amp; Walsh-Weller J (1998) An Introduction to Pcr Primer Design and Optimization of Amplification Reactions.  Methods Mol Biol  98:121-154.  
     [0295] Rose D (2000) in Schena M ed,  Microarray Biochip Technology, pp.  19-38, Eaton Publishing, Natick, Mass., United States of America.  
     [0296] Roux K H (1995) Optimization and Troubleshooting in Pcr.  PCR Methods Appl  4:S185-194.  
     [0297] Rupp G M &amp; Locker J (1988) Purification and Analysis of RNA from Paraffin-Embedded Tissues. Biotechniques 6:56-60.  
     [0298] Sambrook &amp; Russell (2001)  Molecular Cloning: A Laboratory Manual,  3 rd  Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., United States of America.  
     [0299] Sapolsky R J &amp; Lipshutz R J (1996) Mapping Genomic Library Clones Using Oligonucleotide Arrays.  Genomics  33:445-456.  
     [0300] Schena M, Shalon D, Davis R W &amp; Brown P O (1995) Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray.  Science  270:467-470.  
     [0301] Schena M, Shalon D, Heller R, Chai A, Brown P O &amp; Davis R W (1996) Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes.  Proc Natl Acad Sci U S A  93:10614-10619.  
     [0302] Shalon D, Smith S J &amp; Brown P O (1996) A DNA Microarray System for Analyzing Complex DNA Samples Using Two-Color Fluorescent Probe Hybridization.  Genome Res  6:639-645.  
     [0303] Sherlock G (2000) Analysis of Large-Scale Gene Expression Data.  Curr Opin Immunol  12:201-205.  
     [0304] Shoemaker D D, Lashkari D A, Morris D, Mittmann M &amp; Davis R W (1996) Quantitative Phenotypic Analysis of Yeast Deletion Mutants Using a Highly Parallel Molecular Bar-Coding Strategy.  Nat Genet  14:450-456.  
     [0305] Shriver-Lake L C (1998) in Cass T &amp; Ligler F S, eds, Immobilized Biomolecules in Analysis, pp. 1-14, Oxford Press, Oxford, United Kingdom.  
     [0306] Smith P L, WalkerPeach C R, Fulton R J &amp; DuBois D B (1998) A Rapid, Sensitive, Multiplexed Assay for Detection of Viral Nucleic Acids Using the Flowmetrix System. Clin Chem 44:2054-2056.  
     [0307] Smith T F &amp; Waterman M (1981) Comparison of Biosequences.  Adv Appl Math  2:482-489.  
     [0308] Southern E M (1975) Detection of Specific Sequences among DNA Fragments Separated by Gel Electrophoresis.  J Mol Biol  98:503-517.  
     [0309] Steel A, Torres M, Hartwell J, Yu Y Y, Ting N, Hoke G &amp; Yang, H (2000) in Schena M, ed,  Microarray Biochip Technology, pp.  87-118, Eaton Publishing, Natick, Mass., United States of America.  
     [0310] Strain S R &amp; Chmielewski J G (2001) ROCK: A Spreadsheet-Based Program for the Generation and Analysis of Random Oligonucleotide Primers used in PCR.  BioTechniques  30:1286-1293.  
     [0311] Tanaka S, Minagawa H, Toh Y, Liu Y &amp; Mori R (1994) Analysis by RNA-Pcr of Latency and Reactivation of Herpes Simplex Virus in Multiple Neuronal Tissues.  J Gen Virol 75 ( Pt 10):2691-2698.  
     [0312] Telenius H, Carter N P, Bebb C E, Nordenskjold M, Ponder B A &amp; Tunnacliffe A (1992) Degenerate Oligonucleotide-Primed Pcr: General Amplification of Target DNA by a Single Degenerate Primer.  Genomics  13:718-725.  
     [0313] Theriault T P, Winder S C &amp; Gamble R C (1999) in Schena M, ed,  DNA Microarrays: A Practical Approach,  pp. 101-120, Oxford University Press Inc., New York, N.Y., United States of America.  
     [0314] Tijssen P (1993)  Laboratory Techniques in Biochemistry and Molecular Biology - Hybridization with Nucleic Acid Probes.  Elsevier, N.Y.  
     [0315] Ufret-Vincenty R L, Quigley L, Tresser N, Pak S H, Gado A, Hausmann S, Wucherpfennig K W &amp; Brocke S (1998) In Vivo Survival of Viral Antigen-Specific T Cells That Induce Experimental Autoimmune Encephalomyelitis.  J Exp Med  188:1725-1738.  
     [0316] U.S. Pat. No. 4,729,947  
     [0317] U.S. Pat. No. 5,346,603  
     [0318] U.S. Pat. No. 5,445,934  
     [0319] U.S. Pat. No. 5,207,880  
     [0320] U.S. Pat. No. 5,230,781  
     [0321] U.S. Pat. No. 5,360,523  
     [0322] U.S. Pat. No. 5,534,125  
     [0323] U.S. Pat. No. 5,571,388  
     [0324] U.S. Pat. No. 5,743,960  
     [0325] U.S. Pat. No. 5,843,767  
     [0326] U.S. Pat. No. 5,846,717  
     [0327] U.S. Pat. No. 5,916,524  
     [0328] U.S. Pat. No. 5,965,352  
     [0329] U.S. Pat. No. 5,985,557  
     [0330] U.S. Pat. No. 5,994,069  
     [0331] U.S. Pat. No. 6,001,567  
     [0332] U.S. Pat. No. 6,066,457  
     [0333] U.S. Pat. No. 6,090,543  
     [0334] U.S. Pat. No. 6,017,696  
     [0335] U.S. Pat. No. 6,086,737  
     [0336] U.S. Pat. No. 6,123,819  
     [0337] U.S. Pat. No. 6,162,603  
     [0338] U.S. Pat. No. 6,225,059  
     [0339] U.S. Pat. No. 6,245,508  
     [0340] Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A &amp; Speleman F (2002) Acurate Normalization of Real-Time Quantitative RT-PCR Data by Geometric Averaging of Multiple Internal Control Genes.  Genome Biol  3:1-12.  
     [0341] Van Gelder R N, von Zastrow M E, Yool A, Dement W C, Barchas J D &amp; Eberwine J H (1990) Amplified RNA Synthesized from Limited Quantities of Heterogeneous cDNA.  Proc Natl Acad Sci U S A  87:1663-1667.  
     [0342] Van Kerckhoven I, Fransen K, Peeters M, De Beenhouwer H, Piot P &amp; van der Groen G (1994) Quantification of Human Immunodeficiency Virus in Plasma by RNA Pcr, Viral Culture, and P24 Antigen Detection.  J Clin Microbiol  32:1669-1673.  
     [0343] Vignali D A (2000) Multiplexed Particle-Based Flow Cytometric Assays.  J Immunol Methods  243:243-255.  
     [0344] Wang A M, Doyle M V &amp; Mark D F (1989) Quantitation of Mrna by the Polymerase Chain Reaction.  Proc Nat Acad Sci U S A  86:9717-9721.  
     [0345] Wang E, Miller L D, Ohnmacht G A, Liu E T &amp; Marincola F M (2000) High-Fidelity Mrna Amplification for Gene Profiling.  Nat Biotechnol  18:457-459.  
     [0346] Warrington J A, Dee S &amp; Trulson M (2000) in Schena M, ed,  Microarray Biochip Technology,  pp. 119-148, Eaton Publishing, Natick, Mass., United States of America.  
     [0347] Williams J F (1989) Optimization Strategies for the Polymerase Chain Reaction.  Biotechniques  7:762-769.  
     [0348] Williams J G, Kubelik A R, Livak K J, Rafalski J A &amp; Tingey S V (1990) DNA Polymorphisms Amplified by Arbitrary Primers Are Useful as Genetic Markers.  Nucleic Acids Res  18:6531-6535.  
     [0349] Worley J et al. (2000) in Schena M, ed,  Microarray Biochip Technology,  pp. 65-86, Eaton Publishing, Natick, Mass., United States of America,  
     [0350] Yang P, Deng T, Zhao D, Feng P, Pine D, Chmelka B F, Whitesides G M &amp; Stucky G D (1998) Hierarchically Ordered Oxides.  Science  282:2244-2246.  
     [0351] Yershov G, Barsky V, Belgovskiy A, Kirillov E, Kreindlin E, lvanov I, Parinov S, Guschin D, Drobishev A, Dubiley S &amp; Mirzabekov A (1996) DNA Analysis and Diagnostics on Oligonucleotide Microchips.  Proc Natl Acad Sci U S A  93:4913-4918.  
     [0352] It will be understood that various details of the presently claimed subject matter can be changed without departing from the scope of the presently claimed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.  
    
     
       
         1 
         
           
             70  
           
           
             1  
             435  
             DNA  
             Homo sapiens  
           
            1 

gtagagacaa ggtctcacca cactgcccag gctggtctca aactcccggc ctcaagcaat     60 

cctcatgtct tgagtctacg ttcttagcca gcatgtgatg ctaacccatt ctcataagca    120 

ccatcatcag cctggcaaca atcatcgaca ttttctggcc ttaaattttg aagatttttg    180 

ttttagattt attttacttt tttggtttta aattgctcga tattccccct ctacatttta    240 

gaacatgctt tctttcttga cactgatatt actgttagga tccagttatt actggctaat    300 

atttgccgag agtgacactg ggctaggttc tgtgctgagt agcttcatgt cacacccact    360 

ctaggaggaa ggtcttgatg gttgtcccca ttttccagac gaggaaactg agggttcaga    420 

aagaagtcat ttgca                                                     435 

 
           
             2  
             3257  
             DNA  
             Homo sapiens  
           
            2 

aacaggcgtg acgccagttc taaacttgaa acaaaacaaa acttcaaagt acaccaaaat     60 

agaacctcct taaagcataa atctcacgga gggtctcggc cgccagtgga aggagccacc    120 

gcccccgccc cgaccatggc cgaggagctg gtcttagaga ggtgtgatct ggagctggag    180 

accaatggcc gagaccacca cacggccgac ctgtgccggg agaagctggt ggtgcgacgg    240 

ggccagccct tctggctgac cctgcacttt gagggccgca actaccaggc cagtgtagac    300 

agtctcacct tcagtgtcgt gaccggccca gcccctagcc aggaggccgg gaccaaggcc    360 

cgttttccac taagagatgc tgtggaggag ggtgactgga cagccaccgt ggtggaccag    420 

caagactgca ccctctcgct gcagctcacc accccggcca acgcccccat cggcctgtat    480 

cgcctcagcc tggaggcctc cactggctac cagggatcca gctttgtgct gggccacttc    540 

attttgctct tcaacgcctg gtgcccagcg gatgctgtgt acctggactc ggaagaggag    600 

cggcaggagt atgtcctcac ccagcagggc tttatctacc agggctcggc caagttcatc    660 

aagaacatac cttggaattt tgggcagttt caagatggga tcctagacat ctgcctgatc    720 

cttctagatg tcaaccccaa gttcctgaag aacgccggcc gtgactgctc ccggcgcagc    780 

agccccgtct acgtgggccg ggtgggtagt ggcatggtca actgcaacga tgaccagggt    840 

gtgctgctgg gacgctggga caacaactac ggggacggcg tcagccccat gtcctggatc    900 

ggcagcgtgg acatcctgcg gcgctggaag aaccacggct gccagcgcgt caagtatggc    960 

cagtgctggg tcttcgccgc cgtggcctgc acagtgctga ggtgcctagg catccctacc   1020 

cgcgtcgtga ccaactacaa ctcggcccat gaccagaaca gcaaccttct catcgagtac   1080 

ttccgcaatg agtttgggga gatccagggt gacaagagcg agatgatctg gaacttccac   1140 

tgctgggtgg agtcgtggat gaccaggccg gacctgcagc cggggtacga gggctggcag   1200 

gccctggacc caacgcccca ggagaagagc gaaggaacgt actgctgtgg cccagttcca   1260 

gttcgtgcca tcaaggaggg cgacctgagc accaagtacg atgcgccctt tgtctttgcg   1320 

gaggtcaatg ccgacgtggt agactggatc cagcaggacg atgggtctgt gcacaaatcc   1380 

atcaaccgtt ccctgatcgt tgggctgaag atcagcacta agagcgtggg ccgagacgag   1440 

cgggaggata tcacccacac ctacaaatac ccagaggggt cctcagagga gagggaggcc   1500 

ttcacaaggg cgaaccacct gaacaaactg gccgagaagg aggagacagg gatggccatg   1560 

cggatccgtg tgggccagag catgaacatg ggcagtgact ttgacgtctt tgcccacatc   1620 

accaacaaca ccgctgagga gtacgtctgc cgcctcctgc tctgtgcccg caccgtcagc   1680 

tacaatggga tcttggggcc cgagtgtggc accaagtacc tgctcaacct aaccctggag   1740 

cctttctctg agaagagcgt tcctctttgc atcctctatg agaaataccg tgactgcctt   1800 

acggagtcca acctcatcaa ggtgcgggcc ctcctcgtgg agccagttat caacagctac   1860 

ctgctggctg agagggacct ctacctggag aatccagaaa tcaagatccg gatccttggg   1920 

gagcccaagc agaaacgcaa gctggtggct gaggtgtccc tgcagaaccc gctccctgtg   1980 

gccctggaag gctgcacctt cactgtggag ggggccggcc tgactgagga gcagaagacg   2040 

gtggagatcc cagaccccgt ggaggcaggg gaggaagtta aggtgagaat ggacctcgtg   2100 

ccgctccaca tgggcctcca caagctggtg gtgaacttcg agagcgacaa gctgaaggct   2160 

gtgaagggct tccggaatgt catcattggc cccgcctaag ggacccctgc tcccagcctg   2220 

ctgagagccc ccaccttgat cccaatcctt atcccaagct agtgagcaaa atatgcccct   2280 

tattgggccc cagaccccag ggcagggtgg gcagcctatg ggggctctcg gaaatggaat   2340 

gtgcccctgg cccatctcag cctcctgagc ctgtgggtcc ccactcaccc cctttgctgt   2400 

gaggaatgct ctgtgccaga aacagtggga gccctgacct gtgctgactg gggctggggt   2460 

gagagaggaa agacctacat tccctctcct gcccagatgc cctttggaaa gccattgacc   2520 

acccaccata ttgtttgatc tacttcatag ctccttggag caggcaaaaa agggacagca   2580 

tgcccttggc tggatcagga atccagctcc ctagactgca tcccgtacct cttcccatga   2640 

ctgcacccag ctccaggggc ccttgggaca cccagagctg ggtggggaca gtgataggcc   2700 

caaggtcccc tccacatccc agcagcccaa gcttaatagc cctccccctc aacctcacca   2760 

ttgtgaagca cctactatgt gctgggtgcc tcccacactt gctggggctc acggggcctc   2820 

caacccattt aatcaccatg ggaaactgtt gtgggcgctg cttccaggat aaggagactg   2880 

aggcttagag agaggaggca gccccctcca caccagtggc ctcgtggtta taagcaaggc   2940 

tgggtaatgt gaaggcccaa gagcagagtc tgggcctctg actctgagtc cactgctcca   3000 

tttataaccc cagcctgacc tgagactgtc gcagaggctg tctggggcct ttatcaaaaa   3060 

aagactcagc caagacaagg aggtagagag gggactgggg gactgggagt cagagccctg   3120 

gctgggttca ggtcccacgt ctggccagcg actgccttct cctctctggg cctttgtttc   3180 

cttgttggtc agaggagtga ttgaacctgc tcatctccaa ggatcctctc cactccatgt   3240 

ttgcaataca caattcc                                                  3257 

 
           
             3  
             368  
             DNA  
             Homo sapiens  
           
            3 

tttttttttc tattttctgt agaaacaagg tattgccatg ttgcccaggc tagtctcaaa     60 

ctcctgggct caagcaatgc cccctgcctc ggccacccaa agtgctggga ttacggttgt    120 

gtgccactgc gcccggccaa catccaatag cttttatcag aggctttgaa aggcagacat    180 

caggttcacc agatgctgag cctactcacc ttcgtcctcc tcctcttcat ccacaccatc    240 

cacctcggca tctgagtcag gtgcttcctg gtcctctcgg tcatagccat ccaagtaggt    300 

aagctggggc aggagcttga agacactctc tcggtagtca ttcaggttgg taacctcaca    360 

gttaaaga                                                             368 

 
           
             4  
             1475  
             DNA  
             Homo sapiens  
           
            4 

gtcgacgcgg ccgcgctccg ctcccgtgag taacttggct ccgggggctc cgctcgcctg     60 

cccgcacgcc gcccgccacc caggaccgcg ccgccggcct ccgccgctag caaacccttc    120 

cgacggccct cgctgcgcaa gccgggacgc ctctcccccc tccgcccccg ccgcggaaag    180 

ttaagtttga agagggggga agaggggaac atggacatga agaggaggat ccacctggag    240 

ctgaggaacc ggaccccggc agctgttcga gaacttgtct tggacaattg caaatcaaat    300 

gatggaaaaa ttgagggctt aacagctgaa tttgtgaact tagagttcct cagtttaata    360 

aatgtaggct tgatctcagt ttcaaatctc cccaagctgc ctaaattgaa aaagcttgaa    420 

ctcagtgaaa atagaatctt tggaggtctg gacatgttag ctgaaaaact tccaaatctc    480 

acacatctaa acttaagtgg aaataaactg aaagatatca gcaccttgga acctttgaaa    540 

aagttagaat gtctgaaaag cctggacctc tttaactgtg aggttaccaa cctgaatgac    600 

taccgagaga gtgtcttcaa gctcctgccc cagcttacct acttggatgg ctatgaccga    660 

gaggaccagg aagcacctga ctcagatgcc gaggtggatg gtgtggatga agaggaggag    720 

gacgaagaag gagaagatga ggaagacgag gacgatgagg atggtgaaga agaggagttt    780 

gatgaagaag atgatgaaga tgaagatgta gaaggggatg aggacgacga tgaagtcagt    840 

gaggaggaag aagaatttgg acttgatgaa gaagatgaag atgaggatga ggatgaagag    900 

gaggaagaag gtgggaaagg tgaaaagagg aagagagaaa cagatgatga aggagaagat    960 

gattaagacc ccagatgacc tgcagaaaca gaactgttca gtattggttg gactgctcat   1020 

ggattttgta gctgtttaaa aaaaaaaaaa aggtagctgt gatacaaacc ccaggacacc   1080 

cacccaccca aagagccaaa gaatagttcc tgtgacattc cgccttcctt ccatgtagtc   1140 

cctcttggta atctaccacc aagcttgtgg acttcacccc aacaaaattg taagcgttgt   1200 

taggtttttg tgtaagattc ttgctgtagc gtggatagct gtgattggtg agtcaaccgt   1260 

ctgtggctac cagttacact gagattgtaa cagcattttt actttctgta caacaaaaaa   1320 

gctttgtaaa taaaatctta acattttggg tctgtttttt catgctttgc tttttaatta   1380 

ttattattat tttttttaca ttaggacatt ttatgtgaca actgccaaaa aagtattttt   1440 

aagaatttaa gcgaaataaa cagttactct ttggc                              1475 

 
           
             5  
             476  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(476)  
               N IS A, C, G, OR T  
             
           
            5 

gcaagttgga aaacagttta atgatcactc accaaaatcc acaggagaat cttaaatgtt     60 

tacaagcacc aattattctg ctattcctgc cattaccgca tccttcatgg tagagtatca    120 

caagtaaaag tttctggttg tttcatctac ttaaaaccag atataagaaa caacctaagt    180 

cttagcaact tcaggcttca atgtgaaacc attaaagccc tcagcacttt aggaggctga    240 

ggcaggagga ctgcttgaag ccaggagttc acgaccagcc tgggcaacaa agcaagaccc    300 

catctccata aaaaataaaa ataagttagc tgggcacagt agtgtgtgcc tgtagtccta    360 

ggtactcagg agactgaagt tgggaagggt cacttnaagc ccaggaagtt caaggctgca    420 

gtcatgccgc tggaactcca gcctaggtga tagagcaaga ccctatctca aacaaa        476 

 
           
             6  
             1599  
             DNA  
             Homo sapiens  
           
            6 

aagatcctgg cctgtgcagc tcgggtttcc gagcttctgc ctcaggcatc tccgcgatct     60 

cctctcccct ccaatcctat ccgtgatgga cgatgcccac gagtcgccct ccgacaaagg    120 

tggagagaca ggggagtcgg atgagacggc cgctgtgccc ggggacccgg gggctaccga    180 

caccgatgga atcccagagg aaactgacgg agacgcagat gtggacttga aagaagctgc    240 

agcggaggaa ggcgagctcg agagtcagga tgtctcagat ttaacaacag ttgaaaggga    300 

agactcatca ttacttaatc ctgcagccaa aaaactgaaa atagatacca aagaaaagaa    360 

agagaaaaag cagaaagtag atgaagatga gattcagaag atgcaaatcc tggtttcttc    420 

tttttctgag gagcagctga accgttatga aatgtatcgc cgctcagctt tccctaaggc    480 

agccatcaaa aggctgatcc agtccatcac tggcacctct gtgtctcaga atgttgttat    540 

tgctatgtct ggtatttcca aggttttcgt cggggaggtg gtagaagaag cactggatgt    600 

gtgtgagaag tggggagaaa tgccaccact acaacccaaa catatgaggg aagccgttag    660 

aaggttaaag tcaaaaggac agatccctaa ctcgaagcac aaaaaaatca tcttcttcta    720 

gaccaaagtc tagaaaggcc tatgttactg acggaagaag tattggttcc agacttccta    780 

taagactgtc tgcattggtg ctttagtatc tcaggcctcc aaggattcca tgatgatttt    840 

aatgtctttc tcaaaactct gatatttgtc acacctagaa agtatgtagc ctgattgata    900 

cttgccttga ctaaattttg ggacctcttg gggcattttg aagtatttaa ctgtcttgac    960 

cagttggaag aagatacgtg ggccataagc atcttctgga caggggaact gctttcagag   1020 

agaaaacctt tccaagagag ttttgttttg ttttggtttc gttttgtttg agatagggtc   1080 

ttgctctatc acctaggctg gagtgcagcg gcatgactgc agccttgaac tcctgggctt   1140 

aagtgaccct cccacctcag tctcctgagt agctaggact acaggcacac actactgtgc   1200 

ccagctaact tatttttatt ttttatggag atggggtctt gctttgttgc ccaggctggt   1260 

cgtgaactcc tggcttcaag cagtcctcct gcctcagcct cctaaagtgc cgagggcttt   1320 

aatggtttca cattgaagcc tgaagttgct aagacttagg ttgtttctta tatctggttt   1380 

taagtagatg aaacaaccag aaacttttac ttgtgatact ctaccatgaa ggatgcggta   1440 

atggcaggaa tagcagaata attggtgctt gtaaacattt aagattctcc tgtggatttt   1500 

ggtgagtgat cattaaactg ttttccaact tgcaaaaaaa aaaaaaaaaa aaaaaaaaaa   1560 

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa                          1599 

 
           
             7  
             294  
             DNA  
             Homo sapiens  
           
            7 

tcctggctaa tttttttatt ttttgtagag acaagggtct ccctacgttg tccaggctgg     60 

acttgaactc ctgggttcaa gcgatcctac caccttggcc tcccacagca ctggggttac    120 

aggcaggagc actgcacctg gccctgtctt tactgatggt cctgccccat gcctcccaca    180 

cctaaccctg ggcacccact cccgaagctc tcctactggc tgcagggtct gcctctgtga    240 

ggacagtgaa gccgatgaca cgggaggtga agtcgaaggc cgtctgctgg ccat          294 

 
           
             8  
             3480  
             DNA  
             Homo sapiens  
           
            8 

cgcccagcag cccgtgggca ggcgcggcgg agcgagcggg gccggcggcg ggcgccgagg     60 

gacgccgagg cctcgggcgg gggctggccc ggggttccag gtctccagtg ggggctgcag    120 

actaagcaaa atgaggcggt tcctgaggcc agggcatgac cctgtgcggg agaggctcaa    180 

gcgggacctg ttccagttta acaagacggt ggagcatggc ttcccgcacc agcccagcgc    240 

cctcggctac agcccgtccc tgcacatcct ggccatcggc acccgttctg gagccatcaa    300 

gctctacgga gccccaggcg tggagttcat ggggctgcac caggagaaca acgctgtgac    360 

gcagatccac ctcctgcccg gccagtgcca gctggtcacc ctgctggatg acaacagcct    420 

gcacctttgg agcctgaagg tcaagggcgg ggcatcggag ctgcaggagg atgagagctt    480 

cacactgcgt ggacccccag gggctgcccc cagtgccaca cagatcaccg tggtcctgcc    540 

acattcctcc tgcgagctgc tctacctggg caccgagagt ggcaacgtgt ttgtggtgca    600 

gctgccagct tttcgtgcgc tggaggaccg gaccatcagc tcggacgcgg tgctgcagcg    660 

gttgccagag gaggcccgcc accggcgtgt gttcgagatg gtggaggcac tgcaggagca    720 

ccctcgagac cccaaccaga tcctgatcgg ctacagccga ggcctcgttg tcatctggga    780 

cctacagggc agccgcgtgc tctaccactt cctcagcagc cagcaactgg agaacatctg    840 

gtggcagcgg gacggccgcc tgctcgtcag ctgtcactct gacggcagct actgccagtg    900 

gcccgtgtcc agcgaagccc agcaaccaga gcccctccgc agcctcgtgc cttacggtcc    960 

ctttccttgc aaagcgatta ccagaatcct ctggctgacc actaggcagg ggttgccctt   1020 

caccatcttc cagggtggca tgccacgggc cagctacggg gaccgccact gcatctcagt   1080 

gatccacgat ggccagcaga cggccttcga cttcacctcc cgtgtcatcg gcttcactgt   1140 

cctcacagag gcagaccctg cagccacctt tgacgacccc tatgccctgg tggtgctggc   1200 

tgaggaggag ctggtggtga ttgacctgca gacagcaggc tggccaccgg tccagctgcc   1260 

ctacctggct tctctgcact gttccgccat cacctgctct caccacgtct ccaacatccc   1320 

gctgaagctg tgggagcgga tcattgccgc cggcagccgg cagaacgcac acttctccac   1380 

catggagtgg ccaattgatg gtggcaccag cctgacccca gccccacccc agagggacct   1440 

gctgctcaca gggcacgagg acggcacggt gcggttctgg gatgcctcgg gtgtctgcct   1500 

gcggctgctc tacaaactca gcactgtgcg cgtgttcctc accgacacgg accccaacga   1560 

gaacttcagt gcccagggcg aggacgagtg gcccccactc cgcaaggtgg gctcctttga   1620 

cccctacagt gatgaccccc ggctgggcat ccagaagatc ttcctctgca agtacagcgg   1680 

ctacctggct gtggcaggca cggcagggca ggtgctggta ctggaactga atgacgaggc   1740 

agcggagcag gctgtggagc aggtggaggc cgacctgctg caggaccaag agggctaccg   1800 

ctggaagggg cacgagcgcc tggcagcccg ctcagggccc gtgcgctttg agcctggctt   1860 

tcagcccttc gtgttggtgc agtgtcagcc cccggctgtg gtcacctcct tggccctgca   1920 

ctctgagtgg cggctcgtgg ccttcggcac cagccatggc tttggcctct ttgaccacca   1980 

gcagcggcgg caggtctttg ttaagtgcac actgcacccc agtgaccagc tggccttgga   2040 

gggcccactc tcccgcgtca agtccctcaa gaagtccttg cgtcagtcat tccgccggat   2100 

gcgtcggagc cgggtgtcca gccggaagcg gcacccggct ggccccccag gagaggcaca   2160 

ggaggggagt gccaaggctg agcggccagg cctccagaac atggagctgg cgcctgtgca   2220 

gcgcaagatc gaggctcgct cggcagagga ctccttcaca ggcttcgtcc ggaccctgta   2280 

ctttgctgac acctacctga aggacagctc ccggcactgc ccctcgctgt gggctggcac   2340 

caatgggggc accatctatg ccttctccct gcgtgtgcct cccgccgagc ggagaatgga   2400 

tgagcctgtg cgggcagagc aggccaagga gatccagctg atgcaccggg cgccggtggt   2460 

gggcatcctg gtgctcgacg gacacagcgt accccttccc gagcccctcg aagtggccca   2520 

tgatctgtcg aagagccctg acatgcaggg aagccaccag ctgctcgtcg tatcagagga   2580 

gcagttcaag gtgttcacgc tgcccaaggt gagtgccaag ctgaagttga agctgacggc   2640 

cctggagggc tcaagagtgc ggcgggtcag cgtggcccac ttcggcagtc gtcgagccga   2700 

ggactacggg gagcaccacc tggcagtcct taccaacctg ggcgacatcc aggtggtctc   2760 

gctgcccctg ctcaagcccc aggtgcgcta cagctgcatc cgccgggagg acgtcagtgg   2820 

catcgcctcc tgcgtcttca ccaaatatgg ccaaggcttc tacctgatct caccctcgga   2880 

gtttgagcgc ttctctctct ccaccaagtg gctggtggag ccccggtgtc tggtggattc   2940 

agcagaaacc aagaaccacc gccctggtaa cggtgcgggc cccaagaagg ccccgagccg   3000 

agccaggaac tcagggactc agagtgatgg cgaggagaag cagcccggcc tggtgatgga   3060 

gcgcgctctg ctcagtgatg agagagcggc aactggcgtt cacatcgagc cgccgtgggg   3120 

tgcagcctca gcaatggcgg agcagagtga gtggctgagc gtccaggctg cgcgatgagc   3180 

acacactact actgatggcc tttcgggggt ccctgcccca accggagagg ccggtgcaca   3240 

gggccccgcc aggggctggg ggcatcccgg cttccacaat gcagctgctc tgggcctcgg   3300 

gagaggagag accccagtcc cctgggctgc ccttcccggg cctcgtctgt ctgggtcctt   3360 

tggtcaatgt tgcacagttt ttattgctcc catccctttt tgtagtgggc tgggttttaa   3420 

gttataaatg ttaactgcct ctgggtgaaa aagtttttaa taaacaccta ttacctcttg   3480 

 
           
             9  
             464  
             DNA  
             Homo sapiens  
           
            9 

tttttttgaa ttctgtttta tatcaagcta taaaaacctg gatcctgttc aacatacata     60 

caaaagcagt actctaaaaa ataattatta ttatattaac aatatcaaac acgctaactc    120 

ctacacacgt acaaagacct tgggcatcct ttataccggc cacttcctgg ccacagcttt    180 

gtaaggcagt acctgggaaa aggggacaga cccaagagag ccggccccaa atcctgactc    240 

agcactgcag aggcatcagc gggcctgagt catgcctgag atcgaagggc cccctctcag    300 

gctgagaagg aactttcagg cccagggagg agcagagcct tagggggagc acatgccgag    360 

caggaaaacg agctcacatt ttcctggggt agagcgaggt gcccggcacg aggggatgaa    420 

cggagggtgc ggtgggcaga ataacggcct cccaaagatg tcca                     464 

 
           
             10  
             4180  
             DNA  
             Homo sapiens  
           
            10 

ccagggtgat gctgaagatg atgaccttct tccaaggcct ctagagccat cagcctgtgc     60 

caggcaccct cgacttgcct agaggccccc aaaagttgca gtccacatca gaggcagagt    120 

cagaggcctc catgtcggag gcctcctctg aggacctggt gccacccctg gaggctgggg    180 

cagccccata tagggaggag gaagaggcgg cgaagaagaa gaaggagaag aagaagaagt    240 

ccaaaggcct ggccaatgtg ttctgcgtct tcaccaaagg gaagaagaag aagggtcagc    300 

ccagctcagc ggagcccgag gacgcagccg ggtccaggca ggggctggat ggcccgcccc    360 

ccacagtgga ggagctgaag gcggcgctgg agcgcgggca gctggaggcg gcgcggccgc    420 

tgctggcgct ggagcgggag ctggcggcgg cggcggcggc gggcggtgtg agcgaggagg    480 

agctggtgcg gcgccagagc aaggtggagg cgctgtacga gctgctgcgc gaccaggtgc    540 

tgggcgtgct gcggcggccg ctggaggcgc cgcccgagcg gctgcgccag gcgctggccg    600 

tggtggcgga gcaggagcgc gaggaccgcc aggcggcggc ggcggggccg gggacctcgg    660 

ggctggcggc cacgcgcccg cggcgctggc tgcagctgtg gcggcgcggc gtggcggagg    720 

cggccgagga gcgcatgggc cagcggccgg ccgcgggcgc cgaggtcccc gagagcgtct    780 

ttctgcactt gggccgcacc atgaaggagg acctggaggc cgtggtggag cggctgaagc    840 

cgctgttccc cgccgagttc ggcgtcgtgg cggcctacgc cgagagctac caccagcact    900 

tcgcggccca cctggccgcc gtggcgcagt tcgagctgtg cgagcgcgac acctacatgc    960 

tgctgctctg ggtgcagaac ctctacccca atgacatcat caacagcccc aagctggtgg   1020 

gtgagctgca gggtatgggg ctcgggagcc tcctgccccc caggcagatc cgactgctgg   1080 

aggccacatt cctgtccagt gaggcggcca atgtgaggga gttgatggac cgagctctgg   1140 

agctagaggc acggcgctgg gctgaggatg tgcctcccca gaggctggac ggccactgcc   1200 

acagcgagct ggccatcgac atcatccaga tcacctccca ggcccaggcc aaggccgaga   1260 

gcatcacgct ggacttgggc tcacagataa agcgggtgct gctggtggag ctgcctgcgt   1320 

tcctgaggag ctaccagcgc gcctttaatg aatttctgga gagaggcaag cagctgacga   1380 

attacagggc caatgttatt gccaacatca acaactgcct gtccttccgg atgtccatgg   1440 

agcagaattg gcaggtaccc caggacaccc tgagcctcct gctgggcccc ctgggtgagc   1500 

tcaagagcca cggctttgac accctgctcc agaacctgca tgaggacctg aagccactgt   1560 

tcaagaggtt cacgcacacc cgctgggcgg cccctgtgga gaccctggaa aacatcatcg   1620 

ccactgtaga cacgaggctg cctgagttct cagagctgca gggctgtttc cgggaggagc   1680 

tcatggaggc cttgcacctg cacctggtga aggagtacat catccaactc agcaaggggc   1740 

gcctggtcct caagacggcc gagcagcagc agcagctggc tgggtacatc ctggccaatg   1800 

ctgacaccat ccagcacttc tgcacccagc acggctcccc ggcgacctgg ctgcagcctg   1860 

ctctccctac gctggccgag atcattcgcc tgcaggaccc cagtgccatc aagattgagg   1920 

tggccactta tgccacctgc taccctgact tcagcaaagg ccacctgagc gctatcctgg   1980 

ccatcaaggg gaacctatcc aacagtgagg tcaagcgcat ccggagcatc ttggacgtca   2040 

gcatgggggc gcaggagccc tcccggcccc tattttccct tataaaggtt ggttagcttt   2100 

tcctgtggcc tgacctgcct gtgagtgccc agcaagcctt gggcacaccc cgctgggagc   2160 

tgttaagagc agcgctggtt ctcggttcct cccgggtctc ctgtgctctg atgctacttc   2220 

tgcctagccc tggcggaggt gcaggccctg tcagctggaa ctggacagac cttggtttgt   2280 

ttacatgtcc gatgggggca ggagctccca tcctgggcag ccaaccaggc aacaccaagg   2340 

actctttgta aacgatagct gatcgtgtgc acgcaaggaa agaaccagga gggagagtgc   2400 

agccaggctc agggatcccc ggacacctct gtccagagcc cctccacagt cggcctcatg   2460 

actgtcctcc tcgtgggtgg ggccgagggc cctcttcagc tctctggaga caggggccga   2520 

gcctcaccca tctgccctct gcagcccagg gccgccgtga gcgggattca gcaatggtgg   2580 

aatggaagac agaactggaa gagaaagaag gaaaagatga gctctcgtct ggcaggggct   2640 

tttagggtcc tgtggcgagc tgtgagcacc gccagcatta gacgtcacat ccaggtggcc   2700 

ccacggcccc tacaggctgg ccctgcaatg gggccctgag ccctccctct tcatccccca   2760 

aggcctcaac tagagggtgg tcccccgagg gcttggtgtc tactaccgaa gggcccaaga   2820 

cctcctgggt cctctcaggc tcccccttcc ccaaggcagg gacaggccct gggggtgcca   2880 

ccgtgggccc tgccacccag aagtctggct gaggtctggg caggggcagg gcaagcttga   2940 

cctctcactg ttgacccttt ggcctctgta tttgtttcct attgccgtga caggtttcca   3000 

caaacttcgt ggatcaaaac gaggtcttcc agttctgcgg gtcagaaggc tgacccgggg   3060 

ctcaaatctg ggtgtcggca gtcctgcact ccttctggag gctctagggg agaattcatt   3120 

tctggccttt tcatttttag aggctgaccg taattcttga cttcaggctc ctccatcttc   3180 

agagccagct gtgggtagtt gaatcttttt cccgtcacct cattgaggcc tcccctctcc   3240 

tgcctccctc caccactttt tttttttttt ttttgagaca gggtcttgct gtgttgccca   3300 

ggctggagtg cagtggcctg gtcatggcat caaggctcac tgcagcctgg acctcctggt   3360 

tcaagtgatc ctcttgtctc agtcccctga gacaatcccc cacgcccagc tacatatttt   3420 

ttgtggatac agggtctcat tctgttgcct aggcttgtct ggaactcctg ggctcaaggg   3480 

atcttgtagc cttagcctcc taaagtgctg ggattatagg catgagtcac tgtacccggc   3540 

ctgctctacc gcttttaagg acgcttatga tcacattgcg cctacccaga gaacccaggt   3600 

cgtctttcta ttttcaggtc agctgattag ccaccttagt tccatctgca actttagttc   3660 

ccactggctg tgtaacctaa catagtcaca ggctctgggg actgtcacgt ggacatcttt   3720 

gggaggccgt tattctgccc accgcaccct ccgttcatcc cctgccctgc cgggcacctc   3780 

gctctacccc aggaaaatgt gagctcgttt tcctgctcgg catgtgctcc ccctaaggct   3840 

ctgctcctcc ctgggcctga aagttccttc tcagcctgag agggggccct tcggactcag   3900 

gcatgactca gcccggctga tgcctctgca gtgctgagtc aggatttggg gccggctctc   3960 

ttgggtccgt ccccttttcc caggtactgc cttacaaagc tgtggccagg aagtggccgg   4020 

tataaaggat gcccaaggtc tttgtacgtg tgtaggagtt agcgtgtttg atattgttaa   4080 

tataataata attatttttt agagtactgc ttttgtatgt atgttgaaca ggatccaggt   4140 

ttttatagct tgatataaaa cagaattcaa aagtgaaaaa                         4180 

 
           
             11  
             557  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(557)  
               N IS A, C, G, OR T  
             
           
            11 

actaggtatt ttgaccaacg tgatttagct gatgagccat cttgatgtag ctgatctctc     60 

agggatagaa gatatttctc atgaaggcag cctaactctg aggaaaacaa tgccaattca    120 

agtacagatt tcaacacatc ttcaacacta tgtgaagggt tcacatctta acctgtgcaa    180 

ttcagattga tactcagaat atgggttgat ttgaatatct gaaatatcaa tggaaaatcc    240 

cactcagttt ttgatgaaca gtttgaacag ttttctgtaa tcaagcagct tgcatagaaa    300 

ttgtatgatg aaattttaca taggttcttg gtgctgtttt gttctttttt tgttttttgt    360 

tgttttgtta tttacttata tacatataaa attttattga aaatatgttt tggttacnaa    420 

aattttgttt gactcctaac aaaagacaat ggatggcctt agcatcagaa ttaaaataat    480 

cngggattaa atgggcatgt gttcatagtc agccataaaa ttaaacattt ttccccctta    540 

agcncagcac ctttttt                                                   557 

 
           
             12  
             1285  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(1285)  
               N IS A, C, G, OR T  
             
           
            12 

taacgctccc taaactgcca cttgntcagc tccgcgccta aggtgtctat tagtgcgcct     60 

gcgctgtgac ctagaatggg cgcatgcgcc gagcggaact ggctggtttg aaaaccatgg    120 

cgtgggtacc agcggagtcc gcagtggaag agttgatgcc tcggctattg ccggtagagc    180 

cttgcgactt gacggaaggt ttcgatccct cggtaccccc gaggacgcct caggaatacc    240 

tgaggcgggt ccagatcgaa gcagctcaat gtccagatgt tgtggtagct caaattgacc    300 

caaagaagtt gaaaaggaag caaagtgtga atatttctct ttcaggatgc caacccgccc    360 

ctgaaggtta ttccccaaca cttcaatggc aacagcaaca agtggcacag ttttcaactg    420 

ttcgacagaa tgtgaacaaa catagaagtc actggaaatc acaacagttg gatagtaatg    480 

tgacaatgcc aaaatctgaa gatgaagaag gctggaagaa attttgtctg ggtgaaaagt    540 

tatgtgctga cggggctgtt ggaccagcca caaatgaaag tcctggaata gattatgtac    600 

aaattggttt tcctcccttg cttagtattg ttagcagaat gaatcaggca acagtaacta    660 

gtgtcttgga atatctgagt aattggtttg gagaaagaga ctttactcca gaattgggaa    720 

gatggcttta tgctttattg gcttgtcttg aaaagccttt gttacctgag gctcattcac    780 

tgattcggca gcttgcaaga aggtgctctg aagtgaggct cttagtggat agcaaagatg    840 

atgagagggt tcctgctttg aatttattaa tctgcttggt tagcaggtat tttgaccaac    900 

gtgatttagc tgatgagcca tcttgatgta gctgatctct cagggataga agatatttct    960 

catgaaggca gcctaactct gaggaaaaca atgccaattc aagtacagat ttcaacacat   1020 

cttcaacact atgtgaaggg ttcacatctt aacctgtgca attcagattg atactcagaa   1080 

tatgggttga tttgaatatc tgaaatatca atggaaaatc ccactcagtt tttgatgaac   1140 

agtttgaaca gttttctgta atcaagcagc ttgcatagaa attgtatgat gaaattttac   1200 

ataggttctt ggtgctgttt tgttcttttt ttgttttttg ttgttttgtt atttacttat   1260 

atacatataa aattttattg aaaat                                         1285 

 
           
             13  
             412  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(412)  
               N IS A, C, G, OR T  
             
           
            13 

ggtggctgtc tgggcggccg gggcgtgttg cgctgcgntg cttctctcag cgctgaancc     60 

gggatccacg tcccacgggc cggacccgcg gcgcgttcgg caccatcggt aacctctgcc    120 

aaagtggctg tgaatggcgt tcanctgcat taccagcaga ctggagaggg agatcacgca    180 

gtccatgcta cttcctggga tgttaggaag tggagagact gattttggac ctcagctcaa    240 

gaacctcaat aagaagctct tcacggtggt cgcctgggat cctccgaggc tatggacatt    300 

ccaggccccc agatcgcgat ttcccagcag acttttttga aagggatgca aaagatgctg    360 

ttgatttgat gaaggcgctg aagtttaaga aggtttctct gctggggtgg ag            412 

 
           
             14  
             1521  
             DNA  
             Homo sapiens  
           
            14 

ggatccacgt cccacgggcc ggacccgcgg ccgcgttcgg aaatcagcct gagcctgagt     60 

accgctaagg ctttaatcac gggtcccgag agccctaagt cttctctttg cttgctgatc    120 

tcgtacctta atgtgcaaaa gaatcacgtt gggaactgaa aattcagaat cctgggcctc    180 

actcccagag gatctgatct acatgtgtgg agatgcccag gaatctgctt tattctcttt    240 

tgtcctccca cctgtccccc catttcagca cctcggtaac ctctgccaaa gtggctgtga    300 

atggcgttca gctgcattac cagcagactg gagagggaga tcacgcagtc ctgctacttc    360 

ctgggatgtt aggaagtgga gagactgatt ttggacctca gctcaagaac ctcaataaga    420 

agctcttcac ggtggtcgcc tgggatcctc gaggctatgg acattccagg cccccagatc    480 

gcgatttccc agcagacttt tttgaaaggg atgcaaaaga tgctgttgat ttgatgaagg    540 

cgctgaagtt taagaaggtt tctctgctgg ggtggagtga tgggggcata accgcactca    600 

ttgctgctgc aaaatatcca tcttacatcc acaagatggt gatctggggc gccaacgcct    660 

acgtcactga cgaagacagc atgatatatg agggcatccg agatgtttcc aaatggagtg    720 

agagaacaag aaagcctcta gaagccctct atgggtatga ctactttgcc agaacctgtg    780 

aaaagtgggt ggatggcata agacagttta aacatctccc agatggtaac atctgccggc    840 

acctgctgcc ccgggtccag tgccccgcct tgattgtgca cggtgagaag gatcctctgg    900 

tcccacggtt tcatgccgac ttcattcata agcacgtgaa aggctcacgg ctgcatttga    960 

tgccagaagg caaacacaac ctgcatttgc gttttgcaga tgaattcaac aagttagcag   1020 

aagacttcct acaatgagaa tgcacactcc agtcttggtg gttccttcgt gtggggcttg   1080 

atcgtgttgc tgcctgttaa catgatgcct ttgaaactct ccgcctttga aactttctac   1140 

ccctcccttc aatcttatcc taaccaaatg agaataatga catattgaaa acagcctcta   1200 

gcttcaggct gggcacggtg gctcacagct ataatctcag cactttggga ggctgaggtg   1260 

ggagaattgc ctgagcccag gagttcaaga ccagcttgtg caatataggg agactccggc   1320 

tctacaaaaa agagtttttc aaaattagcc aggcgaagtg gcacacatct gtggtcccag   1380 

gtgctcagga agctgaggtg ggaggatcac ttgagcccaa ttcaaagctg cagtgagctg   1440 

taattgcatc actgcactcc aacctgggca acagagtaag accttgtctt aaaaaaaaat   1500 

aaaaacataa aaaaaaaaaa a                                             1521 

 
           
             15  
             379  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(379)  
               N IS A, C, G, OR T  
             
           
            15 

ttttttttgg cagcaaagtt ttattgtaaa ataagagatc gatataaaaa tgggatataa     60 

aaagggagaa ggaggggaag ggtggggtga aaatgcagat gtgcttgcag aatgtaaaag    120 

atgttgaccc ttccagctgg acgtggtggc tcacaattgt aatcccagca ctctgggagg    180 

ctgagacagg tggatcgcct gagcccagga gtttgagacc agcctgggca acactntgag    240 

accccatctc tacaaaacat gcaaaagttg gctggccatg gtngcatnaa cctgcggtcc    300 

cagctactcc cggagcttga ggcaggactn ctcgagccng gtttaggcaa aaggcctnca    360 

agtnagccca agntcacgc                                                 379 

 
           
             16  
             2629  
             DNA  
             Homo sapiens  
           
            16 

acttgtcatg gcgactgtcc agctttgtgc caggagcctc gcaggggttg atgggattgg     60 

ggttttcccc tcccatgtgc tcaagactgg cgctaaaagt tttgagcttc tcaaaagtct    120 

agagccaccg tccagggagc aggtagctgc tgggctccgg ggacactttg cgttcgggct    180 

gggagcgtgc tttccacgac ggtgacacgc ttccctggat tggcagccag actgccttcc    240 

gggtcactgc catggaggag ccgcagtcag atcctagcgt cgagccccct ctgagtcagg    300 

aaacattttc agacctatgg aaactacttc ctgaaaacaa cgttctgtcc cccttgccgt    360 

cccaagcaat ggatgatttg atgctgtccc cggacgatat tgaacaatgg ttcactgaag    420 

acccaggtcc agatgaagct cccagaatgc cagaggctgc tccccgcgtg gcccctgcac    480 

cagcagctcc tacaccggcg gcccctgcac cagccccctc ctggcccctg tcatcttctg    540 

tcccttccca gaaaacctac cagggcagct acggtttccg tctgggcttc ttgcattctg    600 

ggacagccaa gtctgtgact tgcacgtact cccctgccct caacaagatg ttttgccaac    660 

tggccaagac ctgccctgtg cagctgtggg ttgattccac acccccgccc ggcacccgcg    720 

tccgcgccat ggccatctac aagcagtcac agcacatgac ggaggttgtg aggcgctgcc    780 

cccaccatga gcgctgctca gatagcgatg gtctggcccc tcctcagcat cttatccgag    840 

tggaaggaaa tttgcgtgtg gagtatttgg atgacagaaa cacttttcga catagtgtgg    900 

tggtgcccta tgagccgcct gaggttggct ctgactgtac caccatccac tacaactaca    960 

tgtgtaacag ttcctgcatg ggcggcatga accggaggcc catcctcacc atcatcacac   1020 

tggaagactc cagtggtaat ctactgggac ggaacagctt tgaggtgcgt gtttgtgcct   1080 

gtcctgggag agaccggcgc acagaggaag agaatctccg caagaaaggg gagcctcacc   1140 

acgagctgcc cccagggagc actaagcgag cactgcccaa caacaccagc tcctctcccc   1200 

agccaaagaa gaaaccactg gatggagaat atttcaccct tcagatccgt gggcgtgagc   1260 

gcttcgagat gttccgagag ctgaatgagg ccttggaact caaggatgcc caggctggga   1320 

aggagccagg ggggagcagg gctcactcca gccacctgaa gtccaaaaag ggtcagtcta   1380 

cctcccgcca taaaaaactc atgttcaaga cagaagggcc tgactcagac tgacattctc   1440 

cacttcttgt tccccactga cagcctccca cccccatctc tccctcccct gccattttgg   1500 

gttttgggtc tttgaaccct tgcttgcaat aggtgtgcgt cagaagcacc caggacttcc   1560 

atttgctttg tcccggggct ccactgaaca agttggcctg cactggtgtt ttgttgtggg   1620 

gaggaggatg gggagtagga cataccagct tagattttaa ggtttttact gtgagggatg   1680 

tttgggagat gtaagaaatg ttcttgcagt taagggttag tttacaatca gccacattct   1740 

aggtaggtag gggcccactt caccgtacta accagggaag ctgtccctca tgttgaattt   1800 

tctctaactt caaggcccat atctgtgaaa tgctggcatt tgcacctacc tcacagagtg   1860 

cattgtgagg gttaatgaaa taatgtacat ctggccttga aaccaccttt tattacatgg   1920 

ggtctaaaac ttgaccccct tgagggtgcc tgttccctct ccctctccct gttggctggt   1980 

gggttggtag tttctacagt tgggcagctg gttaggtaga gggagttgtc aagtcttgct   2040 

ggcccagcca aaccctgtct gacaacctct tggtcgacct tagtacctaa aaggaaatct   2100 

caccccatcc cacaccctgg aggatttcat ctcttgtata tgatgatctg gatccaccaa   2160 

gacttgtttt atgctcaggg tcaatttctt ttttcttttt tttttttttt tttctttttc   2220 

tttgagactg ggtctcgctt tgttgcccag gctggagtgg agtggcgtga tcttggctta   2280 

ctgcagcctt tgcctccccg gctcgagcag tcctgcctca gcctccggag tagctgggac   2340 

cacaggttca tgccaccatg gccagccaac ttttgcatgt tttgtagaga tggggtctca   2400 

cagtgttgcc caggctggtc tcaaactcct gggctcaggc gatccacctg tctcagcctc   2460 

ccagagtgct gggattacaa ttgtgagcca ccacgtggag ctggaagggt caacatcttt   2520 

tacattctgc aagcacatct gcattttcac cccacccttc ccctccttct ccctttttat   2580 

atcccatttt tatatcgatc tcttatttta caataaaact ttgctgcca               2629 

 
           
             17  
             455  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(455)  
               N IS A, C, G, OR T  
             
           
            17 

gcgnccgcct catgcaggag gtgaatcggc agctgcaggg ccacctgggc gagatccgcg     60 

agctcaagca gctcaaccgg cgtctgcagg cagagaaccg tgagctgcgc acctctgctg    120 

cttcctggac tcggagcgcc agcggngcgg cgccgannca ngtggcagct cttcgggacc    180 

caagcatccc gggccgtgcg cgaggacctg ggcggctgtt ggcagaagct ggccgagctg    240 

gagggccgcc aggaggagct gctgcgggag aacctagcgc ttaaggagct ctgcctggcg    300 

ctgggcgaag aatggggccc ccgcggcggc ccagcggcgc cgggggatca ggagccgggc    360 

cagcaccgag cttgcttgcc ccgtgcggcc ccngacctag cgatggaact canatgcagc    420 

gtgggatcgg atanttgcct gntgttcccg atgat                               455 

 
           
             18  
             879  
             DNA  
             Homo sapiens  
           
            18 

gggcgatgct ccagaggcct gaccagccat ggaggccgag gcaggcggcc tggaggagct     60 

gacggacgag gagatggcgg cgctaggcaa ggaagagcta gtgcggcgcc tgcggcggga    120 

ggaggcgacg cgcctggcgg cactggtgca gcgcggccgc ctcatgcagg aggtgaatcg    180 

gcagctgcag ggccacctgg gcgagatccg cgagctcaag cagctcaacc ggcgtctgca    240 

ggcagagaac cgtgagctgc gcgacctctg ctgcttcctg gactcggagc gccagcgcgg    300 

gcggcgcgcc gcacgccagt ggcagctctt cgggacccaa gcatcccggg ccgtgcgcga    360 

ggacctgggc ggctgttggc agaagctggc cgagctggag ggccgccagg aggagctgct    420 

gcgggagaac ctagcgctta aggagctctg cctggcgctg ggcgaagaat ggggcccccg    480 

cggcggcccc agcggcgccg ggggatcagg agccgggcca gcacccgagc ttgccttgcc    540 

cccgtgcggg ccccgcgacc taggcgatgg aagctccagc actggcagcg tgggcagtcc    600 

ggatcagttg cccctggcct gttcccccga tgattgaagg cactgcttcc tccacgccga    660 

cgcccgcccg gattgctccc cgagccccgg gaccgctgtg gacctcggga cctggacgcc    720 

gtcctggctg cgcaggaggg gccgctggca tggactaaga aatcctgaca ccaagaaggg    780 

cccctcgctc ttgctggcag ggcagcaggg ggactgaagg ctggagcgga gggacttgct    840 

gggggttgga ttgggggtaa taaacccgga cggaagcgg                           879 

 
           
             19  
             607  
             DNA  
             Homo sapiens  
           
            19 

tttttttttc gtttatttat ttatttttag agataggttc tcactctgtt atccaggctg     60 

gaatgcagtg gcgtgatcat agctcactgc agcctccact cctgggcaca agtgtcctct    120 

cacctcagcc ttacaagtag ctgggactat atgcatgggc caccacgcca ggctatttgt    180 

tttattattg agtagagatg ggggtctccc tgtgttgccc aggctgtgtc aaactcctgg    240 

cctcaagcat cctcggacct tgcccttcaa aagtgctggg attacaggcc accctgccct    300 

gcctctccag tccctgactg tccccactgg ccagccccga aagcccagca acgagggagc    360 

caggctgggg caggaaacac acagcagcct cctctcgcgc ccactttatt agggggcagg    420 

tgtgggagga cctaggcctg ctgtgcctgc agtagcgccc gcacctggcg gatctgccag    480 

tcgacgctgg agcgcgcagt gccgcccagg gcaccatact gctccaactg tgcccgtagt    540 

ccacacgcag atcacgtcgc cgagaacagg ggctgatggc tgcagctctg agtgacactg    600 

gttgagg                                                              607 

 
           
             20  
             1502  
             DNA  
             Homo sapiens  
           
            20 

gacactatcc gtgcggccag gcggagaccc ggaggaccga gccctccgga cgacgaggaa     60 

ccgcccaaca tggcctcgga gagtgggaag ctttggggtg gccggtttgt gggtgcagtg    120 

gaccccatca tggagaagtt caacgcgtcc attgcctacg accggcacct ttgggaggtg    180 

gatgttcaag gcagcaaagc ctacagcagg ggcctggaga aggcagggct cctcaccaag    240 

gccgagatgg accagatact ccatggccta gacaaggtgg ctgaggagtg ggcccagggc    300 

accttcaaac tgaactccaa tgatgaggac atccacacag ccaatgagcg ccgcctgaag    360 

gagctcattg gtgcaacggc agggaagctg cacacgggac ggagccggaa tgaccaggtg    420 

gtcacagacc tcaggctgtg gatgcggcag acctgctcca cgctctcggg cctcctctgg    480 

gagctcatta ggaccatggt ggatcgggca gaggcggaac gtgatgttct cttcccgggg    540 

tacacccatt tgcagagggc ccagcccatc cgctggagcc actggattct gagccacgcc    600 

gtggcactga cccgagactc tgagcggctg ctggaggtgc ggaagcggat caatgtcctg    660 

cccctgggga gtggggccat tgcaggcaat cccctgggtg tggaccgaga gctgctccga    720 

gcagaactca actttggggc catcactctc aacagcatgg atgccactag tgagcgggac    780 

tttgtggccg agttcctgtt ctggcgttcg ctgtgcatga cccatctcag caggatggcc    840 

gaggacctca tcctctactg caccaaggaa ttcagcttcg tgcagctctc agatgcctac    900 

agcacgggaa gcagcctgat gccccagaag aaaaaccccg acagtttgga gctgatccgg    960 

agcaaggctg ggcgtgtgtt tgggcggtgt gccgggctcc tgatgaccct caagggactt   1020 

cccagcacct acaacaaaga cttacaggag gacaaggaag ctgtgtttga agtgtcagac   1080 

actatgagtg ccgtgctcca ggtggccact ggcgtcatct ctacgctgca gattcaccaa   1140 

gagaacatgg gacaggctct cagccccgac atgctggcca ctgaccttgc ctattacctg   1200 

gtccgcaaag ggatgccatt ccgccaggcc cacgaggcct ccgggaaagc tgtgttcatg   1260 

gccgagacca agggggtcgc cctcaaccag ctgtcactgc aggagctgca gaccatcagc   1320 

cccctgttct cgggcgacgt gatctgcgtg tgggactacg ggcacagtgt ggagcagtat   1380 

ggtgccctgg gcggcactgc gcgctccagc gtcgactggc agatccgcca ggtgcgggcg   1440 

ctactgcagg cacagcaggc ctaggtcctc ccacacctgc cccctaataa agtgggcgcg   1500 

ag                                                                  1502 

 
           
             21  
             401  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(401)  
               N IS A, C, G, OR T  
             
           
            21 

tttttttttt tttcaaatat aattattatg tttatttgaa gtgagatgat ggaaaagatg     60 

gcctggctga ttttggaccg agtggcccat cacgatacct gaacaagcag ttntgagggt    120 

gggcctggca cacccctggn atgtttacag gagcatctgg tccagtcctg tcttatggct    180 

ntgccagctc cagctctcga agagtctctc tgaggagcag ggcctggnag ctgggcctgc    240 

aaagccagag ctaccactag aagaagggct gggctggagc agggccaggg aaaggagacc    300 

tttccagggg gacaaggttg cacgcagcct tcagggtgca gccagaacct gccggcagac    360 

cccagggcca ccgacggagg gcaggccttc accagggatt t                        401 

 
           
             22  
             1822  
             DNA  
             Homo sapiens  
           
            22 

tcacctctca ccatctgctc tgtggctccc agtgctgact ctggaagctt tatcttgggt     60 

aaaagatgtg tgatcagacc tttctcgtta atgtatttgg ctcatgtgac aaatgtttca    120 

aacaacgagc tctgagacca gttttcaaga agtctcaaca actcagctac tgttcaacat    180 

gtgcagaaat tatggcaacc gaggggctgc acgagaacga gacgctggcg tcgctgaaga    240 

gcgaggccga gagcctcaag ggcaagctgg aggaggagcg agccaagctg cacgatgtgg    300 

agctgcacca ggtggcggag cgggtggagg ccctggggca gtttgtcatg aagaccagaa    360 

ggaccctcaa aggccacggg aacaaagtcc tgtgcatgga ctggtgcaaa gataagagga    420 

ggatcgtgag ctcgtcacag gatgggaagg tgatcgtgtg ggattccttc accacaaaca    480 

aggagcacgc ggtcaccatg ccctgcacgt gggtgatggc atgtgcttat gccccatcgg    540 

gatgtgccat tgcttgtggt ggtttggata ataagtgttc tgtgtacccc ttgacgtttg    600 

acaaaaatga aaacatggct gccaaaaaga agtctgttgc tatgcacacc aactacctgt    660 

cggcctgcag cttcaccaac tctgacatgc agatcctgac agcgagcggc gatggcacat    720 

gtgccctgtg ggacgtggag agcgggcagc tgctgcagag cttccacgga catggggctg    780 

acgtcctctg cttggacctg gccccctcag aaactggaaa caccttcgtg tctgggggat    840 

gtgacaagaa agccatggtg tgggacatgc gctccggcca gtgcgtgcag gcctttgaaa    900 

cacatgaatc tgacatcaac agtgtccggt actaccccag tggagatgcc tttgcttcag    960 

ggtcagatga cgctacgtgt cgcctctatg acctgcgggc agatagggag gttgccatct   1020 

attccaaaga aagcatcata tttggagcat ccagcgtgga cttctccctc agtggtcgcc   1080 

tgctgtttgc tggatacaat gattacacta tcaacgtctg ggatgttctc aaagggtccc   1140 

gggtctccat cctgtttgga catgaaaacc gcgttagcac tctacgagtt tcccccgatg   1200 

ggactgcttt ctgctctgga tcatgggatc ataccctcag agtctgggcc taatcatctt   1260 

ctgacagtgc actcatgtat acctgagaat ttgaaatctt cacatgtaaa tagatattac   1320 

ttctagagga gcttagagtt tattgcagtg tagcttaggg gagcaaccca tggctcacag   1380 

gtcactaagc gtctccaata tgactattaa aactgtcacc tctggaaata cactagtgtg   1440 

agccttcagc actgcgagaa taccttcaag tacagtattt ttcttttgga acacttttta   1500 

aaatgtatct gtttttaagg ttattctaaa ttatagtagc ctcaactcat tctgtcacca   1560 

gtagaattca gcagttaata tattccatat tatttctttg aatcaattca ttttcagagc   1620 

actttaaagt ctgatatttc tcgatgtgca ctgtgatgcc tggaaccttc ctctggaagt   1680 

gctgatttta tggactgagg actggtgact ggtctgtgat agaagcaaat tccaattcca   1740 

aatgtaatta gacaaaaatc atttttttag aatgtgtttt tattgtaaaa gtatcttttt   1800 

cagcaaaaaa aaaaaaaaaa aa                                            1822 

 
           
             23  
             270  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(270)  
               N IS A, C, G, OR T  
             
           
            23 

acactaatat aattaaccaa caaaaatata ctgcagttcc gatgaaatga ggtcaacatg     60 

acatgatcct tttggaatga ctttctaatt tgaattacaa tgtgagtgaa gtattttaga    120 

agacattcta tcaaataatg atagacctgc ataaggaggc tgtcacagaa gatctgtctc    180 

tggtggacag acaanccaga ttaacatgan attgtaaagg aaaaagcttt tttatactta    240 

ttattatggc tttttgcaac atgggcaaaa                                     270 

 
           
             24  
             4139  
             DNA  
             Homo sapiens  
           
            24 

agtgctcgcg gggccgcggc ggagtgtacc gtgctgctct actcgctgcc attcgcccgc     60 

aggtcggcgc gctcgcccac ctgagccgcg ccggggctgc gggaccgtgg gacagcgcgc    120 

tcagcccagc ctaggaaaga ggcagcagtc tcagcgcgga gatggggagc gggcgaagtt    180 

gacgagtctc ccgcccacgc tgcgcccctc ctgcccagag gggctgcagc cagcggtctg    240 

tcgcgcgtgc ctgtgtgccc gaggagccgc cccggggaga agacccggcg cggagttgtt    300 

cccccaggga ggatccgcag cccagccgag ggggtcgggc ggcctggcta cgcaggaccc    360 

agccccgcag ccgcggactc ccagcggcgg cgaagtttgg ctgctgagcg gcgcggcgcc    420 

ggaccactgg acagcgggag cgatgcccgt ggggggcctg ttgccgctct tcagcagccc    480 

cgcgggcggc gtcctgggcg gggggctcgg cggcggcggt ggcaggaagg ggtcgggccc    540 

cgccgccctc cgcctgacgg agaagttcgt gctgctgctg gtattcagcg ccttcatcac    600 

gctctgcttc ggggcgatct tcttcctgcc agactcctcc aagctgctca gcggggtcct    660 

gttccactcc agccccgcct tgcagccggc cgccgaccac aagcccgggc ccggggcgcg    720 

cgccgaggac gcggccgagg ggcgagcccg gcgccgcgag gagggggcac ccggggaccc    780 

ggaggccgcc ctggaggaca acttggccag gatccgcgaa aaccacgagc gggctctcag    840 

ggaagccaag gagaccctgc agaagctgcc cgaggagatc caaagagaca tcctactgga    900 

gaagaagaag gtggcccagg accagctgcg tgacaaggcg ccgttcagag gcctgccccc    960 

ggtggacttc gtgcccccaa tcggggtgga gagccgggag cccgccgacg ccgccatccg   1020 

cgagaaaagg gcaaagatca aagagatgat gaaacatgct tggaataatt ataaaggtta   1080 

tgcctgggga ttaaatgaac tcaaacctat atcaaaagga ggccattcaa gcagtttgtt   1140 

tggtaacatc aaaggagcaa ctatagtaga tgccctggat acacttttta ttatggaaat   1200 

gaaacatgaa tttgaagaag caaaatcatg ggttgaagaa aatttagatt ttaatgtgaa   1260 

tgctgaaatt tctgtctttg aagtaaatat acgctttgtt ggtggactac tctcagccta   1320 

ctatctgtct ggagaagaga tttttcgaaa gaaagcagtg gaacttgggg taaaattgct   1380 

acctgcattt catactccct ctggaatacc ttgggcattg ctgaatatga aaagtggtat   1440 

tggaaggaac tggccctggg cctctggagg cagcagtatt ctggcagaat ttggaaccct   1500 

gcatttggag tttatgcact tgagccactt atcaggaaac cccatctttg ctgaaaaggt   1560 

aatgaatatt cgaacagtac tgaacaaact ggaaaaacca caaggccttt atcctaacta   1620 

tctgaatccc agtagtggac agtggggtca acatcatgta tcagttggag gacttggaga   1680 

cagcttctat gagtatttgc tgaaggcctg gttaatgtct gacaagacag atctggaagc   1740 

taagaagatg tattttgatg ctgttcaggc tatcgagact catttgatcc gcaagtctag   1800 

cagcggacta acttatatcg cagagtggaa agggggcctc ctggagcaca agatgggcca   1860 

cctgacctgc ttcgcggggg gcatgttcgc actcggggct gatgcagctc ccgaaggcat   1920 

ggcccaacac taccttgaac tcggggctga aattgcccgt acttgtcatg aatcatataa   1980 

tcgaacattt atgaaactgg gaccagaagc tttcagattt gatggtggtg ttgaagccat   2040 

cgctacaaga caaaatgaaa aatactacat cttacggcca gaagttatgg agacttacat   2100 

gtatatgtgg agactgactc atgatccaaa gtacaggaaa tgggcctggg aagccgtaga   2160 

ggccttggaa aaccattgca gagtgaatgg aggctattca ggcctaaggg atgtttacct   2220 

tcttcatgag agttatgatg atgtgcagca gagtttcttc ctggcagaga cattgaaata   2280 

tttgtaccta atattttctg acgacgatct tcttccactg gagcattgga tcttcaatag   2340 

cgaggcacat cttctcccta tcctccctaa agataaaaag gaagttgaaa tcagagagga   2400 

ataaaaagac attttatatt ttattctgct ccattccctt cactgtatac cttaataatt   2460 

ccttttctgg taatcaggca catgatgaac tttgattagt aggtctgtga ttaagttctt   2520 

aaattgtttt gcagtctttt atgtttatta tcataggtat aggtggacct aaattcctta   2580 

tcatatcctt tattaattca gccagtgtat ccaccagttt tttgtttatg tttttaagta   2640 

acctattatc tctggatttc atgaaggtgt aatatcgttt ttgttaaact gaatagaatt   2700 

gtatagcgat gacctcttaa ttataatttg atttgactgc aaaacttttt cctcctctaa   2760 

gaggagatga tgtctgcttt aagctgtaat gttttgccat gttgcaaaaa gccataataa   2820 

taagtataaa aaagcttttt cctttacaat ttcatgttaa tctggtttgt ctgtccacca   2880 

gagacagatc ttctgtgaca gcctccttat gcaggtctat cattatttga tagaatgtct   2940 

tctaaaatac ttcactcaca ttgtaattca aattagaaag tcattccaaa aggatcatgt   3000 

catgttgacc tcatttcatc ggaactgcag tatatttttg ttggttaatt atattagtgt   3060 

tttctatttt gtaaatgtgt cctttaattt tactttaaat gccctgtgtc atttctggat   3120 

tatatactag ttaatttctt ccattcccta ctacacagag aggtgagctt tcaaattttg   3180 

cagagctctg ctatcactga attacattta tctgaagaaa atagtacaac ttaatggatt   3240 

agcttttggg tttaactgaa tatatgaaga aattgggtct gtctaaagag agggtatttc   3300 

atatggcttt tagttcactt gtttgtattt catcttgatt tttttctttg gaaaataaag   3360 

cattctattt ggttcagatt tctcagattt gaaaaaggct ctatctcaga tgtagtaaat   3420 

tatttccttt cagtttgtga aagcaggatt tgactctgaa agaagctttg ccaattttac   3480 

ttattcgtga tcaatcaagg aaaatctaat aaattttagg ccaaataaga atatagcata   3540 

tttagtatgg ttatagtcaa cacagagatc acaacttaga agaaatataa agaaatggcc   3600 

actccccatc ccccacagtc ctggagtaaa tcaaaatcaa tatatgattc ttttaaacat   3660 

taagtttgaa ataggaatgg ttttctcaag aatagatttg gtgtgatacc ttgtgtttgc   3720 

ttacattggc ccactatata tacatatata tttatgtaga tatacttcca tgaaagggct   3780 

aatacgatgc atatactgaa gggcaaggac tttgaccatg tcaattttca gccgagaatg   3840 

gtcagaaaga tcagtacaac cccatggatt aggctgaaac atatgaaatt gctgcatttg   3900 

tagtttaaaa actgtcagca gtttcatatg gttccaccta atattattga agacaattat   3960 

tttcttagct atcaataggc ttaatagttt tagttatttt agcttttgaa agtgttttaa   4020 

aagatttcct ttatcggaca ggaccatctt tatgacctgc tttctgtttt tcaatatcat   4080 

acattggtgt atgtcaaaga ataaattagt aaaattagta aaaaaaaaaa aaaaaaaaa    4139 

 
           
             25  
             342  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(342)  
               N IS A, C, G, OR T  
             
           
            25 

gatcttgctc agtcgctcag gcaggagtgc agtggcgcaa tcatagctca ctgcagcctc     60 

aacctcctga gctcaaatga tctctccacc tcagcctttc aagtagttgg gactacaggc    120 

atgcactatc aagaccaact aattaaaaaa atttttttta aagacaggag ctctctatgt    180 

tgcccaggnt ggtctcaaac tgctgggctc aagcaattct cctgccttag cctcccaaag    240 

tgctggggat tatagggggt gagccaccca tgccaggggc tgataggcat catttctagg    300 

gtgggaaatt actttgggct tccaaatgtt aaaggnttaa ac                       342 

 
           
             26  
             310  
             DNA  
             Homo sapiens  
           
            26 

gatcttgctc agtcgctcag gcaggagtgc agtggcgcaa tcatagctca ctgcagcctc     60 

aacctcctga gctcaaatga tctctccacc tcagcctttc aagtagttgg gactacaggc    120 

atgcactatc aagaccaact aattaaaaaa atttttttta aagacaggag ctctctatgt    180 

tgcccaggct ggtctcaaac tgctgggctc aagcaattct cctgccttag cctcccaaag    240 

tgctgggatt ataggggtga gccaccatgc caggactgat agcatcattt ctaggtggaa    300 

attactttgg                                                           310 

 
           
             27  
             505  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(505)  
               N IS A, C, G, OR T  
             
           
            27 

ggaggcaggg tctctccgta gcccagcctg gactacagtg gcaagatcac ggctcactgc     60 

agtctcgaat tcttagaatc aggtgatcct cctgcctcag cctcccgagc agctgggact    120 

accagggcat accaccacgc ctggctaatt tttgtacttt ttgtagagac ggggtttcat    180 

catgttgctc aggctggtct cgaactcctt agctcaagca atctgcccgc cttggccttt    240 

caaagtgctg ggattacagg tgtgaaccac cgtgcctggc tgactacagt tttttaattg    300 

cacgtttgtt ctttgaactg accactgtgg gcattccatg cttcctccac tgccgccttt    360 

ttcccaagct gaaaagacaa ggaagatgtg gcatcaaatc aaccagaaag agcacgcctg    420 

gacctcccat cancacgtaa caacaggtgc acatcaaagc tgtactcaag aaaaggtaga    480 

catagaatga taaatcccca aaatg                                          505 

 
           
             28  
             1325  
             DNA  
             Homo sapiens  
           
            28 

atgtggtcga gtgtaggctc ccacgttgga ccgggaccgg taggggtagc tgttgccatc     60 

atggctgacc ccgacccccg gtaccctcgc tcctcgatcg aggacgactt caactatggc    120 

agcagcgtgg cctccgccac cgtgcacatc cgaatggcct ttctgagaaa agtctacagc    180 

attctttctc tgcaggttct cttaactaca gtgacttcaa cagttttttt atactttgag    240 

tctgtacgga catttgtaca tgagagtcct gccttaattt tgctgtttgc cctcggatct    300 

ctgggtttga tttttgcgtt gactttaaac agacataagt atccccttaa cctgtaccta    360 

ctttttggat ttacgctgtt ggaagctctg actgtggcag ttgttgttac tttctatgat    420 

gtatatatta ttctgcaagc tttcatactg actactacag tattttttgg tttgactgtg    480 

tatactctac aatctaagaa ggatttcagc aaatttggag cagggctgtt tgctcttttg    540 

tggatattgt gcctgtcagg attcttgaag tttttttttt atagtgagat aatggagttg    600 

gtcttagccg ctgcaggagc ccttcttttc tgtggattca tcatctatga cacacactca    660 

ctgatgcata aactgtcacc tgaagagtac gtattagctg ccatcagcct ctacttggat    720 

atcatcaatc tattcctgca cctgttacgg tttctggaag cagttaataa aaagtaatta    780 

aaagtatctc agctcaactg aagaacaaca aaaaaaattt aacgagaaaa aaggattaaa    840 

gtaattggaa gcagtatata gaaactgttt cattaagtaa taaagtttga aacaatgatt    900 

aaatactgtt acaatcttta tttgtatcat atgtaatttt gagagcttta aaatcttact    960 

attctttatg atacctcatt tctaaatcct tgatttagga tctcagttaa gagctatcaa   1020 

aattctatta aaaatgcttt tctggctggg cacagtggct cacgcctgta atcccaccac   1080 

tttgggagac cgaggcaggt ggatcacgag gtcaagaggt tgagaccatc ctggccaaca   1140 

tggtgaaacc ccgtctctac taaaaataca aaaattagct ggatgtggtg gcacacacct   1200 

gtagtcccag ctagtcaaga ggctgaggcc agagaatcgc ttgaacctgg gaggtggagg   1260 

ttgcattgag ccaagatcac gccactgcat tccagcctgg tgacagagcg agactcagtc   1320 

tcaaa                                                               1325 

 
           
             29  
             580  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(580)  
               N IS A, C, G, OR T  
             
           
            29 

tttagagacg gggtctcgct atgttgccca ggctggagtg caggaggatt gcttgagctc     60 

aggagttcaa gactggcctg ggcaaagttt aagaccggcc tgggcaacat agtgagacct    120 

ggtttctata aaaaatataa aaattagctg ggtatggtgg cgtgtgcctg tcatcccagc    180 

aactcgggct gaggtgggag gattgcttga gctgtgacag catttaaggg ttttcagcct    240 

ctgcagggcc cgatccagat gagaagggtg gctgcagtag ggctgggcgg gctgactcag    300 

tggcagccgc agcnttgacc accatgttgc ggtgcttgcg caggatgacg ttgttgctgc    360 

tgtcatagta gagcacagag gtggcgctca gcttggtggg tgcacgcacg ccttggggac    420 

tgcgtttggc ttcatcaggt gcaccaggga ctgcaggatg gcgtggttgg tggcgttcat    480 

gcaggagtcc agcgggaagg agcactcccc tcacagtaat aggctgagta gccttggggg    540 

cgatgaccag tccagcagcc gagtcctgaa gcgacgagag                          580 

 
           
             30  
             3536  
             DNA  
             Homo sapiens  
           
            30 

ccgcccgtcc cgccccgccc cgccgcccgc cgcccgccga gcccagcctc cttgccgtcg     60 

gggcgtcccc aggccctggg tcggccgcgg agccgatgcg cgcccgctga gcgccccagc    120 

tgagcgcccc cggcctgcca tgaccgcgct ccccggcccg ctctggctcc tgggcctggc    180 

gctatgcgcg ctgggcgggg gcggccccgg cctgcgaccc ccgcccggct gtccccagcg    240 

acgtctgggc gcgcgcgagc gccgggacgt gcagcgcgag atcctggcgg tgctcgggct    300 

gcctgggcgg ccccggcccc gcgcgccacc cgccgcctcc cggctgcccg cgtccgcgcc    360 

gctcttcatg ctggacctgt accacgccat ggccggcgac gacgacgagg acggcgcgcc    420 

cgcggagcgg cgcctgggcc gcgccgacct ggtcatgagc ttcgttaaca tggtggagcg    480 

agaccgtgcc ctgggccacc aggagcccca ttggaaggag ttccgctttg acctgaccca    540 

gatcccggct ggggaggcgg tcacagctgc ggagttccgg atttacaagg tgcccagcat    600 

ccacctgctc aacaggaccc tccacgtcag catgttccag gtggtccagg agcagtccaa    660 

cagggagtct gacttgttct ttttggatct tcagacgctc cgagctggag acgagggctg    720 

gctggtgctg gatgtcacag cagccagtga ctgctggttg ctgaagcgtc acaaggacct    780 

gggactccgc ctctatgtgg agactgagga cgggcacagc gtggatcctg gcctggccgg    840 

cctgctgggt caacgggccc cacgctccca acagcctttc gtggtcactt tcttcagggc    900 

cagtccgagt cccatccgca cccctcgggc agtgaggcca ctgaggagga ggcagccgaa    960 

gaaaagcaac gagctgccgc aggccaaccg actcccaggg atctttgatg acgtccacgg   1020 

ctcccacggc cggcaggtct gccgtcggca cgagctctac gtcagcttcc aggacctcgg   1080 

ctggctggac tgggtcatcg ctccccaagg ctactcggcc tattactgtg agggggagtg   1140 

ctccttccca ctggactcct gcatgaatgc caccaaccac gccatcctgc agtccctggt   1200 

gcacctgatg atgccagacg cagtccccaa ggcgtgctgt gcacccacca agctgagcgc   1260 

cacctctgtg ctctactatg acagcagcaa caatgtcatc ctgcgcaagc accgcaacat   1320 

ggtggtcaag gcctgcggct gccactgagt ccacccgccc ggcccagctg cagccaccct   1380 

tctcatctgg atcgggcccc tcagaagcag gaaaccctca aacccagcca gaccccaggc   1440 

cggggcattg ccagggagga ccctcacaac cacgtacatg accctttctc cttcatgcca   1500 

ggctcctatg ctccccttgc cctgccaggc atttgtgtga ctgtcctgtt tccagcccag   1560 

gtggtctcaa tcatcaggca gtgttctacc caaatgcaaa cgcctctccc ggaggcatgt   1620 

cctggctggt tctttggggt tggcacagaa gtcctgtctg aggtcctatc catgcccctt   1680 

actggctcag gtcgtgagat agatgtggaa tgacctgaga ggcacctgga gcccactgtt   1740 

ggccaccttg agctcttcac catccatcac agggtgtggt gtgtgtagtc agggtctggt   1800 

tggctcccca ttgcctgccc gaggtgcaag gtggggtata aaactggata acccctgaag   1860 

tattgtatat tcatggatct gaagcactga tccactggtc acaggtagac atgtggagtc   1920 

aactcaagaa aaagctgagt gaacagcatg atttagggct aaagccaatg gcatttatct   1980 

tcccttgtct tcctgctttg catttgcctc tgccatctag gaaagacatg taagagcatg   2040 

gacattttac tttggagaaa cagaaaaatc ttggggcttc caattgaccc atctatctgc   2100 

caccatgttg ccccaccagg agctcagctc tgtggagttt tccctttgct gagcaagcat   2160 

gtggttgcat tgggtggccc aggatgacaa tgcacagcac agatgccatc atttcccttt   2220 

cccctctgaa tggcagacat cagtaatcaa tctggaatgt ttttcttcca aatctgagtg   2280 

gaattttcaa atgatcagca cagccactgc caacagatat gatgtaaagt gaaacctggt   2340 

tgccatcttc tgccatgctg aggagcagtc catccctgcc cgagcatgta tcggcaacat   2400 

gggcagcctg tgaccgggtc tggggcgagg ccaggggcca tcaaaaacag gctgatcacc   2460 

aaagtcagtg tcaccctgga tgcccagcag ccctgtcctg tgtcttgggc ctgtgagtca   2520 

aagaaaaggt ccttttcagg gagtgacaag tagtaattag gctgagttgg gtggagaggt   2580 

ttgtctcagc ctctgctgtt ctcggaaact gctgttctcc ttggagcagc cactgggagt   2640 

tggagtgttt atttgatttc tgacttgcta agcctgtaat ttacctgctg gaatagacag   2700 

agtccagctg cccaaaccgt gtcattaaaa gcagatcctg cgcccgcccc atccacaggc   2760 

acagcccggc agagtggttc cacctcccca tgggcccaag gatgcgcctc tctggagttc   2820 

acgtgctgca cccccaggga ggggcctggg gaaagctggt ccagcagcag gggtggaggc   2880 

tggggccaca ctgcgggaca gcagcccctc cacctggacc agggagggcc tccatgtgca   2940 

agcgcagagg aagagaccct cccatgtacg caaagggcag ccccaggctg tctggaagtt   3000 

ggagaattcc ctatcagcac agggatctca gctctggcct ggaggtgaag agacctgcct   3060 

tgtaggtggc ttccttatct gcgcctccat tttctatctg cactttttga tctccaaaca   3120 

accttcagcc aaagaatctg tctaccaact cctcatagtg agccagaagc agcctcataa   3180 

ccctgaatgt ggggctctgg tggctgtcac gaagcagagt tggcacataa catggaacct   3240 

ggccaggcat ggtggctcac acctataacc ccagcacttt gggaggccaa ggcaggcaga   3300 

tcacctgaag tcaggagttc aagaccatcc tggccaacac agtgaaaccc catctgtact   3360 

aaaaatacaa gattacctgg gcatggtggt gcatgcctat aatcccagct actcaggagg   3420 

ctgaggcaga attgcttgaa cctgggaggt ggaggttgca gtgagcagag atcacaacat   3480 

tgcacttcag cctggtgaca tgagcaaaac tgttgtctca acaaaatgaa attatg       3536 

 
           
             31  
             324  
             DNA  
             Homo sapiens  
           
            31 

ggcagtttta agtttaatag gtgcaaacct ttacttcagg aattaaaccc cttatgataa     60 

ataaaagaat taaatcagat ttttttttaa tacagatagg ggtctcgcta tgttgcccag    120 

gctggtcttg aactcttggc ctcaagcgat cttcccacct tggcctccca aagtgccagg    180 

attacaggcc tgagccacca cacctagccc taaatcagaa ttttttaaaa aaaatttact    240 

taaaagaaaa atggaaaaat aaaactttca acactagact gccgccctgt taagaatgtc    300 

taatatgcaa tcaaagtatt ggaa                                           324 

 
           
             32  
             1810  
             DNA  
             Homo sapiens  
           
            32 

ctcagttagc ggtggagagg cagtatgtcc ggttcaatgg cgactgcgga agctagcggc     60 

agcgatggga aagggcagga agtcgagacc tcagtcacct attaccggtt ggaggaggtg    120 

gcaaagcgca actccttgaa ggaactgtgg cttgtgatcc atgggcgagt ctacgatgtc    180 

acccgcttcc tcaacgagca ccctggagga gaagaggttc tgctggaaca agctggtgta    240 

gatgcaagtg aaagctttga agatgtagga cactcttctg atgccagaga aatgctaaag    300 

cagtactaca ttggtgatat ccatccgagt gaccttaaac ctgaaagtgg tagcaaggac    360 

ccttcaaaaa atgatacatg caaaagttgc tgggcatatt ggattttacc catcataggc    420 

gctgttctct taggtttcct gtaccgctac tacacatcgg aaagcaaatc ctcctgagga    480 

ggccttgctg aagttagaaa gtgcatccac tttggggcga aaactagaga cttgcttggg    540 

ggctgcagaa gtgccctctc ctcgaatcct gccagttgca ttcttccccc ttggagccaa    600 

gacgattggc cagacatcac ctcagatctg agaccagcgt cttccatctc tcagagcctt    660 

actcccaaag tacctgctca ctgttccgtg ttgaacaatt gccggtgttt cctctcttca    720 

ctggtttcca tgagtaccct tatatttcac aactttctgt tcataagtta tagtgacatt    780 

gctctttggt aaaaatgcct gctttccaat actttgattg catattagac attcttaaca    840 

gggcggcagt ctagtgttga aagttttatt tttccatttt tcttttaagt aaattttttt    900 

taaaaaattc tgatttaggg ctaggtgtgg tggctcaggc ctgtaatcct ggcactttgg    960 

gaggccaagg tgggaacatc gcttgaggcc aagagttcaa gaccagcctg ggcaacatag   1020 

cgagacccct atctgtatta aaaaaaaatc tgatttaatt cttttattta tcataagggg   1080 

tttaattcct gaagtaaagg tttgcaccta ttaaacttaa aactgccaaa tgatttttgt   1140 

tcttttatgt gcgtgataaa aatacaaaga atggtgtggc cacctcctcc ctttcaagct   1200 

agggcagcag gtagctcttc ccagcccctg agcccagccc cttcccaagt ggtgccggac   1260 

aaaaaactac atggcccttt cgtgtcttgg gggtggaaag ggagggatga attggggtga   1320 

tagaaccctg gtgaattcag agtaatcttt ctttagaaaa ctggtgtttt ctaaagaaac   1380 

aggataggag tttagagaag gcaccaaagc tttcactttg gtttggcacc agtttctaac   1440 

catctgtttt ttctacccta gctatctttt attggtaaaa tataaatgta taattatgtt   1500 

tgtagagctt taccaaggag tttccctcct ttttttgttt gttgattagc aaatttttga   1560 

ttctccattt tccaaaagta agagactcca gcatggcctt ctgtttgccc cgcagtaaag   1620 

taacttccat ataaaatggt atttgaaagt gagagttcat gacaacagac cgttttccat   1680 

ttcatctgta ttttatctcc gtgactccaa cttgtgggtt tgttctgttt ttccatgaga   1740 

ataaaatact ggcggttttt tttcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa   1800 

aaaaaaaaaa                                                          1810 

 
           
             33  
             451  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(451)  
               N IS A, C, G, OR T  
             
           
            33 

anattncaaa ttatttaatg gaaaattcca aaatacatga gagccatttc cattcaatat     60 

actttgttac aacaattcca tgtacttcca aaatcagatg ctttgtagac tagcttggca    120 

acatggtgaa gccctgtctc tacaaaaaat cagctgggca tggtggcatg tgcctgtagt    180 

ttcagccacc tggggaggat gaggttgggg ggtcacctaa gcctgagaag tcaaggctgc    240 

agtgagccat gatcgtgcca ctgcactcca gcctggggcg acagagcaag accctgtctc    300 

aaaaaacaaa acccagcaag accccagtct tttaacttgt gaagcccctt tactcgtctt    360 

tnagcgctta cagcacatca tcccggggtt nacgttnagg ccgnacccga gggggcagtt    420 

cgttcccgct nggggttccn caaggcaggg a                                   451 

 
           
             34  
             3153  
             DNA  
             Homo sapiens  
           
            34 

ccggggccac gcgattggcg cgaagttttc ttttctcctt ccaccttctt ttcatttcta     60 

gtgagacaca cgctttggtc ctggctttcg gcccgtagtt gtagaaggag ccctgctggt    120 

gcaggttaga ggtgccgcat cccccggagc tctcgaagtg gaggcggtag gaaacggagg    180 

gcttgcggct agccggagga agctttggag ccggaagcca tggcacacta ccccacaagg    240 

ctgaagacca gaaaaactta ttcatgggtt ggcaggccct tgttggatcg aaaactgcac    300 

taccaaacct atagagaaat gtgtgtgaaa acagaaggtt gttccaccga gattcacatc    360 

cagattggac agtttgtgtt gattgaaggg gatgatgatg aaaacccgta tgttgctaaa    420 

ttgcttgagt tgttcgaaga tgactctgat cctcctccta agaaacgtgc tcgagtacag    480 

tggtttgtcc gattctgtga agtccctgcc tgtaaacggc atttgttggg ccggaagcct    540 

ggtgcacagg aaatattctg gtatgattac ccggcctgtg acagcaacat taatgcggag    600 

accatcattg gccttgttcg ggtgatacct ttagccccaa aggatgtggt accgacgaat    660 

ctgaaaaatg agaagacact ctttgtgaaa ctatcctgga atgagaagaa attcaggcca    720 

ctttcctcag aactatttgc ggagttgaat aaaccacaag agagtgcagc caagtgccag    780 

aaacccgtga gagccaagag taagagtgca gagagccctt cttggacccc agcagaacat    840 

gtggccaaaa ggattgaatc aaggcactcc gcctccaaat ctcgccaaac tcctacccat    900 

cctcttaccc caagagccag aaagaggctg gagcttggca acttaggtaa ccctcagatg    960 

tcccagcaga cttcatgtgc ctccttggat tctccaggaa gaataaaacg gaaagtggcc   1020 

ttctcggaga tcacctcacc ttctaagaga tctcagcctg ataaacttca aaccttgtct   1080 

ccagctctga aagccccaga gaaaaccaga gagactggac tctcttatac tgaggatgac   1140 

aagaaggctt cacctgaaca tcgcataatc ctgagaaccc gaattgcagc ttcgaaaacc   1200 

atagacatta gagaggagag aacacttacc cctatcagtg ggggacagag atcttcagtg   1260 

gtgccatccg tgattctgaa accagaaaac atcaaaaaga gggatgcaaa agaagcaaaa   1320 

gcccagaatg aagcgacctc tactccccat cgtatccgca gaaagagttc tgtcttgact   1380 

atgaatcgga ttaggcagca gcttcggttt ctaggtaata gtaaaagtga ccaagaagag   1440 

aaagagattc tgccagcagc agagatttca gactctagca gtgacgaaga agaggcttcc   1500 

acaccgcccc ttccaaggag agcacccaga actgtgtcca ggaacctgcg atcttccttg   1560 

aagtcatcct tacataccct cacgaaggtg ccaaagaaga gtctcaagcc tagaacgcca   1620 

cgttgtgccg ctcctcagat ccgtagtcga agcctggctg cccaggagcc agccagtgtg   1680 

ctggaggaag cccgactgag gctgcatgtt tctgctgtac ctgagtctct tccctgtcgg   1740 

gaacaggaat tccaagacat ctacaatttt gtggaaagca aactccttga ccataccgga   1800 

gggtgcatgt acatctccgg tgtccctggg acagggaaga ctgccactgt tcatgaagtg   1860 

atacgctgcc tgcagcaggc agcccaagcc aatgatgttc ctccctttca atacattgag   1920 

gtcaatggca tgaagctgac ggagccccac caagtctatg tgcacatctt gcagaagcta   1980 

acaggccaaa aagcaacagc caaccatgcg gcagaactgc tggcaaagca attctgcacc   2040 

cgagggtcac ctcaggaaac caccgtcctg cttgtggatg agctcgacct tctgtggact   2100 

cacaaacaag acataatgta caatctcttt gactggccca ctcataagga ggcccggctt   2160 

gtggtcctgg caattgccaa cacaatggac ctgccagagc gaatcatgat gaaccgggtg   2220 

tccagccgac tgggtcttac caggatgtgc ttccagccct atacatatag ccagctgcag   2280 

cagatcctaa ggtcccggct caagcatcta aaggcctttg aagatgatgc catccagctg   2340 

gtagccagga aggtagcagc actgtctgga gatgcacgac ggtgcctgga catctgcagg   2400 

cgtgccacag agatctgtga gttctcccag cagaagcctg actcccctgg cctggtcacc   2460 

atagcccact caatggaagc tgtggatgag atgttttcat catcatacat cacggccatc   2520 

aaaaattcct ctgttctgga acagagcttc ctgagagcca tcctcgcaga gttccgtcga   2580 

tcaggactgg aggaagccac gtttcaacag atatatagtc aacatgtggc actgtgcaga   2640 

atggagggac tgccgtaccc caccatgtca gagaccatgg ccgtgtgttc tcacctgggc   2700 

tcctgtcgcc tcctgcttgt ggagcccagc aggaacgatc tgctccttcg ggtgcggctc   2760 

aacgtcagcc aggatgatgt gctgtatgcg ctgaaagacg agtaaagggg cttcacaagt   2820 

taaaagactg gggtcttgct gggttttgtt ttttgagaca gggtcttgct ctgtcgccca   2880 

ggctggagtg cagtggcacg atcatggctc actgcagcct tgacttctca ggcttaggtg   2940 

accccccaac ctcatcctcc caggtggctg aaactacagg cacatgccac catgcccagc   3000 

tgattttttg tagagacagg gcttcaccat gttgccaagc tagtctacaa agcatctgat   3060 

tttggaagta catggaattg ttgtaacaaa gtatattgaa tggaaatggc tctcatgtat   3120 

tttggaattt tccattaaat aatttgcttt tta                                3153 

 
           
             35  
             235  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(235)  
               N IS A, C, G, OR T  
             
           
            35 

gctccccaaa gtgttgagcc accgcatctg gctgagaatt tttaactttc agaaaacctg     60 

gntgcagcag gtgcggtaga tcacgcctgt aaccccagct ctttgggagg ccgaggtagg    120 

cggatcacaa ggncaagaga tcaagactat cttggccaac atgatgaaac cctgtctcta    180 

ctaaaaatac taaatttagc tgggtgtggt ggtgtacatc tgtaatccca gttaa         235 

 
           
             36  
             231  
             DNA  
             Homo sapiens  
           
            36 

gctccccaaa gtgttgagcc accgcatctg gctgagaatt tttaactttc agaaaacctg     60 

gttgcagcag gtgcggtaga tcacgcctgt aaccccagct ctttgggagg ccgaggtagg    120 

cggatcacaa ggtcaagaga tcaagactat cttggccaac atgatgaaac cctgtctcta    180 

ctaaaaatac taaatttagc tgggtgtggt ggtgtacatc tgtaatccca g             231 

 
           
             37  
             442  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(442)  
               N IS A, C, G, OR T  
             
           
            37 

cgtttaacaa aattgtttaa taaaatttat aaaaatgcat ctttgagaat acttttctca     60 

gcttgaattg ttttcctttt ccacccccaa agaaaataca caattatcag cacccacaca    120 

tgtatacact caaaactaca gtgacattct ctacacagaa ctatattcga tatagcttga    180 

actgccgaaa aatcaagaca attccaaaaa gtgattgcag ggttgatttt tttctccaaa    240 

acactttgag aaacacgtaa agctatttca acaaaagtct tttctttgat tgtcaaaagt    300 

tgaaattcac atttaaataa aaagagatcc aaatcaagat cctcactnac cccctacccc    360 

tcaactgaac ccccttttag ggccacattt tcttcttgct cctaagaaaa aaatttggaa    420 

ttttgaatat tctcggtttt ct                                             442 

 
           
             38  
             4828  
             DNA  
             Homo sapiens  
           
            38 

agtggcgtcg gaactgcaaa gcacctgtga gcttgcggaa gtcagttcag actccagccc     60 

gctccagccc ggcccgaccc gaccgcaccc ggcgcctgcc ctcgctcggc gtccccggcc    120 

agccatgggc ccttggagcc gcagcctctc ggcgctgctg ctgctgctgc aggtctcctc    180 

ttggctctgc caggagccgg agccctgcca ccctggcttt gacgccgaga gctacacgtt    240 

cacggtgccc cggcgccacc tggagagagg ccgcgtcctg ggcagagtga attttgaaga    300 

ttgcaccggt cgacaaagga cagcctattt ttccctcgac acccgattca aagtgggcac    360 

agatggtgtg attacagtca aaaggcctct acggtttcat aacccacaga tccatttctt    420 

ggtctacgcc tgggactcca cctacagaaa gttttccacc aaagtcacgc tgaatacagt    480 

ggggcaccac caccgccccc cgccccatca ggcctccgtt tctggaatcc aagcagaatt    540 

gctcacattt cccaactcct ctcctggcct cagaagacag aagagagact gggttattcc    600 

tcccatcagc tgcccagaaa atgaaaaagg cccatttcct aaaaacctgg ttcagatcaa    660 

atccaacaaa gacaaagaag gcaaggtttt ctacagcatc actggccaag gagctgacac    720 

accccctgtt ggtgtcttta ttattgaaag agaaacagga tggctgaagg tgacagagcc    780 

tctggataga gaacgcattg ccacatacac tctcttctct cacgctgtgt catccaacgg    840 

gaatgcagtt gaggatccaa tggagatttt gatcacggta accgatcaga atgacaacaa    900 

gcccgaattc acccaggagg tctttaaggg gtctgtcatg gaaggtgctc ttccaggaac    960 

ctctgtgatg gaggtcacag ccacagacgc ggacgatgat gtgaacacct acaatgccgc   1020 

catcgcttac accatcctca gccaagatcc tgagctccct gacaaaaata tgttcaccat   1080 

taacaggaac acaggagtca tcagtgtggt caccactggg ctggaccgag agagtttccc   1140 

tacgtatacc ctggtggttc aagctgctga ccttcaaggt gaggggttaa gcacaacagc   1200 

aacagctgtg atcacagtca ctgacaccaa cgataatcct ccgatcttca atcccaccac   1260 

gtacaagggt caggtgcctg agaacgaggc taacgtcgta atcaccacac tgaaagtgac   1320 

tgatgctgat gcccccaata ccccagcgtg ggaggctgta tacaccatat tgaatgatga   1380 

tggtggacaa tttgtcgtca ccacaaatcc agtgaacaac gatggcattt tgaaaacagc   1440 

aaagggcttg gattttgagg ccaagcagca gtacattcta cacgtagcag tgacgaatgt   1500 

ggtacctttt gaggtctctc tcaccacctc cacagccacc gtcaccgtgg atgtgctgga   1560 

tgtgaatgaa gcccccatct ttgtgcctcc tgaaaagaga gtggaagtgt ccgaggactt   1620 

tggcgtgggc caggaaatca catcctacac tgcccaggag ccagacacat ttatggaaca   1680 

gaaaataaca tatcggattt ggagagacac tgccaactgg ctggagatta atccggacac   1740 

tggtgccatt tccactcggg ctgagctgga cagggaggat tttgagcacg tgaagaacag   1800 

cacgtacaca gccctaatca tagctacaga caatggttct ccagttgcta ctggaacagg   1860 

gacacttctg ctgatcctgt ctgatgtgaa tgacaacgcc cccataccag aacctcgaac   1920 

tatattcttc tgtgagagga atccaaagcc tcaggtcata aacatcattg atgcagacct   1980 

tcctcccaat acatctccct tcacagcaga actaacacac ggggcgagtg ccaactggac   2040 

cattcagtac aacgacccaa cccaagaatc tatcattttg aagccaaaga tggccttaga   2100 

ggtgggtgac tacaaaatca atctcaagct catggataac cagaataaag accaagtgac   2160 

caccttagag gtcagcgtgt gtgactgtga aggggccgcc ggcgtctgta ggaaggcaca   2220 

gcctgtcgaa gcaggattgc aaattcctgc cattctgggg attcttggag gaattcttgc   2280 

tttgctaatt ctgattctgc tgctcttgct gtttcttcgg aggagagcgg tggtcaaaga   2340 

gcccttactg cccccagagg atgacacccg ggacaacgtt tattactatg atgaagaagg   2400 

aggcggagaa gaggaccagg actttgactt gagccagctg cacaggggcc tggacgctcg   2460 

gcctgaagtg actcgtaacg acgttgcacc aaccctcatg agtgtccccc ggtatcttcc   2520 

ccgccctgcc aatcccgatg aaattggaaa ttttattgat gaaaatctga aagcggctga   2580 

tactgacccc acagccccgc cttatgattc tctgctcgtg tttgactatg aaggaagcgg   2640 

ttccgaagct gctagtctga gctccctgaa ctcctcagag tcagacaaag accaggacta   2700 

tgactacttg aacgaatggg gcaatcgctt caagaagctg gctgacatgt acggaggcgg   2760 

cgaggacgac taggggactc gagagaggcg ggccccagac ccatgtgctg ggaaatgcag   2820 

aaatcacgtt gctggtggtt tttcagctcc cttcccttga gatgagtttc tggggaaaaa   2880 

aaagagactg gttagtgatg cagttagtat agctttatac tctctccact ttatagctct   2940 

aataagtttg tgttagaaaa gtttcgactt atttcttaaa gctttttttt ttttcccatc   3000 

actctttaca tggtggtgat gtccaaaaga tacccaaatt ttaatattcc agaagaacaa   3060 

ctttagcatc agaaggttca cccagcacct tgcagatttt cttaaggaat tttgtctcac   3120 

ttttaaaaag aaggggagaa gtcagctact ctagttctgt tgttttgtgt atataatttt   3180 

ttaaaaaaaa tttgtgtgct tctgctcatt actacactgg tgtgtccctc tgcctttttt   3240 

ttttttttta agacagggtc tcattctatc ggccaggctg gagtgcagtg gtgcaatcac   3300 

agctcactgc agccttgtcc tcccaggctc aagctatcct tgcacctcag cctcccaagt   3360 

agctgggacc acaggcatgc accactacgc atgactaatt ttttaaatat ttgagacggg   3420 

gtctccctgt gttacccagg ctggtctcaa actcctgggc tcaagtgatc ctcccatctt   3480 

ggcctcccag agtattggga ttacagacat gagccactgc acctgcccag ctccccaact   3540 

ccctgccatt ttttaagaga cagtttcgct ccatcgccca ggcctgggat gcagtgatgt   3600 

gatcatagct cactgtaacc tcaaactctg gggctcaagc agttctccca ccagcctcct   3660 

ttttattttt ttgtacagat ggggtcttgc tatgttgccc aagctggtct taaactcctg   3720 

gcctcaagca atccttctgc cttggccccc caaagtgctg ggattgtggg catgagctgc   3780 

tgtgcccagc ctccatgttt taatatcaac tctcactcct gaattcagtt gctttgccca   3840 

agataggagt tctctgatgc agaaattatt gggctctttt agggtaagaa gtttgtgtct   3900 

ttgtctggcc acatcttgac taggtattgt ctactctgaa gacctttaat ggcttccctc   3960 

tttcatctcc tgagtatgta acttgcaatg ggcagctatc cagtgacttg ttctgagtaa   4020 

gtgtgttcat taatgtttat ttagctctga agcaagagtg atatactcca ggacttagaa   4080 

tagtgcctaa agtgctgcag ccaaagacag agcggaacta tgaaaagtgg gcttggagat   4140 

ggcaggagag cttgtcattg agcctggcaa tttagcaaac tgatgctgag gatgattgag   4200 

gtgggtctac ctcatctctg aaaattctgg aaggaatgga ggagtctcaa catgtgtttc   4260 

tgacacaaga tccgtggttt gtactcaaag cccagaatcc ccaagtgcct gcttttgatg   4320 

atgtctacag aaaatgctgg ctgagctgaa cacatttgcc caattccagg tgtgcacaga   4380 

aaaccgagaa tattcaaaat tccaaatttt ttcttaggag caagaagaaa atgtggccct   4440 

aaagggggtt agttgagggg tagggggtag tgaggatctt gatttggatc tctttttatt   4500 

taaatgtgaa tttcaacttt tgacaatcaa agaaaagact tttgttgaaa tagctttact   4560 

gtttctcaag tgttttggag aaaaaaatca accctgcaat cactttttgg aattgtcttg   4620 

atttttcggc agttcaagct atatcgaata tagttctgtg tagagaatgt cactgtagtt   4680 

ttgagtgtat acatgtgtgg gtgctgataa ttgtgtattt tctttggggg tggaaaagga   4740 

aaacaattca agctgagaaa agtattctca aagatgcatt tttataaatt ttattaaaca   4800 

attttgttaa accataaaaa aaaaaaaa                                      4828 

 
           
             39  
             561  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(561)  
               N IS A, C, G, OR T  
             
           
            39 

cctggagatn gagtttccct ctgtcaccta ggccggagtc aggtggcatg atctcagctc     60 

actgcaacct ctgcctcccg ggttcaagcg attctcctgt ctcagcctcc tgagaagctg    120 

agattacaga gaagtgccac cacacccggc taatttttgt atttttagta gagacagggt    180 

ttcgccatgt tgcccaggct ggtcttgaac tcctgacctc aagtgatcca cccgccttgg    240 

tctcccaaag tgctgggatt acaggtttga gccatcgtgc ctgggccccc aaattgtttt    300 

atatatacct ttcatcctta ggatttaata tttctaattt gtgatatttc tctggaaaat    360 

caatcaagta cacagttcta ggtgaaatat aaactgaatt ttgcttcatt aactaaatta    420 

aaatacggtc aaacagggtt aaatcttata ttctggtcct ttcaggataa tttacatttt    480 

attggataaa tgtgggttag gccacaccng ggggtatatn cctaaccatt ttacctaaat    540 

gtggggaagg ctggaaggtg n                                              561 

 
           
             40  
             3497  
             DNA  
             Homo sapiens  
           
            40 

cggacgcggc cgccgccgtc gccgccatct gtcacctcca ctccggcatc agcagccagt     60 

cgcccgtgtc ccgcctgtct cctcggcgga gcctgctgcc cgtcctgcca cctctctgct    120 

ctgttcttgt ctctgccttc attcccgaat ggatctggta ggagtggcat cgcctgagcc    180 

cgggacggca gcggcctggg gacccagcaa gtgtccatgg gctattcctc aaaatacaat    240 

atcttgttct ttggctgatg taatgagtga acagctggcc aaagaattgc agttagaaga    300 

agaagctgcc gtttttcctg aagttgctgt tgctgaagga ccatttatta ctggagaaaa    360 

cattgatact tccagtgacc ttatgctggc tcagatgcta cagatggaat atgacagaga    420 

atatgatgca cagcttaggc gtgaagaaaa aaaattcaat ggagatagca aagtttccat    480 

ttcctttgaa aattatcgaa aagtgcatcc ttatgaagac agcgatagct ctgaagatga    540 

ggttgactgg caggatactc gtgatgatcc ctacagacca gcaaaaccgg ttcccactcc    600 

taaaaagggc tttattggaa aaggaaaaga tatcaccacc aaacatgatg aagtagtatg    660 

tgggagaaag aacacagcaa gaatggaaaa ttttgcacct gagtttcagg taggagatgg    720 

aattggaatg gatttaaaac tatcaaacca tgttttcaat gctttaaaac aacatgccta    780 

ctcagaagaa cgtcgaagtg cccgcctaca tgagaaaaag gagcattcta cagcagaaaa    840 

agcagttgat cctaagacac gtttacttat gtataaaatg gtcaactctg gaatgttgga    900 

gacaatcact ggctgtatta gtacaggaaa ggagtctgtt gtctttcatg catatggagg    960 

gagcatggag gatgaaaagg aagatagtaa agttatacct acagaatgtg ccatcaaggt   1020 

atttaaaaca acccttaatg aatttaagaa tcgtgacaaa tatattaaag atgatttcag   1080 

gtttaaagat cgcttcagta aactaaatcc acgtaagatc atccgcatgt gggcagaaaa   1140 

agaaatgcac aatctcgcaa gaatgcagag agctggaatt ccttgtccaa cagttgtact   1200 

actgaagaaa cacattttag ttatgtcttt tattggccat gatcaagttc cagcccctaa   1260 

attaaaagaa gtaaagctca atagtgaaga aatgaaagaa gcctactatc aaactcttca   1320 

tttgatgcgg cagttatatc atgaatgtac gcttgtccat gctgacctca gtgagtataa   1380 

catgctgtgg catgctggaa aggtctggtt gatcgatgtc agtcagtcag tagaacctac   1440 

ccaccctcac ggcctggagt tcttgttccg ggactgcagg aatgtctcgc agtttttcca   1500 

gaaaggagga gtcaaggaag cccttagtga acgagaactc ttcaatgctg tttcaggctt   1560 

aaacatcaca gcagataatg aagctgattt tttagctgag atagaagctt tggagaaaat   1620 

gaatgaagat cacgttcaga agaatggaag gaaagctgct tcatttttga aagatgatgg   1680 

agacccacca ctactatatg atgaatagca ctaataccca ctgcttcagt gttaacacag   1740 

cagtgattgt cagctgccaa tagcaaatga agttatgggt gacttgaaat accaaaacct   1800 

gaggagtggg caatggtgct tctgtgcttt tcccccttgt aacccatgtg ccagatgtgt   1860 

ggaattttta gctcagcatt gagagaataa aatgtcacta cctctcatct tatgaacagg   1920 

ataatataat tctttaacag ctataggtta tctggctgaa gtagacctaa ttttatgtga   1980 

cttgtggtgt aaaatgtctt gatgataatt tttaaaactt gggtaacact tccaaatatg   2040 

ggaggaaagg acagatgtgt ttacaaggga ggattttaca acatacttgc tttattcacc   2100 

tccctgtttt gtgttgcgtc tttccttgaa tattttattg gcccagagtt agcctttctc   2160 

aattatgttt ccagactgtg gccgtgattc taaaggaaaa tgtgtgctct ttagtgggta   2220 

gaacaaatgg aaatttggtt tcagaatggc tgacagaaat cgacataagt catgtaattt   2280 

ttgttgatat atcatgaaaa tgaacagaat tctttttcca tacttatatc taagaaaagg   2340 

catcataggt ttctgaaaga gataactata taacagcttt ttaactatcc agtcaacttt   2400 

cagcttttct acatttaggt aaaatggtta ggatataact catggtgtgg ctaatctaca   2460 

tttatcaata aaatgtaaat tatctgaaag gacagaatat aagatttaac catgtttgac   2520 

gtattttaat ttagttaatg aagcaaaatt cagtttatat ttcactagaa ctgtgtactt   2580 

gattgatttt cagagaaata tcacaaatta gaaatattaa atctaaggat gaaaggtata   2640 

tataaaacaa tttgggggcc aggcacgatg gctcaaacct gtaatcccag cactttggga   2700 

gaccaaggcg ggtggatcac ttgaggtcag gagttcaaga ccagcctggg caacatggcg   2760 

aaaccctgtc tctactaaaa atacaaaaat tagccgggtg tggtggcact tctctgtaat   2820 

ctcagcttct caggaggctg agacaggaga atcgcttgaa cccgggaggc agaggttgca   2880 

gtgagctgag atcatgccac tgcactccgg cctaggtgac agagggaaac tccatctcca   2940 

ggaaaaaaaa aaaaaaaccc aatttggata ccaaattaat caactaattt gagctatctg   3000 

gccttactct tagtagtttt tagtacgtgc tggacaccac ttttaaaaag caatcactgt   3060 

gctagaaaag tatattggct ttgttaggat taaagttcat taacttcaat gtaatcatgc   3120 

ctcctattac tgaagtcaga ttggaaccac taaagatcca aactttctgt ctggtaatag   3180 

aaagtaaaaa tctagacatc atttacattt gagaagctgt ttttaacatt attttaaaat   3240 

gccaaatatg ttctttctag aaaaatattt atttttgttt ttgttggata gcttttaatt   3300 

acatttcaga gaggtgtaat tttgggtaga tgctcattac atttttgaaa ggtttatgat   3360 

tccaaaataa agatttatat gactggtgat actggcttta cagaaatttc agagaactaa   3420 

tttttaaaat ctttagcatt taaaactttt tttgttttgt tttctgacat attctgacaa   3480 

agagcagcaa accactg                                                  3497 

 
           
             41  
             346  
             DNA  
             Homo sapiens  
           
            41 

tatagaacgt agagaaaatt ttattaaaaa attaaaacta tttaaaacct gatatatgaa     60 

aataggcaac agtgagaaaa aagcactttt gtgacaaata tttagctggt ttgaaagaca    120 

gaacaaggag gaatcattta ctcataaaga aggctcaaat aagttaaaac atggatgtat    180 

ttttaaaatg accactctag tagtgaattt aaaagtcttt taagggttag agtaatcttt    240 

ttcattagtc ttgggctatt tcctctagtt ctgacaagta cagggcaagg aaaatgggct    300 

actctcaagg taagggatta ttctggaaac acggtctggg atttag                   346 

 
           
             42  
             2997  
             DNA  
             Homo sapiens  
           
            42 

ggactgcggt ctcgggcagc aatggccgag aagcgcgaca cacgggactc cgaagcccag     60 

cggctccccg actccttcaa ggacagcccc agtaagggcc ttggaccttg cggatggatt    120 

ttggtggcgt tctcattctt attcaccgtt ataactttcc caatctcaat atggatgtgc    180 

ataaagatta taaaagagta tgaaagagcc atcatcttta gattgggtcg cattttacaa    240 

ggaggagcca aaggacctgg tttgtttttt attctgccat gcactgacag cttcatcaaa    300 

gtggacatga gaactatttc atttgatatt cctcctcagg agatcctgac aaaggattca    360 

gtgacaatta gcgtggatgg tgtggtctat taccgcgttc agaatgcaac cctggctgtg    420 

gcaaatatca ccaacgctga ctcagcaacc cgtcttttgg cacaaactac tctgaggaat    480 

gttctgggca ccaagaatct ttctcagatc ctctctgaca gagaagaaat tgcacacaac    540 

atgcagtcta ctctggatga tgccactgat gcctggggaa taaaggtgga gcgtgtggaa    600 

attaaggatg tgaaactacc tgtgcagctc cagagagcta tggctgcaga agcagaagcg    660 

tcccgcgagg cccgcgccaa ggttattgca gccgaaggag aaatgaatgc atccagggct    720 

ctgaaagaag cctccatggt catcactgaa tctcctgcag cccttcagct ccgatacctg    780 

cagacactga ccaccattgc tgctgagaaa aactcaacaa ttgtcttccc tctgcccata    840 

gatatgctgc aaggaatcat aggggcaaaa cacagccatc taggctagtg tagagatgag    900 

cgctagcctt ccaagcatga agtcggggac caaattagcc tttaactcat aaagagaggg    960 

tagggctttt ctttttccat atgtcaattg tggtgttccc agaatgtata gcagttataa   1020 

aaataggtga aagaattgtt agcttgtaaa tactgagaga ttggtgattt atataaggta   1080 

atctgttagt cttaaaatag ttaaaagttt gtatttttag attattatgt agtaggttag   1140 

atccctcttg ttttgacttc cactgactca ttctgaaccc cctaagcacc caggccacag   1200 

gcaagaacct gggctgtaac tgccacctga caccgctgac tggctaaatg ctttgcagaa   1260 

agtgatgacc ttacaccaca accagcttct ccaggtcata tgtgccttac ctccagaagt   1320 

cttttttttt ttttttttct gagatggagt ttcactcttg ttgcccaggc tggagtgcaa   1380 

tagcatgatc tcggctcact gcaacctccg cctcctgggt tcaagagatt ctcctgcctc   1440 

agcctcccca gtagctggga ttacaggctc atgccaccat gcccagctaa tttttgtatt   1500 

attattattg ttttttagta gagacggggt ttcaccatgt tggccaggct agtcacgaac   1560 

tcctaacctc aggtgatcca cccacctctg cctccaaagt gctggattac aggctgagct   1620 

accaccctgg tttggagagt cttaattaat tgaaatttcc ctaatgttca tttattttct   1680 

aaatccagcc gtgtttcaga ataatcctta cttgagagta gccattttct tgtgtacttg   1740 

tcagaactag aggaaatagc caagactaat gaaaaacatt actctaaccc ttaaaagact   1800 

tttaaattca ctactagagt ggtcatttta aaaatacatc catgttttaa cttattttga   1860 

gcctttcttt tatgagtaaa tgattcctcc ttgttctgtc tttcaaacca gctaaatatt   1920 

tgtcacaaaa gtgacttttt tctcactgtt gcctattttc atatatcagg ttttaaatag   1980 

ttttaatttt ttaataaaat ttttctctac gttctatatg caattgttat atatctattt   2040 

gaatagctga aggactaaaa tactttttta agagataact tcaggaaacc attatatttt   2100 

actatctgca tgctgttaac tgtggtacac tgtgaaatat gttgattaca aacccattca   2160 

ttacatagta taaggaattc acagtatatt gactatatag tgtctaatga ctgggcagat   2220 

actgtcaact tacaatatct atatagagag gctttaaact taccttactc attctctatg   2280 

atgtatgact tgatgctgaa agaggaagct ggtcagctcc tcatggacaa caaattctta   2340 

gtctataata ttaggagaca tctctagttt tgcaaatgtc tgtgaatctg agcaacctgg   2400 

acttctgctt actggccaga aagctggcgg gtgacatttg taacatttcc tctttgagac   2460 

tctgagttca cctagagaag tctaagcata acagctttct ttcccagcac gagcctttat   2520 

agctctcttt agctcaacca ctctgtccat ccagccaatg gatgtccttc cctgtaccca   2580 

attcaagctt attttaggga agccttgaaa ctaccatgta tctggctcta gctgagttat   2640 

tgaggattga gccagtgcaa cgttaaactc agtgcactta catttgattt aaatgatggt   2700 

tttatctgtt gtgtgaagtg gttcaccctt gaggaccagg agcctccata tcctgactga   2760 

aaaccttttc tgagacttag agtaacagta cttttggttc cttgagttct cctgtctcca   2820 

gatacctaaa tgaccttgac ttttctgcct tgtgaattcg tagtccaatc agctgaaatt   2880 

aaatcacttg ggagggacgc atagaaggag ctctaggaac acagtgccag tgcagaagtt   2940 

tctccaggtg gcctcccttt ccaacaatgt acataataaa gtgtatgcac tttcact      2997 

 
           
             43  
             380  
             DNA  
             Homo sapiens  
           
            43 

tttagctatg gaagttttct ttattgatta cttaatgtgt aacaataatt ggcatctttt     60 

tcacacatta caaaaaatta tacttggctc agtatgcaac cttttaagca tagccatatt    120 

atttaacaaa agaggggaaa acctattcta cccaacacag catttacaaa tgcacaaaac    180 

atgccacttt ggcttgtata ttgtctagat taaaaacaat cttttaacat aaataagtta    240 

gtataatttt tcagtgtttt tacagagtta tgtacacagg tacacttcaa atggtttttc    300 

catacacagg caatgaaata ctgtttaaag atgtagtatc catttcactt atcctacaag    360 

tgtgcttttc tctacatgaa                                                380 

 
           
             44  
             2422  
             DNA  
             Homo sapiens  
           
            44 

gtcagcctcc cttccaccgc catattgggc cactaaaaaa agggggctcg tcttttcggg     60 

gtgtttttct ccccctcccc tgtccccgct tgctcacggc tctgcgactc cgacgccggc    120 

aaggtttgga gagcggctgg gttcgcggga cccgcgggct tgcacccgcc cagactcgga    180 

cgggctttgc caccctctcc gcttgcctgg tcccctctcc tctccgccct cccgctcgcc    240 

agtccatttg atcagcggag actcggcggc cgggccgggg cttccccgca gcccctgcgc    300 

gctcctagag ctcgggccgt ggctcgtcgg ggtctgtgtc ttttggctcc gagggcagtc    360 

gctgggcttc cgagaggggt tcgggccgcg taggggcgct ttgttttgtt cggttttgtt    420 

tttttgagag tgcgagagag gcggtcgtgc agacccggga gaaagatgtc aaacgtgcga    480 

gtgtctaacg ggagccctag cctggagcgg atggacgcca ggcaggcgga gcaccccaag    540 

ccctcggcct gcaggaacct cttcggcccg gtggaccacg aagagttaac ccgggacttg    600 

gagaagcact gcagagacat ggaagaggcg agccagcgca agtggaattt cgattttcag    660 

aatcacaaac ccctagaggg caagtacgag tggcaagagg tggagaaggg cagcttgccc    720 

gagttctact acagaccccc gcggcccccc aaaggtgcct gcaaggtgcc ggcgcaggag    780 

agccaggatg tcagcgggag ccgcccggcg gcgcctttaa ttggggctcc ggctaactct    840 

gaggacacgc atttggtgga cccaaagact gatccgtcgg acagccagac ggggttagcg    900 

gagcaatgcg caggaataag gaagcgacct gcaaccgacg attcttctac tcaaaacaaa    960 

agagccaaca gaacagaaga aaatgtttca gacggttccc caaatgccgg ttctgtggag   1020 

cagacgccca agaagcctgg cctcagaaga cgtcaaacgt aaacagctcg aattaagaat   1080 

atgtttcctt gtttatcaga tacatcactg cttgatgaag caaggaagat atacatgaaa   1140 

attttaaaaa tacatatcgc tgacttcatg gaatggacat cctgtataag cactgaaaaa   1200 

caacaacaca ataacactaa aattttaggc actcttaaat gatctgcctc taaaagcgtt   1260 

ggatgtagca ttatgcaatt aggtttttcc ttatttgctt cattgtacta cctgtgtata   1320 

tagtttttac cttttatgta gcacataaac tttggggaag ggagggcagg gtggggctga   1380 

ggaactgacg tggagcgggg tatgaagagc ttgctttgat ttacagcaag tagataaata   1440 

tttgacttgc atgaagagaa gcaattttgg ggaagggttt gaattgtttt ctttaaagat   1500 

gtaatgtccc tttcagagac agctgatact tcatttaaaa aaatcacaaa aatttgaaca   1560 

ctggctaaag ataattgcta tttattttta caagaagttt attctcattt gggagatctg   1620 

gtgatctccc aagctatcta aagtttgtta gatagctgca tgtggctttt ttaaaaaagc   1680 

aacagaaacc tatcctcact gccctcccca gtctctctta aagttggaat ttaccagtta   1740 

attactcagc agaatggtga tcactccagg tagtttgggg caaaaatccg aggtgcttgg   1800 

gagttttgaa tgttaagaat tgaccatctg cttttattaa atttgttgac aaaattttct   1860 

cattttcttt tcacttcggg ctgtgtaaac acagtcaaaa taattctaaa tccctcgata   1920 

tttttaaaga tctgtaagta acttcacatt aaaaaatgaa atatttttta atttaaagct   1980 

tactctgtcc atttatccac aggaaagtgt tatttttaaa ggaaggttca tgtagagaaa   2040 

agcacacttg taggataagt gaaatggata ctacatcttt aaacagtatt tcattgcctg   2100 

tgtatggaaa aaccatttga agtgtacctg tgtacataac tctgtaaaaa cactgaaaaa   2160 

ttatactaac ttatttatgt taaaagattt tttttaatct agacaatata caagccaaag   2220 

tggcatgttt tgtgcatttg taaatgctgt gttgggtaga ataggttttc ccctcttttg   2280 

ttaaataata tggctatgct taaaaggttg catactgagc caagtataat tttttgtaat   2340 

gtgtgaaaaa gatgccaatt attgttacac attaagtaat caataaagaa aacttccata   2400 

gctaaaaaaa aaaaaaaaaa aa                                            2422 

 
           
             45  
             454  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(454)  
               N IS A, C, G, OR T  
             
           
            45 

ttttaaggca gttctcttct ctgctaggca ttaaacttta aaacatttga atcattggac     60 

cataatgctt caccctaacg atatttatat aaaaggaaga gaaagacatt ttcttttttt    120 

tttttgagac gganttcact cgttgcccag gctnggagtg caatggcgca atctcggctc    180 

accgcagcct ccacctcctg ggttcaagtg attctcctgc ctcagccttc caagtagctg    240 

ggattgcagg catgcgccgc cactgcctan gctaaatttt tttttgcatt tttagtagag    300 

acggggcttc tccatgttgg tcaggctggt ctccgaactc ccgacctcag gtgatccgcc    360 

caccttggac tcccaaagtg ctgggattac aggtgtgagt aaccacgcct ggctgagaaa    420 

gccattttca atacagagtg taaaattaag atag                                454 

 
           
             46  
             1661  
             DNA  
             Homo sapiens  
           
            46 

ccgagggcgg ggccgggccc gggagcctgt ggcttcagga agaggagggc aaggtgtctg     60 

gctgcgcgtt tggctgcaat gagctcggcc tcggggctcc gcagggggca cccggcaggt    120 

ggggaagaaa acatgacaga aacagatgcc ttctataaaa gagaaatgtt tgatccggca    180 

gaaaagtaca aaatggacca caggaggaga ggaattgctt taatcttcaa tcatgagagg    240 

ttcttttggc acttaacact gccagaaagg cggggcacct gcgcagatag agacaatctt    300 

acccgcaggt tttcagatct aggatttgaa gtgaaatgct ttaatgatct taaagcagaa    360 

gaactactgc tcaaaattca tgaggtgtca actgttagcc acgcagatgc cgattgcttt    420 

gtgtgtgtct tcctgagcca tggcgaaggc aatcacattt atgcatatga tgctaaaatc    480 

gaaattcaga cattaactgg cttgttcaaa ggagacaagt gtcacagcct ggttggaaaa    540 

cccaagatat ttatcattca ggcatgtcgg ggaaaccagc acgatgtgcc agtcattcct    600 

ttggatgtag tagataatca gacagagaag ttggacacca acataactga ggtggatgca    660 

gcctccgttt acacgctgcc tgctggagct gacttcctca tgtgttactc tgttgcagaa    720 

ggatattatt ctcaccggga aactgtgaac ggctcatggt acattcaaga tttgtgtgag    780 

atgttgggaa aatatggctc ctccttagag ttcacagaac tcctcacact ggtgaacagg    840 

aaagtttctc agcgccgagt ggacttttgc aaagacccaa gtgcaattgg aaagaagcag    900 

gttccctgtt ttgcctcaat gctaactaaa aagctgcatt tctttccaaa atctaattaa    960 

ttaatagagg ctatctaatt ccacactctg tattgaaaat ggctttctca gccaggcgtg   1020 

gttactcaca cctgtaatcc cagcactttg ggagtccaag gtgggcggat cacctgaggt   1080 

cgggagttcg agaccagcct gaccaacatg gagaagcccc gtctctacta aaaatgcaaa   1140 

aaaaaattta gctaggcatg gcggcgcatg cctgcaatcc cagctacttg gaaggctgag   1200 

gcaggagaat cacttgaacc caggaggtgg aggctgcggt gagccgagat tgcgccattg   1260 

cactccagcc tgggcaacga gtgaaactcc gtctcaaaaa aaagaaaatg tctttctctt   1320 

ccttttatat aaatatcgtt agggtgaagc attatggtct aatgattcaa atgttttaaa   1380 

gtttaatgcc tagcagagaa ctgccttaaa aaaaaaaaaa aaaagttcat gttggccatg   1440 

gtgaaagggt ttgatatgga gaaacaaaat cctcaggaaa ttagataaat aaaaatttat   1500 

aagcatttgt attatttttt aataaactgc agggttacac aaaaatctag ctgatttaac   1560 

ttgtattttg tcactttttt ataaaagttt attgtttgat gtttttaaag gtttttgaaa   1620 

tccaggaatt aaatcatccc ttaataaaat attcgaaatt c                       1661 

 
           
             47  
             439  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(439)  
               N IS A, C, G, OR T  
             
           
            47 

ntcttntant agagatagga tctcactttg ttgcccaggc tggtctcaaa ctgggctcaa     60 

gttatcttcc caccttggcc tcccaaagtg ctgggattat aggcatgagc accacattca    120 

gcccaaacat ttctgagacc actacttgaa ctatcaagtc tcctcttgta actgattctc    180 

attagaaata atacacattt attgaatgtc attgatatat aaagatacca ttctttgagt    240 

gggggaaata taatttaaaa gtcgcaacta ctgacaatca acaaataaac tctaatgaga    300 

atcataaagc ttgttcccag aggaaccatg atacaggggt ggggacagta cggcaaataa    360 

tggggctncc cgttgtcagn ctttcatggg ngattacact aggngctttt ctnccaggat    420 

cntttcttcc ccnttggta                                                 439 

 
           
             48  
             2564  
             DNA  
             Homo sapiens  
           
            48 

gatttcagtt gaaagatgtg tttttgtgag tagagcaccg cagaagaact gaagactgtt     60 

gtgtgctccc cgcagaaggg gctaccatga tcctttcctc ctataacacc atccagtcgg    120 

ttttctgttg ctgctgttgc tgttcagtgc agaagcgaca aatgagaaca cagataagcc    180 

tgagcacaga tgaagagctt ccagaaaaat acacccagca tcgcaggccg tggctcagcc    240 

aattgtcaaa taagaagcaa tccaacacgg gccgtgtgca gccgtcaaaa cgaaagccac    300 

tgcctcccct cccaccctct gaggttgctg aagagaagat ccaagtcaag gcactttatg    360 

attttctgcc cagagaaccc tgtaatttag ccttaaggag agcagaagaa tacctgatac    420 

tggagaaata caatcctcac tggtggaagg caagagaccg tttggggaat gaaggcttaa    480 

tcccaagcaa ctatgtgact gaaaacaaaa taactaattt agaaatatat gagtggtacc    540 

atagaaacat taccagaaat caggcagaac atctattgag acaagagtct aaagaaggtg    600 

catttattgt cagagattca agacatttag gatcctacac aatttccgta tttatgggag    660 

ctagaagaag tacggaggct gccataaaac attatcagat aaaaaagaat gactcaggac    720 

agtggtatgt ggctgaaaga cacgcctttc aatcaatccc tgagttaatc tggtatcacc    780 

agcacaatgc agccggtctc atgactcgtc tccgatatcc agttgggctg atgggcagtt    840 

gtttaccagc cacagctggg tttagctacg aaaagtggga gatagatcca tctgagttgg    900 

cttttataaa ggagattgga agcggtcagt ttggagtggt ccatttaggt gaatggcggt    960 

cacatatcca ggtagctatc aaggccatca atgaaggctc catgtctgaa gaggatttca   1020 

ttgaagaggc caaagtgatg atgaaattat ctcattcaaa gctagtgcaa ctttatggag   1080 

tctgtataca gcggaagccc ctttacattg tgacagagtt catggaaaat ggctgcctgc   1140 

ttaactatct cagggagaat aaaggaaagc ttaggaagga aatgctactg agtgtatgcc   1200 

aggatatatg tgaaggaatg gaatatctgg agaggaatgg ctatattcat agggatttgg   1260 

cggcaaggaa ttgtttggtc agttcaacat gcatagtaaa aatttcagac tttggaatga   1320 

caaggtacgt tttggatgat gagtatgtca gttcttttgg agccaagttc ccaatcaagt   1380 

ggtcccctcc tgaagttttt cttttcaata agtacagcag taaatctgat gtctggtcat   1440 

ttggagtttt aatgtgggaa gtttttacag aaggaaaaat gccttttgaa aataagtcaa   1500 

atttgcaagt cgtggaagct atttctgaag gcttcaggct atatcgccct cacctggcac   1560 

caatgtccat atatgaagtc atgtacagct gctggcatga gaaacctgaa ggccgcccta   1620 

catttgcgga gctgctgcgg gctgtcacag agattgcgga aacctggtga ccggaaacag   1680 

aatgccaacc caaagagtca tcttgcaaaa ctgtcattta ttgtgaatat cttcaccata   1740 

tggggtcact tatggtgaat atctttcttc agagttgctg actcttgaaa acagtgcaaa   1800 

gatcacagtt tttaaaagtt ttaaaaattt aagaatattc acacaatcgt ttttctatgt   1860 

gtgagaggga tttgcacact cttatttttc tgtaaaatat ttcacatccc aaatgtgaag   1920 

aagtgaaaaa gacttcgcag cagtcttcat tgtggtgctc ttcatgatca tagccccagg   1980 

aacccttgag gttcttcttc acaaggctga gagtgcttcc ttcttgaaga cgagtgtcat   2040 

tcatcacttc agtgatccat gcatagaata tgaaaataaa ttcttccaac tcatgggata   2100 

aaggggactc ccttgaagaa tttcatgttt ttgggctgta tagctcttta cagaaaatgc   2160 

acctttataa atcacatgaa tgttagtatt ctggaaatgt cttttgttaa tataatcttc   2220 

ccatgttatt taacaaattg tttttgcaca tatctgatta tattgaaagc agtttttttg   2280 

cattcgagtt ttaaacactg ttataaaatg tagccaaagc tcacctttga acagatcccg   2340 

gtgacattct atttccagga aaatccggaa cctgatttta gttctgtgat tttacacttt   2400 

ttacatgtga gattggacag tttcagaggc cttattttgt catactaagt gtctcctgta   2460 

attttcagga agatgatttg ttctttccag aagaggagac aaaagcaaga tagccaaatg   2520 

tgacatcaag ctccattgtt tcggaaatcc aggattttga attc                    2564 

 
           
             49  
             381  
             DNA  
             Homo sapiens  
           
            49 

gttgcccagg ctggagtgca gtggtgtact cttggctcac tgcaacctcc acttcccggg     60 

ttcaagtgat tctcccgcct cagcctcccg agtagctggg attagaggcg tgcaccacca    120 

tgcccggcta attttgtatt tccactagag gcggagtttc tccatgtagg tcaggttggt    180 

ctcgaaatcc tgacctcagg ttatctgccc gtctccgcct cccaaagtgc tggggttaca    240 

ggcgtgacga ccatgcccag cctaaaagga cattcttaag gcagaaagaa gggggcaggc    300 

aagggtggtc tcagccccca gatggaagtc agagtgggct gcaaaagatg cagatgggca    360 

ggcagggaga caggtaaaca g                                              381 

 
           
             50  
             3384  
             DNA  
             Homo sapiens  
           
            50 

tccaagctga attcgcggcc gcgtcgacca cgccggccct gggcagtgac ggggttcggg     60 

tgaccatgga cagtgcgctc accgcccgtg acagggtggg ggtgcaggat ttcgtgctgc    120 

tggagaactt caccagcgag gccgccttca tcgagaacct acggcggcga tttcgggaga    180 

atctcatcta cacctacatt ggccccgtcc tggtctctgt caatccctac cgggacctgc    240 

agatctacag ccggcaacat atggagcgtt accgtggcgt cagcttctat gaagtgcccc    300 

ctcacctgtt tgccgtggcg gacactgtgt accgagcact gcgcacggag cgtcgggacc    360 

aggctgtgat gatctctggg gagagcgggg caggcaagac cgaagccacc aagaagctgc    420 

tgcagttcta tgcagagacc tgcccagccc cccaacgcgg aggtgccgtg cgggaccggc    480 

tgctacagag caacccggtg ctggaggcct ttggaaatgc caagaccctc cggaacgata    540 

actccagcag gttcgggaag tacatggatg tgcagtttga cttcaagggt gcccccgtgg    600 

gtggccacat cctcagttac ctcctggaaa agtcacgagt ggtgcaccag aatcatgggg    660 

agcggaactt ccacatcttc taccagctgc tggagggggg cgaggaagaa actcttcgca    720 

ggctgggctt ggaacggaac ccccagagct acctgtacct ggtgaagggc cagtgtgcca    780 

aagtctcctc catcaacgac aagagtgact ggaaggtcgt caggaaggct ctgacagtca    840 

ttgatttcac cgaggatgaa gtggaggacc tgctaagcat cgtggccagc gtccttcatt    900 

tgggcaacat ccactttgct gccaacgagg acagcaatgc ccaggtcacc accgagaacc    960 

agctcaagta tctgaccagg ctcctcagcg tggaaggctc gacgctgcga gaagccctga   1020 

cacacaggaa gatcatcgcc aagggggaag agctcctgag cccgctgaac ctggaacagg   1080 

ccgcgtacgc acgaaacgcc ctcgccaagg ctgtgtacag ccgcactttt acctggctcg   1140 

tcgggaaaat caacaggtcg ctggcctcca aggacgtgga gagccccagc tggcggagca   1200 

ccacggttct cgggctcctg gatatttatg gcttcgaagt gtttcagcat aacagctttg   1260 

agcagttctg catcaattac tgcaacgaaa agctgcagca gctcttcatc gaactcccgc   1320 

tcaagtcgga gcaggaggaa tacgaggcag agggcatcgc gtgggaaccc gtccagtatt   1380 

tcaacaacaa aatcatctgt gatctggtgg aggagaagtt taagggcatc atctcgattt   1440 

tggatgagga gtgtctgcgc ccgggggagg ccacagacct gaccttcctg gagaagctgg   1500 

aggatactgt caagcaccat ccacacttcc tgacgcacaa gctggctgac cagaggacca   1560 

ggaaatctct gggccgaggg gaattccgcc ttctgcacta tgcgggggag gtgacctaca   1620 

gcgtgaccgg gtttctggac aaaaacaatg accttctctt ccggaacctt aaggagacca   1680 

tgtgtagctc aaagaatccc attatgagcc agtgcttcga ccggagcgag ctcagtgaca   1740 

agaagcggcc agagacggtc gccacccagt tcaagatgag cctcctgcag ctggtggaga   1800 

tcctgcagtc taaggagccc gcctacgtcc gctgcatcaa acccaatgat gccaaacagc   1860 

ccggccgctt tgacgaggtg ctgatccgcc accaggtgaa gtacctgggg ctgttggaaa   1920 

acctgcgtgt gcgcagagct ggctttgcct atcgccgcaa atacgaagct ttcctgcaaa   1980 

ggtacaagtc actgtgccca gagacgtggc ccacgtgggc aggacggccg caggatgggg   2040 

tggctgtgct ggtccgacac ctgggctaca agccagaaga gtacaagatg ggcaggacca   2100 

agatcttcat ccgcttcccc aagaccctgt ttgccacaga ggatgccctg gaggtccggc   2160 

ggcagagcct ggccacaaag atccaagctg cctggagggg ctttcactgg cggcagaaat   2220 

tcctccgggt gaagagatca gccatctgca tccagtcgtg gtggcgtgga acactgggcc   2280 

ggaggaaggc agccaagagg aagtgggcgg cacagaccat ccggcggctc atccgaggct   2340 

tcatcctgcg ccacgccccc cgctgccccg agaacgcctt cttcttggac catgtgcgca   2400 

cgtctttttt gctaaacctg aggcggcagc tgccccggaa tgtcctggac acctactggc   2460 

ccacgccccc acctgccctg cgagaggcct cagagcttct gcgggagttg tgcataaaga   2520 

acatggtgtg gaaatactgc cggagtatca gccctgagtg gaagcagcag ctgcagcaga   2580 

aggccgtggc tagtgagatc ttcaagggca agaaggataa ttaccctcag agtgtaccca   2640 

ggctcttcat cagcactcgg cttggtacag atgagatcag cccccgagtg ctgcaggcct   2700 

tgggctctga gcccattcag tatgcggtgc ctgttgtgaa atacgaccgc aagggctaca   2760 

agcctcgctc ccggcagctg ctgctcacgc ccaacgccgt cgtcatcgtg gaggacgcca   2820 

aagtcaagca gaggattgat tacgccaacc tgaccggaat ctctgtcagc agcctgagcg   2880 

acagtctttt tgtgcttcat gtacagcgtg cggacataaa gcaaaaggga gatgtggtgc   2940 

tgcagagtga ccacgtgatt gagacgctga ccaagacagc cctcagtgcc aaccgcgtga   3000 

acagcatcaa catcaaccag ggcagcataa cgtttgcagg gggccccggc agggatggca   3060 

ccattgactt cacacccggc tcggagctgc tcatcaccaa ggccaagaac gggcacctgg   3120 

ctgtggtcgc cccacggctg aattatcggt gataaaggcg cccactggac catcccaacg   3180 

cccaaagctt tgcttttctc ctcctcccct tcccagttac caaagagtcg aatttccaga   3240 

cagggaccca gggacacccc gaagcccacc tgcaatttcc cacctcctgc ccatcccttt   3300 

cttgagggag cagcaggggc caggagctac cccaggagtg ggccaggccg ggccacagca   3360 

ataggaaagc cagggccaga gcga                                          3384 

 
           
             51  
             464  
             DNA  
             Homo sapiens  
           
            51 

tggagtgcag cgtcacaaac atggctcact gaagcctcaa cttcccgggc tcaagtgatc     60 

ctcctacctc agactgccga gtagctgggg ctacaggcac acgatgccct gcctggctaa    120 

ttttttagtt tttgtagaga tggggtctca ctgtgttgcc caggctggtc tcaaacttct    180 

gggctcaagg gatcttccca tctcagcctc ctaaagtgct gggattacag gcatgagcca    240 

ctgtgcccag actcacctta atttttaaaa atgttcatgg tggaggaagg ggcaggaaca    300 

tccaccagca ccagccaggg ttctctgaaa aaggcgctga atattttgct cagctctgtg    360 

cttctgtgct cgagccaacc acacgtatac tttgaacacg aaggaatgtg cttgagcatt    420 

aaggaatgta agccacaggt tcatgcctgg ctgccttcca agga                     464 

 
           
             52  
             3868  
             DNA  
             Homo sapiens  
           
            52 

atgaacctct gaaaactgcc ggcatctgag gtttcctcca aggccctctg aagtgcagcc     60 

cataatgaag gtcttggcgg caggagttgt gcccctgctg ttggttctgc actggaaaca    120 

tggggcgggg agccccctcc ccatcacccc tgtcaacgcc acctgtgcca tacgccaccc    180 

atgtcacaac aacctcatga accagatcag gagccaactg gcacagctca atggcagtgc    240 

caatgccctc tttattctct attacacagc ccagggggag ccgttcccca acaacctgga    300 

caagctatgt ggccccaacg tgacggactt cccgcccttc cacgccaacg gcacggagaa    360 

ggccaagctg gtggagctgt accgcatagt cgtgtacctt ggcacctccc tgggcaacat    420 

cacccgggac cagaagatcc tcaaccccag tgccctcagc ctccacagca agctcaacgc    480 

caccgccgac atcctgcgag gcctccttag caacgtgctg tgccgcctgt gcagcaagta    540 

ccacgtgggc catgtggacg tgacctacgg ccctgacacc tcgggtaagg atgtcttcca    600 

gaagaagaag ctgggctgtc aactcctggg gaagtataag cagatcatcg ccgtgttggc    660 

ccaggccttc tagcaggagg tcttgaagtg tgctgtgaac cgagggatct caggagttgg    720 

gtccagatgt gggggcctgt ccaagggtgg ctggggccca gggcatcgct aaacccaaat    780 

gggggctgct ggcagacccc gagggtgcct ggccagtcca ctccactctg ggctgggctg    840 

tgatgaagct gagcagagtg gaaacttcca tagggaggga gctagaagaa ggtgcccctt    900 

cctctgggag attgtggact ggggagcgtg ggctggactt ctgcctctac ttgtcccttt    960 

ggccccttgc tcactttgtg cagtgaacaa actacacaag tcatctacaa gagccctgac   1020 

cacagggtga gacagcaggg cccaggggag tggaccagcc cccagcaaat tatcaccatc   1080 

tgtgcctttg ctgcccctta ggttgggact taggtgggcc agaggggcta ggatcccaaa   1140 

ggactccttg tcccctagaa gtttgatgag tggaagatag agaggggcct ctgggatgga   1200 

aggctgtctt cttttgagga tgatcagaga acttgggcat aggaacaatc tggcagaagt   1260 

ttccagaagg aggtcacttg gcattcaggc tcttggggag gcagagaagc caccttcagg   1320 

cctgggaagg aagacactgg gaggaggaga ggcctggaaa gctttggtag gttcttcgtt   1380 

ctcttccccg tgatcttccc tgcagcctgg gatggccagg gtctgatggc tggacctgca   1440 

gcaggggttt gtggaggtgg gtagggcagg ggcaggttgc taagtcaggt gcagaggttc   1500 

tgagggaccc aggctcttcc tctgggtaaa ggtctgtaag aaggggctgg ggtagctcag   1560 

agtagcagct cacatctgag gccctgggag gtcttgtgag gtcacacaga ggtacttgag   1620 

ggggactgga ggccgtctct ggtccccagg gcaagggaac agcagaactt agggtcaggg   1680 

tctcagggaa ccctgagctc caagcgtgct gtgcgtctga cctggcatga tttctattta   1740 

ttatgatatc ctatttatat taacttattg gtgctttcag tggccaagtt aattcccctt   1800 

tccctggtcc ctactcaaca aaatatgatg atggctcccg acacaagcgc cagggccagg   1860 

gcttagcagg gcctggtctg gaagtcgaca atgttacaag tggaataagc ttacgggtga   1920 

agctcagaga agggtcggat ctgagagaat ggggaggcct gagtgggagt ggggggcctt   1980 

gctccacccc catcccctac tgtgacttgc tttagcgtgt cagggtccag gctgcagggg   2040 

ctgggccaat ttgtggagag gccgggtgcc tttctgtctt gcttccaggg ggctggttca   2100 

cactgttctt gggcgcccca gcattgtgtt gtgaggcgca ctgttcctgg cagatattgt   2160 

gccccctgga gcagtgggca agacagtcct tgtggcccac cctgtccttg tttctgtgtc   2220 

cccatgctgc ctctgaaata gcgccctgga acaaccctgc ccctgcaccc agcatgctcc   2280 

gacacagcag ggaagctcct cctgtggccc ggacacccat agacggtgcg gggggcctgg   2340 

ctgggccaga ccccaggaag gtggggtaga ctggggggat cagctgccca ttgctcccaa   2400 

gaggaggaga gggaggctgc agacgcctgg gactcagacc aggaagctgt gggccctcct   2460 

gctccacccc catcccactc ccacccatgt ctgggctccc aggcagggaa cccgatctct   2520 

tcctttgtgc tggggccagg cgagtggaga aacgccctcc agtctgagag caggggaggg   2580 

aaggaggcag cagagttggg gcagctgctc agagcagtgt tctggcttct tctcaaaccc   2640 

tgagcgggct gccggcctcc aagttcctcc gacaagatga tggtactaat tatggtactt   2700 

ttcactcact ttgcaccttt ccctgtcgct ctctaagcac tttacctgga tggcgcgtgg   2760 

gcagtgtgca ggcaggtcct gaggcctggg gttggggtgg agggtgcggc ccggagttgt   2820 

ccatctgtcc atcccaacag caagacgagg atgtggctgt tgagatgtgg gccacactca   2880 

cccttgtcca ggatgcaggg actgccttct ccttcctgct tcatccggct tagcttgggg   2940 

ctggctgcat tcccccagga tgggcttcga gaaagacaaa cttgtctgga aaccagagtt   3000 

gctgattcca cccggggggc ccggctgact cgcccatcac ctcatctccc tgtggacttg   3060 

ggagctctgt gccaggccca ccttgcggcc ctggctctga gtcgctctcc cacccagcct   3120 

ggacttggcc ccatgggacc catcctcagt gctccctcca gatcccgtcc ggcagcttgg   3180 

cgtccaccct gcacagcatc actgaatcac agagcctttg cgtgaaacag ctctgccagg   3240 

ccgggagctg ggtttctctt ccctttttat ctgctggtgt ggaccacacc tgggcctggc   3300 

cggaggaaga gagagtttac caagagagat gtctccgggc ccttatttat tatttaaaca   3360 

tttttttaaa aagcactgct agtttacttg tctctcctcc ccatcgtccc catcgtcctc   3420 

cttgtccctg acttggggca cttccaccct gacccagcca gtccagctct gccttgccgg   3480 

ctctccagag tagacatagt gtgtggggtt ggagctctgg cacccgggga ggtagcattt   3540 

ccctgcagat ggtacagatg ttcctgcctt agagtcatct ctagttcccc acctcaatcc   3600 

cggcatccag ccttcagtcc cgcccacgtg ctagctccgt gggcccaccg tgcggcctta   3660 

gaggtttccc tccttccttt ccactgaaaa gcacatggcc ttgggtgaca aattcctctt   3720 

tgatgaatgt accctgtggg gatgtttcat actgacagat tatttttatt tattcaatgt   3780 

catatttaaa atatttattt tttataccaa atgaatcact ttttttttta agaaaaaaaa   3840 

gagaaatgaa taaagaatct actcttcg                                      3868 

 
           
             53  
             410  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(410)  
               N IS A, C, G, OR T  
             
           
            53 

tttttttttt taaagagaca gggtttcact atgttgccca ggctgttctc aaaactccag     60 

ggctcaaggg atcctcctgc ctcagcctct caaaatgcgg ggattacagg catgagctac    120 

ttgcacctgg ctgaaatttt acttttttat cagattttag taagccaatt gttctcaagt    180 

attcttaaag tacattacag cttaccttaa attcgatgat tagggcgacc cttttcatat    240 

gggtctacgg ataaattggg catgcctttc atttaggtac acactttgga tattctccat    300 

ggctttggac aatctggacc ctaaaaacat tggaaggcca agttcttccn ttaaggtatg    360 

ggggccacat tttttattga ggggcagggg ganttttaaa gggaccgggg               410 

 
           
             54  
             1438  
             DNA  
             Homo sapiens  
           
            54 

cggtaactac cccggctgcg cacagctcgg cgctccttcc cgctccctca cacaccgcct     60 

cagcccgcac cggcagtaga agatggtgaa agaaacaact tactacgatg ttttgggggt    120 

caaacccaat gctactcagg aagaattgaa aaaggcttat aggaaactgg ccttgaagta    180 

ccatcctgat aagaacccaa atgaaggaga gaagtttaaa cagatttctc aagcttacga    240 

agttctctct gatgcaaaga aaagggaatt atatgacaaa ggaggagaac aggcaattaa    300 

agagggtgga gcaggtggcg gttttggctc ccccatggac atctttgata tgttttttgg    360 

aggaggagga aggatgcaga gagaaaggag aggtaaaaat gttgtacatc agctctcagt    420 

aaccctagaa gacttatata atggtgcaac aagaaaactg gctctgcaaa agaatgtgat    480 

ttgtgacaaa tgtgaaggta gaggaggtaa gaaaggagca gtagagtgct gtcccaattg    540 

ccgaggtact ggaatgcaaa taagaattca tcagatagga cctggaatgg ttcagcaaat    600 

tcagtctgtg tgcatggagt gccagggcca tggggagcgg atcagtccta aagatagatg    660 

taaaagctgc aacggaagga agatagttcg agagaagaaa attttagaag ttcatattga    720 

caaaggcatg aaagatggcc agaagataac attccatggt gaaggagacc aagaaccagg    780 

actggagcca ggcgatatta tcattgtgtt agatcagaag gaccatgctg tttttactcg    840 

acgaggagaa gaccttttca tgtgtatgga catacagctc gttgaagcac tgtgtggctt    900 

ccagaagcca atatctactc ttgacaaccg aaccatcgtc atcacctctc atccaggtca    960 

gattgtcaag catggagata tcaagtgtgt actaaatgaa ggcatgccaa tttatcgtag   1020 

accatatgaa aagggtcgcc taatcatcga atttaaggta aactttcctg agaatggctt   1080 

tctctctcct gataaactgt ctttgctgga aaaactccta cccgagagga aggaagtgga   1140 

agagactgat gagatggacc aagtagaact ggtggacttt gatccaaatc aggaaagacg   1200 

gcgccactac aatggagaag catatgagga tgatgaacat catcccagag gtggtgttca   1260 

gtgtcagacc tcttaatggc cagtgaataa cactcactgc tggcatttaa tgtgcagtag   1320 

tgaatgagtg aaggactgta atcataatat gctcactact tgctcttgtt tttgttttaa   1380 

taaactatag tagtgttata aaaagttaaa tgaagaataa acgcaaatat aaaagctc     1438 

 
           
             55  
             391  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(391)  
               N IS A, C, G, OR T  
             
           
            55 

gcagtgttaa cagcacaaca tttacaaaac gtattttgta caatcaagtc ttcactgccc     60 

ttgcacacta ggggggctag ggaagaccta gtccttccaa cagctataaa cagtcctgga    120 

taatgggttt atgaaaaaca ctttttcttc cttcagcaag caaaattatt tatgaagctg    180 

tatggtttca gcaacaggga gcaaaggaaa aaaatcacct caaagaaagc aacagcttcc    240 

ttcctggtgg gatctgtcat tttatagata tgaaatattc atgccagagg tcttatattt    300 

taagaggaat ggattatata ccagagctac aacaanaaac attttacnta ttagctaatg    360 

aggaattaga agacggtctt nggaaaccgt t                                   391 

 
           
             56  
             7108  
             DNA  
             Homo sapiens  
           
            56 

aaaactgcga ctgcgcggcg tgagctcgct gagacttcct ggaccccgca ccaggctgtg     60 

gggtttctca gataactggg cccctgcgct caggaggcct tcaccctctg ctctgggtaa    120 

agttcattgg aacagaaaga aatggattta tctgctcttc gcgttgaaga agtacaaaat    180 

gtcattaatg ctatgcagaa aatcttagag tgtcccatct gtctggagtt gatcaaggaa    240 

cctgtctcca caaagtgtga ccacatattt tgcaaatttt gcatgctgaa acttctcaac    300 

cagaagaaag ggccttcaca gtgtccttta tgtaagaatg atataaccaa aaggagccta    360 

caagaaagta cgagatttag tcaacttgtt gaagagctat tgaaaatcat ttgtgctttt    420 

cagcttgaca caggtttgga gtatgcaaac agctataatt ttgcaaaaaa ggaaaataac    480 

tctcctgaac atctaaaaga tgaagtttct atcatccaaa gtatgggcta cagaaaccgt    540 

gccaaaagac ttctacagag tgaacccgaa aatccttcct tgcaggaaac cagtctcagt    600 

gtccaactct ctaaccttgg aactgtgaga actctgagga caaagcagcg gatacaacct    660 

caaaagacgt ctgtctacat tgaattggga tctgattctt ctgaagatac cgttaataag    720 

gcaacttatt gcagtgtggg agatcaagaa ttgttacaaa tcacccctca aggaaccagg    780 

gatgaaatca gtttggattc tgcaaaaaag gctgcttgtg aattttctga gacggatgta    840 

acaaatactg aacatcatca acccagtaat aatgatttga acaccactga gaagcgtgca    900 

gctgagaggc atccagaaaa gtatcagggt agttctgttt caaacttgca tgtggagcca    960 

tgtggcacaa atactcatgc cagctcatta cagcatgaga acagcagttt attactcact   1020 

aaagacagaa tgaatgtaga aaaggctgaa ttctgtaata aaagcaaaca gcctggctta   1080 

gcaaggagcc aacataacag atgggctgga agtaaggaaa catgtaatga taggcggact   1140 

cccagcacag aaaaaaaggt agatctgaat gctgatcccc tgtgtgagag aaaagaatgg   1200 

aataagcaga aactgccatg ctcagagaat cctagagata ctgaagatgt tccttggata   1260 

acactaaata gcagcattca gaaagttaat gagtggtttt ccagaagtga tgaactgtta   1320 

ggttctgatg actcacatga tggggagtct gaatcaaatg ccaaagtagc tgatgtattg   1380 

gacgttctaa atgaggtaga tgaatattct ggttcttcag agaaaataga cttactggcc   1440 

agtgatcctc atgaggcttt aatatgtaaa agtgaaagag ttcactccaa atcagtagag   1500 

agtaatattg aagacaaaat atttgggaaa acctatcgga agaaggcaag cctccccaac   1560 

ttaagccatg taactgaaaa tctaattata ggagcatttg ttactgagcc acagataata   1620 

caagagcgtc ccctcacaaa taaattaaag cgtaaaagga gacctacatc aggccttcat   1680 

cctgaggatt ttatcaagaa agcagatttg gcagttcaaa agactcctga aatgataaat   1740 

cagggaacta accaaacgga gcagaatggt caagtgatga atattactaa tagtggtcat   1800 

gagaataaaa caaaaggtga ttctattcag aatgagaaaa atcctaaccc aatagaatca   1860 

ctcgaaaaag aatctgcttt caaaacgaaa gctgaaccta taagcagcag tataagcaat   1920 

atggaactcg aattaaatat ccacaattca aaagcaccta aaaagaatag gctgaggagg   1980 

aagtcttcta ccaggcatat tcatgcgctt gaactagtag tcagtagaaa tctaagccca   2040 

cctaattgta ctgaattgca aattgatagt tgttctagca gtgaagagat aaagaaaaaa   2100 

aagtacaacc aaatgccagt caggcacagc agaaacctac aactcatgga aggtaaagaa   2160 

cctgcaactg gagccaagaa gagtaacaag ccaaatgaac agacaagtaa aagacatgac   2220 

agcgatactt tcccagagct gaagttaaca aatgcacctg gttcttttac taagtgttca   2280 

aataccagtg aacttaaaga atttgtcaat cctagccttc caagagaaga aaaagaagag   2340 

aaactagaaa cagttaaagt gtctaataat gctgaagacc ccaaagatct catgttaagt   2400 

ggagaaaggg ttttgcaaac tgaaagatct gtagagagta gcagtatttc attggtacct   2460 

ggtactgatt atggcactca ggaaagtatc tcgttactgg aagttagcac tctagggaag   2520 

gcaaaaacag aaccaaataa atgtgtgagt cagtgtgcag catttgaaaa ccccaaggga   2580 

ctaattcatg gttgttccaa agataataga aatgacacag aaggctttaa gtatccattg   2640 

ggacatgaag ttaaccacag tcgggaaaca agcatagaaa tggaagaaag tgaacttgat   2700 

gctcagtatt tgcagaatac attcaaggtt tcaaagcgcc agtcatttgc tccgttttca   2760 

aatccaggaa atgcagaaga ggaatgtgca acattctctg cccactctgg gtccttaaag   2820 

aaacaaagtc caaaagtcac ttttgaatgt gaacaaaagg aagaaaatca aggaaagaat   2880 

gagtctaata tcaagcctgt acagacagtt aatatcactg caggctttcc tgtggttggt   2940 

cagaaagata agccagttga taatgccaaa tgtagtatca aaggaggctc taggttttgt   3000 

ctatcatctc agttcagagg caacgaaact ggactcatta ctccaaataa acatggactt   3060 

ttacaaaacc catatcgtat accaccactt tttcccatca agtcatttgt taaaactaaa   3120 

tgtaagaaaa atctgctaga ggaaaacttt gaggaacatt caatgtcacc tgaaagagaa   3180 

atgggaaatg agaacattcc aagtacagtg agcacaatta gccgtaataa cattagagaa   3240 

aatgttttta aagaagccag ctcaagcaat attaatgaag taggttccag tactaatgaa   3300 

gtgggctcca gtattaatga aataggttcc agtgatgaaa acattcaagc agaactaggt   3360 

agaaacagag ggccaaaatt gaatgctatg cttagattag gggttttgca acctgaggtc   3420 

tataaacaaa gtcttcctgg aagtaattgt aagcatcctg aaataaaaaa gcaagaatat   3480 

gaagaagtag ttcagactgt taatacagat ttctctccat atctgatttc agataactta   3540 

gaacagccta tgggaagtag tcatgcatct caggtttgtt ctgagacacc tgatgacctg   3600 

ttagatgatg gtgaaataaa ggaagatact agttttgctg aaaatgacat taaggaaagt   3660 

tctgctgttt ttagcaaaag cgtccagaaa ggagagctta gcaggagtcc tagccctttc   3720 

acccatacac atttggctca gggttaccga agaggggcca agaaattaga gtcctcagaa   3780 

gagaacttat ctagtgagga tgaagagctt ccctgcttcc aacacttgtt atttggtaaa   3840 

gtaaacaata taccttctca gtctactagg catagcaccg ttgctaccga gtgtctgtct   3900 

aagaacacag aggagaattt attatcattg aagaatagct taaatgactg cagtaaccag   3960 

gtaatattgg caaaggcatc tcaggaacat caccttagtg aggaaacaaa atgttctgct   4020 

agcttgtttt cttcacagtg cagtgaattg gaagacttga ctgcaaatac aaacacccag   4080 

gatcctttct tgattggttc ttccaaacaa atgaggcatc agtctgaaag ccagggagtt   4140 

ggtctgagtg acaaggaatt ggtttcagat gatgaagaaa gaggaacggg cttggaagaa   4200 

aataatcaag aagagcaaag catggattca aacttaggtg aagcagcatc tgggtgtgag   4260 

agtgaaacaa gcgtctctga agactgctca gggctatcct ctcagagtga cattttaacc   4320 

actcagcaga gggataccat gcaacataac ctgataaagc tccagcagga aatggctgaa   4380 

ctagaagctg tgttagaaca gcatgggagc cagccttcta acagctaccc ttccatcata   4440 

agtgactctt ctgcccttga ggacctgcga aatccagaac aaagcacatc agaaaaagca   4500 

gtattaactt cacagaaaag tagtgaatac cctataagcc agaatccaga aggcctttct   4560 

gctgacaagt ttgaggtgtc tgcagatagt tctaccagta aaaataaaga accaggagtg   4620 

gaaaggtcat ccccttctaa atgcccatca ttagatgata ggtggtacat gcacagttgc   4680 

tctgggagtc ttcagaatag aaactaccca tctcaagagg agctcattaa ggttgttgat   4740 

gtggaggagc aacagctgga agagtctggg ccacacgatt tgacggaaac atcttacttg   4800 

ccaaggcaag atctagaggg aaccccttac ctggaatctg gaatcagcct cttctctgat   4860 

gaccctgaat ctgatccttc tgaagacaga gccccagagt cagctcgtgt tggcaacata   4920 

ccatcttcaa cctctgcatt gaaagttccc caattgaaag ttgcagaatc tgcccagagt   4980 

ccagctgctg ctcatactac tgatactgct gggtataatg caatggaaga aagtgtgagc   5040 

agggagaagc cagaattgac agcttcaaca gaaagggtca acaaaagaat gtccatggtg   5100 

gtgtctggcc tgaccccaga agaatttatg ctcgtgtaca agtttgccag aaaacaccac   5160 

atcactttaa ctaatctaat tactgaagag actactcatg ttgttatgaa aacagatgct   5220 

gagtttgtgt gtgaacggac actgaaatat tttctaggaa ttgcgggagg aaaatgggta   5280 

gttagctatt tctgggtgac ccagtctatt aaagaaagaa aaatgctgaa tgagcatgat   5340 

tttgaagtca gaggagatgt ggtcaatgga agaaaccacc aaggtccaaa gcgagcaaga   5400 

gaatcccagg acagaaagat cttcaggggg ctagaaatct gttgctatgg gcccttcacc   5460 

aacatgccca cagatcaact ggaatggatg gtacagctgt gtggtgcttc tgtggtgaag   5520 

gagctttcat cattcaccct tggcacaggt gtccacccaa ttgtggttgt gcagccagat   5580 

gcctggacag aggacaatgg cttccatgca attgggcaga tgtgtgaggc acctgtggtg   5640 

acccgagagt gggtgttgga cagtgtagca ctctaccagt gccaggagct ggacacctac   5700 

ctgatacccc agatccccca cagccactac tgactgcagc cagccacagg tacagagccc   5760 

aggaccccaa gaatgagctt acaaagtggc ctttccaggc cctgggagct cctctcactc   5820 

ttcagtcctt ctactgtcct ggctactaaa tattttatgt acatcagcct gaaaaggact   5880 

tctggctatg caagggtccc ttaaagattt tctgcttgaa gtctcccttg gaaatctgcc   5940 

atgagcacaa aattatggta atttttcacc tgagaagatt ttaaaaccat ttaaacgcca   6000 

ccaattgagc aagatgctga ttcattattt atcagcccta ttctttctat tcaggctgtt   6060 

gttggcttag ggctggaagc acagagtggc ttggcctcaa gagaatagct ggtttcccta   6120 

agtttacttc tctaaaaccc tgtgttcaca aaggcagaga gtcagaccct tcaatggaag   6180 

gagagtgctt gggatcgatt atgtgactta aagtcagaat agtccttggg cagttctcaa   6240 

atgttggagt ggaacattgg ggaggaaatt ctgaggcagg tattagaaat gaaaaggaaa   6300 

cttgaaacct gggcatggtg gctcacgcct gtaatcccag cactttggga ggccaaggtg   6360 

ggcagatcac tggaggtcag gagttcgaaa ccagcctggc caacatggtg aaaccccatc   6420 

tctactaaaa atacagaaat tagccggtca tggtggtgga cacctgtaat cccagctact   6480 

caggtggcta aggcaggaga atcacttcag cccgggaggt ggaggttgca gtgagccaag   6540 

atcataccac ggcactccag cctgggtgac agtgagactg tggctcaaaa aaaaaaaaaa   6600 

aaaaggaaaa tgaaactagg aaaggtttct taaagtctga gatatatttg ctagatttct   6660 

aaagaatgtg ttctaaaaca gcagaagatt ttcaagaacc ggtttccaaa gacagtcttc   6720 

taattcctca ttagtaataa gtaaaatgtt tattgttgta gctctggtat ataatccatt   6780 

cctcttaaaa tataagacct ctggcatgaa tatttcatat ctataaaatg acagatccca   6840 

ccaggaagga agctgttgct ttctttgagg tgattttttt cctttgctcc ctgttgctga   6900 

aaccatacag cttcataaat aattttgctt gctgaaggaa gaaaaagtgt ttttcataaa   6960 

cccattatcc aggactgttt atagctgttg gaaggactag gtcttcccta gcccccccag   7020 

tgtgcaaggg cagtgaagac ttgattgtac aaaatacgtt ttgtaaatgt tgtgctgtta   7080 

acactgcaaa taaacttggt agcaaaca                                      7108 

 
           
             57  
             357  
             DNA  
             Homo sapiens  
           
            57 

ttttgaaaaa aataatttat tacagactct tttacacatt aacatggaac atttatacat     60 

atatcgatgt gctgatatga aatactaaat ttaaaggcaa acatttttac acaaaagtag    120 

ttgcactcta ttttataaag atagatatta ataagttatc agagacattt aagagctaga    180 

ggccaattat tccaacagta atgcattcta tgctgaaagt aaactaagtt ttctgaacat    240 

gatgtcctgg atataatcac attcttctaa gctaaggaaa gggagctcat ttctgggaat    300 

acaaggccaa gaagggctct aacagcagta tcccagcagt gtgtttccag atttatt       357 

 
           
             58  
             2443  
             DNA  
             Homo sapiens  
           
            58 

cccccccccg ccgctgccgc ctctgcctgg gtcccttcgg ccgtacctct gcgtgggggc     60 

tgcctccccg gctcccggtg cagacaccat gtacggattt gtgaatcacg ccctggagtt    120 

gctggtgatc cgcaattacg gccccgaggt gtgggaagac atcaaaaaag aggcacagtt    180 

agatgaagaa ggacagtttc ttgtcagaat aatatatgat gactccaaaa cttatgattt    240 

ggttgctgct gcaagcaaag tcctcaatct caatgctgga gaaatcctcc aaatgtttgg    300 

gaagatgttt ttcgtctttt gccaagaatc tggttatgat acaatcttgc gtgtcctggg    360 

ctctaatgtc agagaatttc tacagaacct tgatgctctg cacgaccacc ttgctaccat    420 

ctacccagga atgcgtgcac cttcctttag gtgcactgat gcagaaaagg gcaaaggact    480 

cattttgcac tactactcag agagagaagg acttcaggat attgtcattg gaatcatcaa    540 

aacagtggca caacaaatcc atggcactga aatagacatg aaggttattc agcaaagaaa    600 

tgaagaatgt gatcatactc aatttttaat tgaagaaaaa gagtcaaaag aagaggattt    660 

ttatgaagat cttgacagat ttgaagaaaa tggtacccag gaatcacgca tcagcccata    720 

tacattctgc aaagcttttc cttttcatat aatatttgac cgggacctag tggtcactca    780 

gtgtggcaat gctatataca gagttctccc ccagctccag cctgggaatt gcagccttct    840 

gtctgtcttc tcgctggttc gtcctcatat tgatattagt ttccatggga tcctttctca    900 

catcaatact gtttttgtat tgagaagcaa ggaaggattg ttggatgtgg agaaattaga    960 

atgtgaggat gaactgactg ggactgagat cagctgctta cgtctcaagg gtcaaatgat   1020 

ctacttacct gaagcagata gcatactttt tctatgttca ccaagtgtca tgaacctgga   1080 

cgatttgaca aggagagggc tgtatctaag tgacatccct ctgcatgatg ccacgcgcga   1140 

tcttgttctt ttgggagaac aatttagaga ggaatacaaa ctcacccaag aactggaaat   1200 

cctcactgac aggctacagc tcacgttaag agccctggaa gatgaaaaga aaaagacaga   1260 

cacattgctg tattctgtcc ttcctccgtc tgttgccaat gagctgcggc acaagcgtcc   1320 

agtgcctgcc aaaagatatg acaatgtgac catcctcttt agtggcattg tgggcttcaa   1380 

tgctttctgt agcaagcatg catctggaga aggagccatg aagatcgtca acctcctcaa   1440 

cgacctctac accagatttg acacactgac tgattcccgg aaaaacccat ttgtttataa   1500 

ggtggagact gttggtgaca agtatatgac agtgagtggt ttaccagagc catgcattca   1560 

ccatgcacga tccatctgcc acctggcctt ggacatgatg gaaattgctg gccaggttca   1620 

agtagatggt gaatctgttc agataacaat agggatacac actggagagg tagttacagg   1680 

tgtcatagga cagcggatgc ctcgatactg tctttttggg aatactgtca acctcacaag   1740 

ccgaacagaa accacaggag aaaagggaaa aataaatgtg tctgaatata catacagatg   1800 

tcttatgtct ccagaaaatt cagatccaca attccacttg gagcacagag gcccagtgtc   1860 

catgaagggc aaaaaagaac caatgcaagt ttggtttcta tccagaaaaa atacaggaac   1920 

agaggaaaca aagcaggatg atgactgaat cttggattat ggggtgaaga ggagtacaga   1980 

ctaggttcca gttttctcct aacacgtgcc aagcccagga gcagttcttc cctatggata   2040 

cagattttct tttgtccttg tccattaccc caagactttc ttctagatat atctctcact   2100 

atccgttatt caaccttagc tctgctttct attacttttt aggctttagt atattatcta   2160 

aagtttggct tttgatgtgg atgatgtgag cttcatgtgt cttaaaatct actacaagca   2220 

ttacctaaca tggtgatctg caagtagtag gcacccaata aatatttgtt gaatttagtt   2280 

aaatgaaact gaacagtgtt tggccatgtg tatatttata tcatgtttac caaatctgtt   2340 

tagtgttcca catatatgta tatgtatatt ttaatgacta taatgtaata aagtttatat   2400 

catgttggtg tatatcatta tagaaatcat tttctaaagg agt                     2443 

 
           
             59  
             440  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(440)  
               N IS A, C, G OR T  
             
           
            59 

ctctcatgag gagaatgtat tttaaacttg ggaagagtca taattctggg atgtttcaca     60 

tgttgtcagc tttaaccttc tacagacaca ggccctctcc tctgtgagga gggacctctg    120 

gcatgtgtgg gtgtgtggtg ggtccctctc cctattagca gaaatgtgtt gggcatgagc    180 

cagggtttat gatttggatt gtgtcctgca cataacacct gtgagaatac aactggggac    240 

taggacaatg cgggaagcat attcttcatg agggcgggta accaaaaggc ttggctatac    300 

caaaggattc tgggtgggcc gggcacggtg gcttcacacc tgtaatgcca gcactttggg    360 

gaggccaagg cgggtagatc nctttgaggt ncccggggnt ttcgagcccc ncctggggcc    420 

aacatggtga aanccctttt                                                440 

 
           
             60  
             2587  
             DNA  
             Homo sapiens  
           
            60 

ggcacgagga gagaaccgtg gctggcaaag atgattcagg cgattctggt tttcaacaac     60 

catgggaagc cacggctagt ccgcttctac cagcgtttcc cagaagaaat tcaacagcag    120 

attgttcgag agactttcca tctagtcctc aagcgggatg acaacatctg taacttcttg    180 

gagggtggaa gtttgattgg tggctctgac tacaaactga tctaccggca ctatgctacc    240 

ctctactttg tattttgtgt ggattcctca gagagtgaac ttggaatctt ggacctcatc    300 

caggtttttg tggaaactct ggataagtgt ttcgaaaatg tgtgtgaatt ggatttgatc    360 

ttccatatgg ataaggtgca ctacatcctc caggaggtgg tgatgggtgg gatggtgttg    420 

gaaacaaaca tgaatgaaat cgtggctcag attgaggctc aaaacaggct ggagaaatcc    480 

gagggtggcc tttcagcagc ccctgcgcgg gctgtgtctg ctgtgaaaaa catcaacctg    540 

ccagagattc ctcggaacat caacattggc gatctcaaca tcaaagttcc caacctgtcc    600 

cagtttgtct gaggatcaag tattggcctg aaatagagtc cttaagacaa gcaaagacaa    660 

gcaaggcaag cacgtctgga aacagaaccc attttgagcc ttagaagagt caagcctcag    720 

gacctggaaa ctttgtgtct ggggaagact gtttggcatg gaatagggaa gggattccta    780 

ttgacactgc tcgggtgcac ccagttctca catgtgcagt catgccgttc tctgatgcat    840 

acggccactg cagatgtgag gggccctgcc ttcctcagta gggagtcaac atgcccaagt    900 

catttgcacc tttacctctc acatggatgc tcccaagggt tagggactgc attgagcagg    960 

cccacctgct tcccagaacc tcctcactag ggctgagcac cttctctgag tagagtcttc   1020 

atccttagca ccacagactt ctgaggtcct gtgcccttta cttgctggtg aggtgtcata   1080 

ggtagaaaag ggctggccct tcagatctgg gggtgtggtg agtggcaagt aagggcagaa   1140 

ttttaggaga accagagtca cccgctggct ctactgagat tgttacaccc agaatccttt   1200 

tgtgtttttt tgtggttttt ttttttgagg tggagtcttg ctctgtcacc caggctggag   1260 

tgctgtggtg caatctcggc tcactgcaac ctctgcttcc cgggttcaag catttctcct   1320 

gtctcagcct ccccagtagc tgggattaca ggcacccacc accatgccca gctaattgtt   1380 

gtatgtttag tagagacagg gtttcaccat gttggccagg ctgggcccga actcctggac   1440 

ctcaagtgat ctacccgcct tggcctccca aagtgctggc attacaggtg tgagccaccg   1500 

tgcccggcca ccagaatcct ttggtatagc caagcctttt ggttaccgcc tcatgaagaa   1560 

tatgcttccc gcattgtcct agtcccagtt gtattctcac aggtgttatg tgcaggacac   1620 

aatccaaatc ataaacctgg ctcatgccca acacatttct gctaataggg agagggaccc   1680 

accacacacc cacacatgcc agaggtccct cctcacagag gagagggcct gtgtctgtag   1740 

aaggttaaag ctgacaacat gtgaaacatc ccagaattat gactcttccc aagtttaaaa   1800 

tacattctcc tcatgagagc agaaggtttg ttgctgtgtt gtgaatgatg agctgcctcc   1860 

atagggaacc cactgccacc tgggccagct tctggagcat gagaacctga gccagggtca   1920 

cccttgtggg gcctggacat gacgcacgct ggctgcgact aggagcaggg ctgcctcttc   1980 

tccctcccca aggtctgctt gtgggcacgc tctgttccct caggtgccat tctcccaggg   2040 

cttaggcgcc cataaatgtt ctttctgtgg tggagtaggg cctcctgctt ccatactgtc   2100 

gcatgggcta gatctcaggt gtggtgttga gccaccttaa gatgagggct gcttcgcagt   2160 

aaagtttcca gcctgggccc ctcttgggcc ttctggctgg ggaccctcag cctcctgatg   2220 

ctgttgcagg gcaggtctga gagggtgccc agcagcaccc ggtgtcaggg ccaccttgtt   2280 

ttccattttt gaacagcgct ccctgtggtt tgtgcccact gctcaataca gcctccgatc   2340 

ctcactcttg aaagctccat gataagcaca gagatgggca gtgtgggtca gaaggtgggc   2400 

cgcttcctgt ggaagaggga agtgtaggtg aatagatatc aaaacccctg atgtcattct   2460 

tttgaggggt tggattttct tttttctggc agacatttca gtacattcac atttctctca   2520 

catttgctga atgtgagatc agaataaagg agatcggcgt ttatttcgta aaaaaaaaaa   2580 

aaaaaaa                                                             2587 

 
           
             61  
             346  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(346)  
               N IS A, C, G, OR T  
             
           
            61 

tatagaaaca gtctcacaat gttgcctagg ctcggtctca aactcctggc ctcaagcaat     60 

ccttccgcct tggctcccaa agtgctggga ttacaggcgt gctactgtgc atggccagga    120 

aaaccttctt ctttttaaaa tgctctctat ataaacaaaa actgtggtgg ataagtgtgg    180 

ccatacacag aagtctctct agaaaggtaa tcctatcaag cgtttttata aaaaaagcaa    240 

aagtgatttt taatcagctt cctttttttc antaaaaagc ngttttaagg gagtattcng    300 

gaattcncgg aaaatccang gggaaccaac cncatgggaa nctgta                   346 

 
           
             62  
             1785  
             DNA  
             Homo sapiens  
           
            62  
           
             63  
             419  
             DNA  
             Homo sapiens  
           
            63 

tcattcaaca acaaacattt attgagcacc tactggtcag ggccctggaa ccactagact     60 

cttagtccag tgctcttcag gaccctggag gaccctctgc aatttggcct gagactccag    120 

ccagcagctg gaaactcctc gtccaggaga ctgtccaggt gaggagctca gcagtgagga    180 

gggcggaccc catcagccca cttgccaacc tgcaatgcca ccaccatcct gtggtccaga    240 

gacatagaag tggcaggatg ggtctggggt gcagcaccca tgggtgaggc aggatggggg    300 

gtccagtcag ctcgtgtcca tcttaaagtt tttttttttt ttttttgaga tgggagtctc    360 

actctgtcgc ccaggctgga gtgcaagtgg caagaatctc gggttaatgg aaagcttcc     419 

 
           
             64  
             2347  
             DNA  
             Homo sapiens  
           
            64 

gcgcggcggg catggctcgg gtggcgtggg ggctgctgtg gttgctgctg ggcagcgccg     60 

gggcgcagta cgagaagtac agcttccggg gcttcccgcc cgaggacctg atgccgctgg    120 

ccgcggcgta cgggcacgct ctggagcagt acgagggaga gagctggcgc gagagcgcgc    180 

gctacctgga ggcggcgctg cggctgcacc ggctcctgcg cgacagcgag gccttctgcc    240 

acgccaactg cagcggcccc gcgcccgcgg ccaagcccga tcccgacggc ggccgcgcag    300 

acgagtgggc ctgcgagctg cggctcttcg gccgcgtcct ggagcgagcc gcctgcctgc    360 

ggcgctgcaa gcggacgctg cccgccttcc aggtgcccta cccgccgcgg cagctgctgc    420 

gtgacttcca gagccgcctg ccctaccagt acctgcacta cgcgctgttc aaggctaacc    480 

ggctggagaa ggcggtggcg gcggcctaca ccttcctcca gaggaacccg aagcacgagc    540 

tgaccgccaa gtatctcaac tactatcagg ggatgctgga cgtcgccgac gagtccctca    600 

cggacctaga ggcccagccc tacgaggccg tgttcctccg ggctgtgaag ctctacaaca    660 

gcggggattt ccgcagcagc acggaggaca tggagcgggc cttgtcagag tacctggcag    720 

tctttgcccg gtgcctggcc ggctgtgaag gggcccatga gcaggtggac ttcaaggact    780 

tctacccggc catagcagat ctctttgcag agtccctgca gtgcaaggtg gactgtgagg    840 

ccaatttgac ccccaatgtg ggtggctact tcgtggacaa gttcgtggcc accatgtacc    900 

actacctgca gtttgcctac tataagttga atgatgtgcg ccaggctgcc cgcagcgccg    960 

ccagctacat gctcttcgac cccaaggaca gcgtcatgca gcagaacctg gtgtattacc   1020 

ggttccaccg ggctcgctgg ggcctggaag aggaggactt ccagccccgg gaggaggcca   1080 

tgctctacca caaccagacc gccgagctgc gggagctgct ggagttcacc cacatgtacc   1140 

tgcagtcaga tgatgagatg gagctggagg agacagaacc gcccctggag cctgaggatg   1200 

ccctatctga cgccgagttt gagggggagg gtgactacga ggagggcatg tatgctgact   1260 

ggtggcagga gccggatgcc aagggtgacg aggccgaggc tgagccagag cctgaactcg   1320 

catgagaagg ggacacccca caccgctcaa gcttgggaag cctggtgccg atggccccac   1380 

cctcaccagc ctgggcagca gcaagaacta tttattaaaa acttaagatg ggccaggtgc   1440 

ggtggctcac acctgtaatc ccagcatttt gggaggccaa ggtgggtgga tcacttgagg   1500 

ccaggagttc aagaccagcc tggccaacat gatgagacct ccgtctctac taaaatacat   1560 

aaattagccg ggtgtggtgg caggcgcctg aaatcccagc tactcaagag gctgaggcag   1620 

gagaatcgct tgaacctggg aggcaaaggt tgcggtgaac tgagattgcg ccaccgcact   1680 

ccagcctggg cgacagagcg agactccatc tttaaaaaaa aacaagacgg gccggcacgg   1740 

tggctcacgc ctgtaatccc agcactgaga ggccgatcac ttgaggtcag gagttcaaga   1800 

cctgcctggc caacatggtg aaaccccatc tctactaaaa aatacaaaaa ttagccaggc   1860 

atggtggcac acacctgtaa tcgtagctga ggcaggagaa tcgcctgaac ccaggaggcg   1920 

gagcttgcag tgagccgaga tcgtgccact gcactccagc ctgggcgaca gagtgagact   1980 

ccatctcaaa aaaaaaaaaa aaaaacttaa gatggacaca gctgactgga cccccatcct   2040 

gcctcaccca tgggtgctgc accccagacc catcctgcca cttctatgtc tctggaccac   2100 

aggatggtgg tggcattgca ggttggcaag tgggctgatg gggtccgccc tcctcactgc   2160 

tgagctcctc acctggacag tctcctggac aaggagtttc cagctgctgg ctggagtctc   2220 

aggccaaatt gcagagggtc ctccagggtc ctgaagagca ctggactaag agtctagtgg   2280 

ttccagggcc ctgaccagta ggtgctcaat aaatgtttgt tgttgaatga aaaaaaaaaa   2340 

aaaaaaa                                                             2347 

 
           
             65  
             411  
             DNA  
             Homo sapiens  
           
            65 

tgagactgag tctcgctctg ttgcccaggc tggagtgcag tggcgggact tcagctcact     60 

gctacctctg cctcccgggt tcaagcgatt ctcctgcctc agcctcctga gtagctgaga    120 

ctacaggcgt gcaccaccac gcccagctaa ttttttgtaa ttttagcaga catggggttt    180 

cactgtatta gccaggatgg tctcaatttc ctgaccttgt gatctacctg ccttggcctc    240 

ccaaagagct gggattacag gcacgaacca ccgcacctgg ccaatcagca ataaatttct    300 

tttctattta ccccatttct tattaattca cacttcaaaa aagcatttcc tggaagtatt    360 

tctaagtgtg atggtttgta atatataaca aatgaaaaga tgtaattaga t             411 

 
           
             66  
             1518  
             DNA  
             Homo sapiens  
           
            66 

cggggcagga ggcacgcgcg cggctgaggc gaggtcgctc ggcgcagctg ttgcggggcc     60 

atggcgggga ccgcgctcaa gaggctgatg gccgagtaca aacaattaac actgaatcct    120 

ccggaaggaa ttgtagcagg ccccatgaat gaagagaact tttttgaatg ggaggcattg    180 

atcatgggcc cagaagacac ctgctttgag tttggtgttt ttcctgccat cctgagtttc    240 

ccacttgatt acccgttaag tcccccaaag atgagattta cctgtgagat gtttcatccc    300 

aacatctacc ctgatgggag agtctgcatt tccatcctcc acgcgccagg cgatgacccc    360 

atgggctacg agagcagcgc ggagcggtgg agtcctgtgc agagtgtgga gaagatcctg    420 

ctgtcggtgg tgagcatgct ggcagagccc aatgacgaaa gtggagctaa cgtggatgcg    480 

tccaaaatgt ggcgcgatga ccgggagcag ttctataaga ttgccaagca gatcgtccag    540 

aagtctctgg gactgtgaga cctggcctcg cacaggcgcg cacacaccgc caagcagctc    600 

agcattctcc cccggcacac ttagtgacag tgatgctctg tgctggtacc aaacaaggca    660 

gacttgcaag aaccatggca tctttttttt ttttcaaacc tttcctactt caaacaggct    720 

tctcttctga aatgatgact taatgtcgaa tattgacagc ttactgcagt tttacagtat    780 

tcctcacaaa gggcttcagg tagattatca gagctgtcag cactacctct ccccgctgaa    840 

accagcagtt catggcttcc tgtggattcc ctccctccct ggagtgttga gggggttgta    900 

cctgccagac ttccagggga cgatggaata cccagaacgc tccttctgaa gaaatggggc    960 

cctgtagctg cagcacaggg gaagggcccg gcaccctttc tgggtccttc ctggttccct   1020 

gtgggcccca tgaggagtcc attacttcct ttcttccttc atattttaca ggcagatgct   1080 

tttcttataa tctaattaca tcttttcatt tgttatatat tacaaaccat cacacttaga   1140 

aatacttcca ggaaatgctt ttttgaagtg tgaattaata agaaatgggg taaatagaaa   1200 

agaaatttat tgctgattgg ccaggtgcgg tggttcgtgc ctgtaatccc agctctttgg   1260 

gaggccaagg caggtagatc acaaggtcag gaaattgaga ccatcctggc taatacagtg   1320 

aaaccccatg tctgctaaaa ttacaaaaaa ttagctgggc gtggtggtgc acgcctgtag   1380 

tctcagctac tcaggaggct gaggcaggag aatcgcttga acccgggagg cagaggtagc   1440 

agtgagctga agtcccgcca ctgcactcca gcctgggcaa cagagcgaga ctcagtctca   1500 

aaaaaaaaaa aaaaaaaa                                                 1518 

 
           
             67  
             396  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(396)  
               N IS A, C, G, OR T  
             
           
            67 

agcaatacat gtttatcata gaaatttaag aacctaagta atacaaagaa agtaaggatt     60 

acctttaatt aagaacctaa gtaatacaaa gaaagtaagg attaccttta atcaataaac    120 

aaagataaac ttttggaggg agcatatacc attccagtca ctaagtaagg ttttaatact    180 

cagattccag anttctgatc aatcaatggc tatgtttcac acttctttaa attaaaaaat    240 

tttctatctt tacatatttt aggtgactga nttaccatgg gcgtaattga ggagtttggg    300 

atttattatg ggtacattcc gatttctatt taatacatan gggtacccgg atttaaaatt    360 

ttaggccnat ttggggtaaa tactaaccat acaggg                              396 

 
           
             68  
             2529  
             DNA  
             Homo sapiens  
           
            68 

cttggctctt acaatgctca cttgttttca caatgcagca aaatgaaatg ccttagaaaa     60 

agagtaacat tccagaaaac ggtgtaattt atttttcttc cttaattgcc ccatctgtgg    120 

aggatttctt tgctgaacac cacatcaaag ggatcttctg catttaaaat agaagaggca    180 

tcatgctgaa gagggagggg aaggtccaac cttacactaa aaccctggat ggaggatggg    240 

gatggatgat tgtgattcat tttttcctgg tgaatgtgtt tgtgatgggg atgaccaaga    300 

cttttgcaat tttctttgtg gtctttcaag aagagtttga aggcacctca gagcaaattg    360 

gttggattgg atccatcatg tcatctcttc gtttttgtgc aggtcccctg gttgctatta    420 

tttgtgacat acttggagag aaaactacct ccattcttgg ggctttcgtt gttactggtg    480 

gatatctgat cagcagctgg gccacaagta ttccttttct ttgtgtgact atgggacttc    540 

tacccggttt gggttctgct ttcttatacc aagtggctgc tgtggtaact accaaatact    600 

tcaaaaaacg attggctctt tctacagcta ttgcccgttc tgggatggga ctgacttttc    660 

ttttggcacc ctttacaaaa ttcctgatag atctgtatga ctggacagga gcccttatat    720 

tatttggagc tatcgcattg aatttggtgc cttctagtat gctcttaaga cccatccata    780 

tcaaaagtga gaacaattct ggtattaaag ataaaggcag cagtttgtct gcacatggtc    840 

cagaggcaca tgcaacagaa acacactgcc atgagacaga agagtctacc atcaaggaca    900 

gtactacgca gaaggctgga ctacctagca aaaatttaac agtctcacaa aatcaaagtg    960 

aagagttcta caatgggcct aacaggaaca gactgttatt aaagagtgat gaagaaagtg   1020 

ataaggttat ttcgtggagc tgcaaacaac tgtttgacat ttctctcttt agaaatcctt   1080 

tcttctacat atttacttgg tcttttctcc tcagtcagtt agcatacttc atccctacct   1140 

ttcacctggt agccagagcc aaaacactgg ggattgacat catggatgcc tcttaccttg   1200 

tttctgtagc aggtatcctt gagacggtca gtcagattat ttctggatgg gttgctgatc   1260 

aaaactggat taagaagtat cattaccaca agtcttacct catcctctgc ggcatcacta   1320 

acctgcttgc tcctttagcc accacatttc cactacttat gacctacacc atctgctttg   1380 

ccatctttgc tggtggttac ctggcattga tactgcctgt actggttgat ctgtgtagga   1440 

attctacagt aaacaggttt ttgggacttg ccagtttctt tgctgggatg gctgtccttt   1500 

ctggaccacc tatagcaggc tggttatatg attataccca gacatacaat ggctctttct   1560 

acttctctgg catatgctat ctcctctctt cagtttcctt tttttttgta ccattggccg   1620 

aaagatggaa aaacagtctg acctgaaaga aagaagactg caatcaagtg agagctaaac   1680 

aaaagaaaac ctaaactaat gtcattggaa acaaaagctt gaaagaaaca catcgcatct   1740 

acatttgtaa catgagaagg aaaacaattt tttttttttt ttttttgaga cggagtctcg   1800 

ctctttcgcc caggctggag tgcagtggcg caatctcggc tcactgtaat ctccgcctcc   1860 

tgggttcaag ggattctcct gcctcagcct cccaagtagc tgggactaca ggcacacgcc   1920 

accacaccca gctaattttt tgtattttta gtagaggcgg ggtttcacca tgttagccag   1980 

gatggtctcc atctcctgac ctcgtgatcc gcccgccttg tcctccaaag tgctgggatt   2040 

acaggcatga gccactgggc gcggccagat aagtttttaa ggttccttct tgctttagca   2100 

ttctgagaaa tgtctaattg gtagtaagac aagagtaata gcaacctgta ttgttagtat   2160 

ttaaccaaat aggctaaaat tttaatcagg taccttatgt attaaataga aatcggaatg   2220 

taccataata aatccaaact ctcaattacg ccatggtaat tcagtcacta aaatatgtaa   2280 

agatagaaaa ttttttaatt taaagaagtg tgaaacatag ccattgattg atcagaattc   2340 

tggaatctga atattaaaac cttacttagt gactggaatg gtatatgctc cctccaaaag   2400 

tttatctttg tttattgatt aaaggtaatc cttactttct ttgtattact taggttctca   2460 

attaaaggta atccttactt tctttgtatt acttaggttc ttaaatttct atgataaaca   2520 

tgtattgct                                                           2529 

 
           
             69  
             130  
             DNA  
             Homo sapiens  
             
               misc_feature  
               (1)..(130)  
               N IS A, C, G, OR T  
             
           
            69 

ttttttttta caaagcaggg agaggtcatg ttggtctgga acgcgtcaca ggggggacgt     60 

gccgcggcac catgtggggg gctcgtctgt ggggagggct gccccactgg gancctgggg    120 

acggaggcct                                                           130 

 
           
             70  
             2438  
             DNA  
             Homo sapiens  
           
            70 

ccggcggggg cgccgcggag agcggagggc gccgggctgc ggaacgcgaa gcggagggcg     60 

cgggaccctg cacgccgccc gcgggcccat gtgagcgcca tgcggcgccg cgcagcccgg    120 

ggacccggcc cgccgccccc agggcccgga ctctcgcggt tgccgctgct gccgctgccg    180 

ctgctgctgc tgctggcgct ggggacccgc gggggctgcg ccgcgcccgc acccgcgccg    240 

cgcgccgagg acctcagcct gggagtggag tggctaagca ggttcggtta cctgcccccg    300 

gctgacccca caacagggca gctgcagacg caagaggagc tgtctaaggc catcacagcc    360 

atgcagcagt ttggtggcct ggaggccacc ggcatcctgg acgaggccac cctggccctg    420 

atgaaaaccc cacgctgctc cctgccagac ctccctgtcc tgacccaggc tcgcaggaga    480 

cgccaggctc cagcccccac caagtggaac aagaggaacc tgtcgtggag ggtccggacg    540 

ttcccacggg actcaccact ggggcacgac acggtgcgtg cactcatgta ctacgccctc    600 

aaggtctgga gcgacattgc gcccctgaac ttccacgagg tggcgggcag caccgccgac    660 

atccagatcg acttctccaa ggccgaccat aacgacggct accccttcga cggccccggc    720 

ggcaccgtgg cccacgcctt cttccccggc caccaccaca ccgccgggga cacccacttt    780 

gacgatgacg aggcctggac cttccgctcc tcggatgccc acgggatgga cctgtttgca    840 

gtggctgtcc acgagtttgg ccacgccatt gggttaagcc atgtggccgc tgcacactcc    900 

atcatgcggc cgtactacca gggcccggtg ggtgacccgc tgcgctacgg gctcccctac    960 

gaggacaagg tgcgcgtctg gcagctgtac ggtgtgcggg agtctgtgtc tcccacggcg   1020 

cagcccgagg agcctcccct gctgccggag cccccagaca accggtccag cgccccgccc   1080 

aggaaggacg tgccccacag atgcagcact cactttgacg cggtggccca gatccgcggt   1140 

gaagctttct tcttcaaagg caagtacttc tggcggctga cgcgggaccg gcacctggtg   1200 

tccctgcagc cggcacagat gcaccgcttc tggcggggcc tgccgctgca cctggacagc   1260 

gtggacgccg tgtacgagcg caccagcgac cacaagatcg tcttctttaa aggagacagg   1320 

tactgggtgt tcaaggacaa taacgtagag gaaggatacc cgcgccccgt ctccgacttc   1380 

agcctcccgc ctggcggcat cgacgctgcc ttctcctggg cccacaatga caggacttat   1440 

ttctttaagg accagctgta ctggcgctac gatgaccaca cgaggcacat ggaccccggc   1500 

taccccgccc agagccccct gtggaggggt gtccccagca cgctggacga cgccatgcgc   1560 

tggtccgacg gtgcctccta cttcttccgt ggccaggagt actggaaagt gctggatggc   1620 

gagctggagg tggcacccgg gtacccacag tccacggccc gggactggct ggtgtgtgga   1680 

gactcacagg ccgatggatc tgtggctgcg ggcgtggacg cggcagaggg gccccgcgcc   1740 

cctccaggac aacatgacca gagccgctcg gaggacggtt acgaggtctg ctcatgcacc   1800 

tctggggcat cctctccccc gggggcccca ggcccactgg tggctgccac catgctgctg   1860 

ctgctgccgc cactgtcacc aggcgccctg tggacagcgg cccaggccct gacgctatga   1920 

cacacagcgc gagcccatga gaggacagag gcggtgggac agcctggcca cagagggcaa   1980 

ggactgtgcc ggagtccctg ggggaggtgc tggcgcggga tgaggacggg ccaccctggc   2040 

accggaaggc cagcagaggg cacggcccgc cagggctggg caggctcagg tggcaaggac   2100 

ggagctgtcc cctagtgagg gactgtgttg actgacgagc cgaggggtgg ccgctccaga   2160 

agggtgccca gtcaggccgc accgccgcca gcctcctccg gccctggagg gagcatctcg   2220 

ggctgggggc ccacccctct ctgtgccggc gccaccaacc ccacccacac tgctgcctgg   2280 

tgctcccgcc ggcccacagg gcctccgtcc ccaggtcccc agtggggcag ccctccccac   2340 

agacgagccc cccacatggt gccgcggcac gtcccccctg tgacgcgttc cagaccaaca   2400 

tgacctctcc ctgctttgta aaaaaaaaaa aaaaaaaa                           2438